Citation Report
List of articles citing

On the origin of cancer cells

DOI: 10.1126/science.123.3191.309
Science, 1956, 123, 309-14.

#	Paper	IF	Citations
2285	On respiratory impairment in cancer cells. *Science*, **1956**, 124, 267-9	33.3	406
2284	Methods in Cancer Research. **1956**, 268, 293-294		
2283	Inhibition of glutamate oxidation by fluorene carcinogens in a phosphorylating mitochondrial system. **1956**, 21, 574-5		10
2282	An Analysis of Warburg's View on the Origin of Cancer Cells. **1956**, 23, 343-347		3
2281	Basic Research on Tobacco. **1956**, 254, 1191-1191		
2280	THE PRESENCE AND SIGNIFICANCE OF RESPIRATORY METABOLISM IN STREAK-FORMING CHICK BLASTODERMS. **1956**, 111, 77-91		7
2279	Biochemical tests for malignancy applied to a new strain of human cells. **1956**, 178, 1179-80		19
2278	Protein Metabolism, Respiration and Growth: A Synthesis of Results from the Use of 14c-Labelled Substrates and Tissue Cultures. **1956**, 178, 789-792		6
2277	Intravascular agglutination of the blood: a factor in certain diseases and disorders of the ear. **1956**, 65, 535-44		5
2276	The problem of arsenic in American cigarette tobacco. **1956**, 254, 1149-54		34
2275	Carbohydrate metabolism. **1957**, 26, 149-80		21
2274	Ion movements in seminal vesicle mucosa. **1957**, 135, 213-25		19
2273	A Unifying Concept of the Etiology of the Leukemias, Lymphomas, and Cancers2. **1957**,		
2272	Transplantation of subcellular particles by micrurgy. **1957**, 68, 380-93		19
2271	Cytoplasmic inheritance. **1957**, 68, 366-79		5
2270	Histologic responses of rat oral tissues to nonoral tumor growth and to cancer chemotherapeutic agents. I. Periodontal tissues. **1957**, 10, 847-56		2
2269	The effect of anaerobiosis on the origin of respiratory-deficient yeast. **1957**, 12, 163-8		11

2268	STUDIES ON THE EFFECTS OF IRRADIATION OF CELLULAR PARTICULATES . II. THE EFFECT OF GAMMA RADIATION ON OXYGEN UPTAKE AND PHOSPHORYLATION. **1957**, 113, 198-206	11
2267	The metabolism of human embryonic and malignant cells and their response to insulin. **1957**, 24, 365-80	46
2266	CANCER BIOLOGY: VIRAL AND EPIGENETIC*. **1957**, 32, 1-37	11
2265	Role of Instinctive Preferences in the Discovery of New and Effective Leads for Cancer Control. **1957**, 3, 365-371	1
2264	Inhibitory Effect of Some Aminoazo Dyes and Other Carcinogens on Glutamate Oxidation in Mitochondria of Riboflavine-Deficient Rat Liver. **1957**,	1
2263	How does the Ehrlich ascites tumour obtain its energy for growth?. **1957**, 180, 131-2	21
2262	Cytochrome oxidase in human brain tumours. **1957**, 2, 37-44	24
2261	[Foundation of a chemotherapy for cancer based upon the primary inhibition of glucose phosphorylation (hexokinase reaction) by influencing the substrate, the coenzyme and the enzyme]. **1957**, 35, 1102-5	15
2260	Seminar on inhibition and stimulation of anaerobic glycolysis of ascites tumor cells. **1957**, 264, 509-516	
2259	A quantitative study of the bone marrow in the guinea pig throughout life. **1957**, 100, 473-507	9
2258	Environmental factors in cancer of the upper alimentary tract; a Swedish study with special reference to Plummer-Vinson (Paterson-Kelly) syndrome. **1957**, 10, 470-87	180
2257	Cell population dynamics and somatic change. **1958**, 52, 337-58; discussion 358-69	9
2256	Quantitative aspects of respiration and glycolysis in the white cells of human blood. **1958**, 46, 1473-1475	
2255	Fractionation, nucleic acid distribution and respiration of Ehrlich ascites tumor cells. **1958**, 45, 368-369	2
2254	Enzymic synthesis of coenzyme I in relation to chemical control of cell growth. **1958**, 181, 540-2	101
2253	A new approach to the chemotherapy of cancer. **1958**, 182, 163-5	25
2252	Mit krebseigenen Stoffen wirkungsidentische, chemisch definierte Substanzen von anoxygen energiefreisetzender Potenz. **1958**, 62, 568-584	3
2251	In menschlichen Krebsgeschw□sten nachweisbare, anoxygene Synthese aus□sende Energiereaktionen. **1958**, 62, 423-433	3

2250	[Induction of an anaerobic energy-effect in cancer cells by oxygen-free decoctions of tumors]. **1958**, 14, 416-7		
2249	On the etiology of cancer. **1958**, 8, 38-57		9
2248	Critique of the linear theory of carcinogenesis. *Science*, **1958**, 128, 693-9	33.3	92
2247	Respiration and glycolysis of human cells grown in tissue culture. **1958**, 5, 206-19		46
2246	[Poloploidy and the effect of anaerobiosis on the production of respiratory defficient yeast]. **1958**, 15, 628-30		7
2245	Radiochemical investigation of the utilisation of glucose by tissue cultures. **1958**, 14, 316-28		16
2244	Pathways of carbohydrate metabolism in normal and neoplastic cells. **1958**, 258, 225-32 concl		42
2243	Inhibition of citrate oxidation by glyoxylate in rat-liver homogenates. **1958**, 68, 270-5		18
2242	MALIGNANCY AND THE GENETICS OF THE SOMATIC CELL. **1958**, 71, 994-1008		2
2241	Data for the calculation of the rate coefficients of sodium transfer by mouse ascites tumour cells. **1958**, 140, 48-60		40
2240	Metabolism and sodium transfer of mouse ascites tumour cells. **1958**, 140, 80-93		28
2239	Respiratory Deficiency and the Zymophage: Two Factors Capable of Causing Degeneration in Brewery Yeasts1. **1958**, 16, 86-91		2
2238	Comparative Chromosomal Studies on Mammalian Cells in Culture. II. Mouse Sarcoma-Producing Cell Strains and Their Derivatives2. **1958**,		
2237	The Action of Analogues of dl-Glyceraldehyde on Glycolysis and Respiration of Tumors2. **1959**,		
2236	Neuroectodermal and Other Cells in Mouse-Brain Tissue Cultures (Part 2 of 2). **1959**, 19, 85-104		
2235	Glycolytic Properties of High and Low Sarcoma-Producing Lines and Clones of Mouse Tissue-Culture Cells. **1959**,		
2234	Influence of Animal Passage on a Line of Tissue-Culture Cells. **1959**,		
2233	Glucose and Lactate Utilization by Myeloblasts and Erythroblasts of Avian Viral Leukemias23. **1959**,		

2232 Bowen's disease and its relationship to systemic cancer. **1959**, 80, 133-59 151

2231 Microbiological Aspects of Tissue Culture. **1959**, 13, 141-176 33

2230 Changes in the activities of aldolase and D-glyceraldehyde-3-phosphate dehydrogenase during the mitotic cycle in microspores of Lilium longiflorum. **1959**, 6, 189-92 6

2229 Hypoglycemia associated with massive intra-abdominal mesothelial-cell sarcoma. **1959**, 260, 847-52 40

2228 Effects of Radiations on Populations of Cells and Multicellular Organisms. **1959**, 31, 289-296 1

2227 Environmental influences on the metabolism and composition of cultured cells. **1959**, 142, 475-505 51

2226 Atmungshemmung durch carcinostatisch wirkende Stoffe. **1959**, 62, 653-657 1

2225 Mitochondria of the Ehrlich ascites tumour cell-swelling characteristics. **1959**, 13, 566-76 1

2224 Metabolism of normal tissues and neoplasms in vitro. **1959**, 183, 281-6 104

2223 Gamma particles, Nadi-positive mitochondria, and development in the water fungi Blasocladiella and Allomyces. **1959**, 184(Suppl 24), 1889-90 3

2222 Efficiency of the mitochondrial oxidative phosphorylations in intact ascites tumour cells. **1959**, 184(Suppl 26), 2024-5 4

2221 Cancer and the respiratory grana. **1959**, 184, 397-400 4

2220 Electron Transfer in Biological Systems. **1959**, 47, 1821-1840 12

2219 Correction. **1959**, 47, 1840-1840

2218 Spectroscopic evidence of metabolic control. *Science*, **1959**, 129, 700-8 33.3 144

2217 MICRO-ORGANISMS AND CANCER RESEARCH. **1959**, 34, 378-406 9

2216 The induction by allyl glycine of heritable respiratory deficiency in Saccharomyces and its reversal by sulphur amino acids. **1959**, 5, 583-8 8

2215 pCO2 Inhibition of Normal and Malignant Growth2. **1959**,

2214	Influence of Altered Atmospheric Oxygen on Urethan-Induced Pulmonary Tumors in Mice2. **1959**,	
2213	Effect of Carcinogenic Dosage and Duration of Exposure on Skin-Tumor Induction in Mice2,3. **1959**,	
2212	Studies on the conversion of glucose into lactic acid in the Ehrlich ascites tumour. **1959**, 72, 160-5	9
2211	Ion transport and metabolism in slices of guinea-pig seminal-vesicle mucosa. **1959**, 72, 638-46	8
2210	The metabolism of neoplastic tissues: the effect of 2:4-dinitrophenol on the respiration of ascites tumour cells. **1959**, 13, 520-36	13
2209	Sodium and potassium movements in kidney cortex slices from new-born animals. **1960**, 153, 358-69	21
2208	Déficiences du métabolisme oxydatif et différenciation sexuelle chez Allomyces et Neurospora. Activité d'une DPN-deshydrogénase lactique chez Allomyces. **1960**, 23, 687-699	
2207	Preparation and properties of mitochondria from Ehrlich ascites tumor cells. **1960**, 7, 381-3	26
2206	The frequency of cancer in diabetes mellitus. **1960**, 14, 449-56	7
2205	Enzymic processes in cells. **1960**, 9, 129-86	7
2204	The study of drug effects at the cytological level. **1960**, 9, 293-304	8
2203	Sodium cyanide as a cancer chemotherapeutic agent. **1960**, 80, 907-918	9
2202	Discussion. **1960**, 13, 109-112	1
2201	Radiation carcinogenesis: a new hypothesis. **1960**, 185, 135-42	28
2200	A Reconsideration of the Nature of the Neoplastic Reaction in the Light of Recent Advances in Cancer Research. **1960**,	
2199	THE INHIBITION OF OXIDATIVE AND PHOSPHORYLATIVE ENZYMES IN RAT LIVER MITOCHONDRIA BY AMINOAZOBENZENE DERIVATIVES. **1960**, 38, 1-11	2
2198	METABOLISM OF NEOPLASTIC CELLS AND THEIR RESPONSE TO CERTAIN DRUGS. **1960**, 38, 409-424	
2197	SOME BIOLOGICAL PROBLEMS IN CANCER BIOCHEMISTRY. **1960**, 38, 425-433	

2196 THE INDUCTION OF RESPIRATORY DEFICIENCY BY ADAPTATIONAL STRESS. **1960**, 2, 1-10 2

2195 Succinic dehydrogenase and cytochrome oxidase activities in cell cultures. **1960**, 7, 265-72 17

2194 Experimental effect of cigarette smoke on human respiratory cilia. **1960**, 263, 832-5 75

2193 Nucleic acids and cancer. **1960**, 29, 1034-59 14

2192 Analysis of the early stages of vaccinia virus infection in KB cells using sodium azide. **1961**, 15, 417-27 16

2191 Pathways of glucose metabolism in fertilized rabbit ova at various pre-implantation stages. **1961**, 22, 303-16 76

2190 The effect of oxygen tension on the growth and metabolism of a mammalian cell. **1961**, 25, 101-13 83

2189 Thiamine diphosphate in growing tissues. I. Thiamine diphosphate in normal and malignant tissues. **1961**, 24, 311-9 5

2188 Environmental factors influencing respiration of strain L cells. **1961**, 24, 344-55 35

2187 Effect of dinitrophenol on bovine kidney culture cells infected with foot-and-mouth disease virus. **1961**, 93, 316-20 4

2186 Advances in cancer chemotherapy. **1961**, 13, 69-83 1

2185 The importance of the Plummer-Vinson syndrome in the aetiology of carcinoma of the upper gastrointestinal tract. **1961**, 37, 523-33 12

2184 Toxohormone-like factor from microorganisms with impaired respiration. *Science*, **1961**, 134, 2041-2 33.3 8

2183 Screening for and biological characterization of antitumor agents using microorganisms. **1961**, 3, 223-56 18

2182 Larg-scale use of animal cell cultures. **1961**, 3, 109-29 8

2181 Astudy of the citric acid cycle in certain tumour tissue. **1961**, 81, 494-503 6

2180 [Cell degeneration as a developmental physiology problem]. **1961**, 48, 609-16 4

2179 Input of energy compelling carcinogen-injured epidermal cells in mice to proceed with differentiation. **1961**, 48, 226-227 7

2178	Chemistry of Bowen's Disease: Relationship to Arsenic11From the Skin and Cancer Hospital of Philadelphia, Unit of the Department of Dermatology, Temple University Medical Center, Philadelphia, Penna., and the Armed Forces Institute of Pathology, Washington, D.C.Associate Professor of Dermatology and Associate Professor of Dermal Pathology, Temple University Medical Center, and Director of Laboratory, The Skin and Cancer Hospital of Philadelphia (Dr. Graham); Research Associate and Biochemist, Skin and Cance. **1961**, 37, 317-332	44
2177	Inhibition of cellular respiration by co-carcinogenic fractions of croton oil. **1961**, 189, 892-5	10
2176	Energy pathways of hepatoma No. 5123. **1961**, 191, 1314-5	41
2175	Cytochemical and Biochemical Studies of Aerobic Oxidative Metabolism of Human Gingiva. **1961**, 40, 304-310	15
2174	Neoplastic disease: tumor metabolism. **1961**, 12, 165-84	5
2173	A STUDY OF THE EFFECTS OF URETHAN ON THE CLEAVAGE OF THE CHAETOPTERUS EGG. I. INHIBITION OF CLEAVAGE. **1961**, 120, 384-400	8
2172	Aging and Cellular Malnutrition. **1962**, 2, 85-88	
2171	Microbial origin of the gummy substance of Fujita and Ging. **1962**, 25, 66-99	1
2170	Metabolism of the placenta. **1962**, 84, 1684-94	33
2169	Effects of Local Roentgen Irradiation on the Rate of Endogenous-dehydrogenase Activity in the Epidermis of Hairless Mice Studied by Means of a Tetrazolium-reduction Method. **1962**, 4, 277-283	6
2168	The pyridine nucleotide content of mitochondria isolated from Ehrlich ascites tumour cells. **1962**, 56, 216-26	15
2167	Effects of Oxygen on Growth in Several Established Cell Lines2. **1962**,	
2166	Comparative Study of Alterations Induced by 7,12-Dimethylbenz[]anthracene and Polymer Films in the Subcutaneous Connective Tissue of Rats2. **1962**,	
2165	On the access of blood-borne dyes to various tumour regions. **1962**, 16, 306-22	147
2164	A histochemical study of the enzymatic activity of lymph nodes. II. Further investigation of normal and hyperplastic lymph nodes. **1962**, 15, 130-8	37
2163	A histochemical study of the enzymatic activity of lymph nodes. III. Granulomatous and primary neoplastic conditions of lymphoid tissue. **1962**, 15, 139-52	47
2162	A histochemical study of the enzymatic activity of human neoplasms. I. Evidence suggesting deficiency of a succinoxidase carrier. **1962**, 15, 184-8	9
2161	Influence of initial tissue metabolism on the experimental blastomogenesis process. **1963**, 198, 699	2

2160 ACTION SPECTRUM OF MITOTIC FERROUS COMPLEX. **1963**, 199, 38-40 8

2159 RELATIONSHIPS OF ENZYMOLOGY TO CANCER: A REVIEW. **1963**, 17, 415-45 11

2158 AEROBIC AND ANAEROBIC CARBOHYDRATE UTILIZATION IN NORMAL AND MELANOTIC FISH PIGMENT CELLS*. **1963**, 100, 857-865

2157 Changes of LDH-isozymes, esterases, acid phosphatases and proteins in malignant and benign human brain tumors. **1963**, 39, 85-111 48

2156 SEQUENTIAL INHIBITION OF LACTIC DEHYDROGENASE ISOZYMES OF HUMAN BRAIN BY HONVAN (STILBOESTROL DIPHOSPHATE).(IN VITRO EXPERIMENTS). **1963**, 39, 305-22 13

2155 NEW PROSPECTS IN CANCER BIOCHEMISTRY. **1963**, 1, 279-308 12

2154 The role of citric acid in the physiology of the prostate. A chromatographic study of citric acid cycle intermediates in benign and malignant prostatic tissue. **1963**, 3, 112-21 23

2153 MICROORGANISMS AND THE MOLECULAR BIOLOGY OF CANCER. **1963**, 5, 65-93

2152 INDUCTION OF RESPIRATION-DEFICIENT MUTANT OF SACCHAROMYCES CEREVISIAE BY CARCINOGENIC AGENT, 4-NITROQUINOLINE N-OXIDE AND THE EXISTENCE OF TOXOHORMONE-LIKE FACTOR IN THE MUTANT. **1963**, 7, 69-79 14

2151 LACTIC DEHYDROGENASE ACTIVITY OF GASTRIC JUICE OF NORMAL SUBJECTS AND OF PATIENTS WITH GASTRIC ULCER, DUODENAL ULCER, GASTRIC CARCINOMA AND PERNICIOUS ANEMIA: A PRELIMINARY REPORT. **1963**, 12, 160-165 5

2150 LACTIC DEHYDROGENASE ISOENZYMES IN HUMAN CANCER CELLS AND MALIGNANT EFFUSIONS. **1963**, 35, 65-72 30

2149 THE MANAGEMENT OF THE PATIENT WITH INOPERABLE MALIGNANT DISEASE. **1963**, 1, 968-974

2148 THE MOLECULAR BASIS OF CANCER CHEMOTHERAPY. **1964**, 53-198 1

2147 CYTOCHEMICAL ASPECTS OF OXIDATIVE ENZYME METABOLISM IN GINGIVA. **1964**, 1, 131-74 6

2146 Characteristics of carcinogenesis in muscles with varying metabolism. **1964**, 55, 186-190

2145 EFFECT OF SODIUM COBALTINITRITE ON THE MINIMAL CARCINOGENIC DOSE-50 (MCD-50) OF METHYLCHOLANTHRENE IN ALBINO MICE. **1964**, 53, 388-91 4

2144 SOME MORPHOLOGIC, HISTOCHEMICAL, AND CHEMICAL OBSERVATIONS ON CHEMODECTOMAS AND THE NORMAL CAROTID BODY, INCLUDING A STUDY OF THE CHROMAFFIN REACTION AND POSSIBLE GANGLION CELL ELEMENTS. **1964**, 17, 185-202 129

2143 STUDIES ON THE TUMORIGENIC PROPERTIES OF BABY HAMSTER KIDNEY CELL LINES AND A METHOD OF SELECTION OF HIGH AND LOW TUMORIGENIC CLONES. **1964**, 22, 314-20 18

2142	STUDIES IN VITRO ON SINGLE BEATING RAT-HEART CELLS. III. ENZYME CHANGES AND LOSS OF SPECIFIC FUNCTION IN CULTURE. **1964**, 86, 65-73	21
2141	ON A UNIFYING CONCEPT OF CANCER. **1964**, 3, 917-28	
2140	CARCINOGENESIS THROUGH SOLID STATE SURFACES. **1964**, 5, 85-133	126
2139	CONFIRMATION OF THE SOURCE OF ELEVATED URINARY LACTIC DEHYDROGENASE IN PATIENTS WITH RENAL TUMOR. **1964**, 92, 416-23	24
2138	Studies on the development, biochemistry, and biology of experimental hepatomas. **1965**, 9, 227-302	114
2137	Biochemistry of normal and leukemic leucocytes, thrombocytes, and bone marrow cells. **1965**, 9, 303-410	28
2136	Alterations in serum lactate dehydrogenase and its fourth and fifth isozymes in patients with prostatic carcinoma. **1965**, 94, 451-61	19
2135	The Significance of Glycolysis2. **1965**,	
2134	THE POSSIBLE ROLE OF RIBOFLAVIN DEFICIENCY IN EPITHELIAL NEOPLASIA. I. EPITHELIAL CHANGES OF MICE IN SIMPLE DEFICIENCY. **1965**, 18, 167-80	53
2133	Variations in the tumour-forming capacity of a line of rat fibroblasts (16C) following selection in vitro. **1965**, 19, 840-54	1
2132	Tests for carcinogenicity of asbestos. **1965**, 132, 456-88	71
2131	[Activity of creatine kinase and other enzymes of the carbohydrate and protein metabolism in benign and malignant tumors of man. Enzyme studies of human tumors. I]. **1965**, 43, 807-13	7
2130	Effect of toxohormone-like substances on respiratory adaptive production of catalase in Saccharomyces cerevisiae. **1965**, 9, 65-73	1
2129	BACTERIAL MENINGITIS--A REVIEW OF SELECTED ASPECTS. I. GENERAL CLINICAL FEATURES, SPECIAL PROBLEMS AND UNUSUAL MENINGEAL REACTIONS MIMICKING BACTERIAL MENINGITIS. **1965**, 272, 898-902 CONTD	43
2128	Intra-arterial hydrogen peroxide and tissue oxygenation. **1965**, 5, 463-70	3
2127	EFFECT OF OXYGEN AND CARBON DIOXIDE CONCENTRATION UPON THE DEVELOPMENT OF HEMATOGENOUS METASTASES AND TRANSPLANTS. **1965**, 5, 90-4	1
2126	METABOLIC CHARACTERISTICS OF EXPERIMENTAL HAMSTER POUCH CARCINOMAS. **1965**, 20, 336-9	22
2125	The precancerous oral lesion. **1965**, 20, 58-70	22

2124	Enzyme histochemistry of human oral carcinoma. **1966**, 21, 764-9	3
2123	Antibody to lactate dehydrogenase. I. Inhibition of glycolysis in tumor and liver homogenates. **1966**, 130, 469-76	4
2122	Histochemical studies of enzymatic patterns during experimental carcinogenesis in the mouse parotid gland. **1966**, 11, 1269-91	10
2121	The internal milieu of tumors. **1966**, 8, 1-25	68
2120	The effect of calcium ions on the glycolytic activity of Ehrlich ascites-tumour cells. **1966**, 101, 480-7	45
2119	Metabolic Control Mechanisms in Insects. **1966**, 3, 133-205	14
2118	Heat fractionation of urine lactic acid dehydrogenase and combined cytopathologic evaluation in the diagnosis of cancer of the urinary tract. **1966**, 96, 551-8	8
2117	The role of diabetogenic hyperinsulinism in the pathogenesis of prostatic hyperplasia and malignancy. **1966**, 14, 795-825	11
2116	A chemical approach to the problem of cellular malignancy in tumours of the nervous system. **1966**, 15, 33-9	3
2115	Fundamental features of the "minimal deviation" hepatoma 5123. **1966**, 53, 228-9	2
2114	Biochemical studies of human tumors. I. Estimation of tumor malignancy from metabolic measurements in vitro. **1966**, 19, 89-102	13
2113	[Enzyme patterns of benign and malignant changes in human tissue. Enzyme studies on human tumors. 3]. **1966**, 44, 887-95	1
2112	The quantitative histochemistry of a chemically induced ependymoblastoma. I. Enzymes. **1966**, 13, 1197-206	32
2111	Preparation and properties of mitochondria from mammalian cells cultured in vitro. **1966**, 113, 421-37	17
2110	DIFFERENTIATION OF ERYTHROID CELL***. **1966**, 16, 457-486	
2109	A comparison of the anaerobic glycolysis of human brain and glioblastoma. **1967**, 27, 45-51	7
2108	On the Significance of Glucolysis for Cancer Growth, With Special Reference to Morris Rat Hepatomas2. **1967**,	2
2107	Glycogen metabolism in Novikoff ascites-hepatoma cells. **1967**, 102, 468-77	15

2106	The kidney as host in cancer-to-cancer metastasis. **1967**, 98, 657-60	17
2105	Lactate dehydrogenase isoenzymes in hyperplasia and carcinoma of the prostate: a clinical study. **1967**, 98, 686-92	26
2104	The enzymic pattern of neoplastic tissue. **1967**, 10, 117-61	42
2103	Recent Advances in Chemical Composition and Metabolism of Brain Tumors. **1968**, 2, 203-266	2
2102	Lactic, Pyruvic, Citric, and Uric Acid and Urea Content of Human Gastric Juice. **1967**, 53, 42-48	27
2101	Relationship between viral neurotropism and oncolysis. I. Study of vaccinia virus. **1967**, 20, 433-9	12
2100	Structural and metabolic distinction between Morris hepatoma 5123 A and normal rat liver. **1967**, 2, 344-54	15
2099	The ionic environment and metabolic control. **1967**, 214, 667-71	182
2098	Quantitative changes in the phosphorus fractions of transplanted brain tumors during complete ischemic incubation. **1967**, 23, 586-8	1
2097	Endocrine factors in the development of transplantable adrenal cortical tumors. I. Inhibition of the growth rate by corticotropin (ACTH). **1968**, 3, 531-45	
2096	Kinetics of gas diffusion in mammalian cell culture systems. II. Theory. **1968**, 10, 741-763	70
2095	Carbohydrate metabolism in cancer cells and the molecular correlation concept. **1968**, 55, 418-29	60
2094	Altered LDH isoenzymes in brain tumors. **1968**, 18, 311-5	27
2093	Tolerance of an experimental glioma to temporary ischemia. **1968**, 19, 321-4	2
2092	The Spectre of Today's Environmental Pollution USA Brand: New Perspectives from an Old Scout. **1969**, 30, 195-217	2
2091	[Metabolic modifications, ex vivo, of tumor cells during the growth of an experimental ascites tumor of the C3H mouse]. **1969**, 5, 85-9	6
2090	Asthma, arsenic, and cancer. **1969**, 44, 315-9	10
2089	Uptake of 51Cr-beta-glycerophosphate by experimental brain tumor. **1969**, 72, 350-5	

2088	Lactate dehydrogenase isoenzymes in carcinoma of the bladder: a clinical study. **1969**, 1, 199-203	1
2087	The significance of the structural and functional similarities of bacteria and mitochondria. **1969**, 25, 55-129	78
2086	HISTOCHEMICAL STUDY ON CARBOHYDRATE METABOLISM OF ASCITES HEPATOMA AH 13 AND AH 39 CELLS. **1969**, 2, 147-163	
2085	Lactate dehydrogenase isozymes of 3-2'-dimethyl-4-amino biphenyl-induced breast carcinoma. **1969**, 23, 446-51	2
2084	Serum lactate dehydrogenase isoenzyme changes in carcinoma of the prostate. **1970**, 103, 770-3	6
2083	Effect of stilbestrol on the isoenzymes of lactate dehydrogenase in benign and malignant prostatic tissue. **1970**, 104, 453-6	7
2082	The characteristics of animal cells transformed in vitro. **1970**, 13, 169-215	73
2081	Paraquat toxicity. **1970**, 3, 462-3	6
2080	Paraquat toxicity. **1970**, 4, 243	1
2079	Changes in the Activity of Certain Enzymes of Acer pseudoplatanus L. Cells at four Stages of Growth in Suspension Culture. **1970**, 23, 1212-1222	19
2078	LDH isoenzymes in benign and malignant prostate tissue. The LDH V-I ratio as an index of malignancy. **1970**, 25, 863-6	33
2077	Selective cancer growth inhibition in mice by dihydroxypropanal without concomitant inhibition of bone marrow or other normal tissue. **1970**, 24, 210-22	11
2076	Petite mutants induced in yeast by optical brighteners. **1971**, 13, 149-54	16
2075	Oxygen consumption of endometrial adenocarcinoma. **1971**, 109, 874-8	4
2074	Problems posed by observations of serum enzyme changes in toxicology. **1971**, 1, 1-32	44
2073	Definition of cancer research. **1971**, 231, 271-2	12
2072	Ultrastructural alteration of the mitochondrial electron transport chain involving electron leak: possible basis of "respiratory impairment" in certain tumors. **1971**, 30, 533-43	7
2071	On the nature of the synthesis of adenosine triphosphate at the surface of intact tumor cells. **1971**, 81, 431-2	8

2070	Fluctuation of lipid content in Ehrlich carcinoma cells during the growth period. **1972**, 108, 63-77	1
2069	Inhibition of mouse ascites tumors by carbohydrate combined with immunization. **1972**, 50, 156-63	9
2068	Mitochondrial alterations associated with avian reticuloendotheliosis virus (strain T) pathogenicity. **1972**, 48, 605-11	9
2067	Experimental oral pathology in the Syrian hamster. **1972**, 16, 518-38	94
2066	Epilogue: Quo Vadis?1. **1972**,	
2065	Glycolytic and respiratory enzyme activity in relation to leucocyte maturation. **1972**, 23, 79-87	3
2064	[Significance of glucose for production of energy and its influence on concentration of nucleotides in Ehrlich ascites tumor cells]. **1972**, 77, 292-9	1
2063	Contact-inhibited revertant cell lines isolated from SV40-transformed cells. V. Contact inhibition of sugar transport. **1973**, 81, 95-103	46
2062	A re-examination of the genetic effects of optical brighteners in yeast. **1973**, 21, 73-82	15
2061	Mitochondrial modification and respiratory deficiency in the yeast cell caused by cadmium poisoning. **1973**, 21, 315-322	21
2060	Comparative study of cytochromes between virus-transformed and untransformed cells. **1973**, 305, 493-502	7
2059	On the malignant transformation of cells during prolonged culture under hypoxic conditions in vitro. **1973**, 7, 241-52	14
2058	Isozymes and cancer. **1973**, 18, 77-153	90
2057	Pasteur effect and phosphofructokinase. **1974**, 8, 297-345	106
2056	Present Status of the Concept of Promoting Action and Cocarcinogenesis in Skin1. **1974**, 1, 155-225	2
2055	Ultrastructural studies of cell-virus interaction in reptilian cell lines. II. Distribution, incidence, and factors enhancing the production of intramitochondrial virions. **1974**, 53, 533-40	7
2054	Cutaneous manifestations of arsenic poisoning due to certain Chinese herbal medicine. **1974**, 15, 121-31	23
2053	Transport of sugars in tumor cell membranes. **1974**, 355, 77-104	94

2052	Energy coupling and extramitochondrial electron transport in slices of Morris hepatoma 3924 A. **1974**, 81, 37-50	2
2051	Retention of calcium by mitochondria isolated from Ehrlich ascites tumor cells. **1974**, 165, 744-8	31
2050	Inhibition by calcium of adenine nucleotide translocation in mitochondria isolated from Ehrlich ascites tumour cells. **1974**, 41, 118-21	20
2049	Analysis of nucleotide pools in animal cells. **1973**, 7, 361-462	67
2048	Cellular metabolism and environment. **1975**, 8, 43-8	2
2047	Enzyme cytochemistry of blood and marrow cells. **1975**, 7, 471-87	20
2046	Effects of Glucose Starvation on Normal and Rous Sarcoma Virus-Transformed Chick Cells2. **1975**,	
2045	ARSENIC POISONING FROM ANTI-ASTHMATIC HERBAL PREPARATIONS. **1975**, 2, 424-428	67
2044	Effects of reducing and oxidizing agents on the adenylate cyclase activity in adipocyte plasma membranes. **1976**, 65, 96-8	46
2043	Thermography to detect breast cancer. **1976**, 295, 1082-3	2
2042	Proliferation of Rous sarcoma virus-infected, but not of normal, chicken fibroblasts in oxygen-enriched environment: preliminary report. **1976**, 73, 1265-8	8
2041	Effects of fasting on growth and glycolysis of the Ehrlich ascites tumor. **1976**, 56, 427-8	8
2040	Histochemical patterns in early lesions and infiltrating adenocarcinomas induced in mouse duodenum by n-ethyl-n'-nitro-n-nitrosoguanidine. **1976**, 56, 791-5	1
2039	Aerobic glycolysis during lymphocyte proliferation. **1976**, 261, 702-5	253
2038	Effect of various antitumor drugs on energetic processes. **1976**, 8, 369-77	2
2037	Glutathione content of human skin carcinomas. **1976**, 257, 53-5	29
2036	The effect of oxygen tension on the growth and metabolism of WI-38 cells. **1976**, 89, 235-49	134
2035	Foreign body tumorigenesis. **1976**, 4, 353-94	59

2034	The migrating thermodynamic quantum hypothesis for cytoplasmic streaming, sodium pumping and other cell biological phenomena, deduced from biofunctional considerations of the ultrastructure of brush border microvilli. **1976**, 81, 201-12		1
2033	The effect of oxygen and vitamin E on the lifespan of human diploid cells in vitro. **1977**, 74, 58-67		81
2032	Expression of murine sarcoma virus genes in uninfected rat cells subjected to anaerobic sress. *Science*, **1977**, 197, 1371-4	33.3	28
2031	Mitosis and hyperthermia: a hypothesis. **1977**, 21, 5-20		2
2030	Enzymology of cancer cells (second of two parts). **1977**, 296, 541-51		410
2029	Hypoxia in neoplastic tissue. **1977**, 13, 399-408		164
2028	Density-dependent changes in hexose transport, glycolytic enzyme levels, and glycolytic rates, in uninfected and murine sarcoma virus-transformed rat kidney cells. **1977**, 110, 387-97		12
2027	Mitochondrial Calcium during Liver Carcinogenesis due to Thioacetamide and 4 - Dimethylaminoazobenzene. **1977**, 63, 7-14		1
2026	Alkalotic disequilibrium in patients with solid tumors: rediscovery of an old finding. **1977**, 13, 793-800		6
2025	Diversity of metabolic patterns in human brain tumors--I. High energy phosphate compounds and basic composition. **1977**, 29, 959-77		82
2024	Identification of the mammalian DNA-binding protein P8 as glyceraldehyde-3-phosphate dehydrogenase. **1977**, 81, 557-62		74
2023	Changes in lactate dehydrogenase isoenzyme patterns in patients with tumours of the central nervous system.?. **1977**, 36, 71-81		20
2022	Studies of mitochondria and mitochondrial DNA extracted from organelles harboring an intramitochondrial virus. **1977**, 14, 129-33		2
2021	Resurgence of glycogen synthesis and storage capacity in cultured hepatoma cells. **1978**, 7, 61-71		25
2020	The mode of mitochondrial degeneration in gliomas. **1978**, 43, 229-37		10
2019	Application of a microchemical technique to the elucidation of enzyme activity profiles within single human mammary tumors. **1978**, 41, 1863-70		5
2018	Influence of hormones on NADH-dehydrogenase in mouse liver plasma membrane. **1978**, 83, 234-40		25
2017	Rapid loss of ATP by tumor cells deprived of glucose: contrast to normal cells. **1978**, 82, 787-94		33

2016	5-Thio-D-glucose selectively potentiates hyperthermic killing of hypoxic tumor cells. *Science*, **1978**, 200, 206-7	33.3	57
2015	Some experiments with respiratory deficient mutants of yeast (iSaccharomyces cerevisiae). **1978**, 12, 39-45		
2014	Clinical enzymology in cancer. **1978**, 9, 85-104		
2013	Aerobic glycolysis and lymphocyte transformation. **1978**, 174, 703-9		128
2012	Hypercalcemia complicating childhood malignancies: a report of seven cases with some pathophysiological considerations. **1979**, 44, 2280-90		16
2011	Selective cytotoxicity of tunicamycin for transformed cells. **1979**, 24, 60-6		29
2010	CO2 biodynamics: a new concept of cellular control. **1979**, 80, 537-51		86
2009	Toxic and mutagenic effects of carcinogens on the mitochondria of Saccharomyces cerevisiae. **1979**, 174, 39-46		62
2008	Abnormal mitochondrial DNA in acute leukaemia and lymphoma. **1979**, 43, 201-6		20
2007	Early changes in the synthesis of proteins with affinity for single-stranded DNA during the onset of transformation in NRK cells. **1979**, 563, 320-35		3
2006	Cell surface glycoproteins and malignant transformation. **1978**, 60, 1221-33		31
2005	A candidate rat-specific gene product of the Kirsten murine sarcoma virus. **1979**, 99, 31-48		25
2004	Elemental Trace Analysis of Biological Materials. **1979**, 8, 287-320		5
2003	The association of DNA and RNA with membranes. **1979**, 61, 1-61		38
2002	Preferential Inhibition by Quercetin of Mitogen-Stimulated Thymocyte Glucose Transport2. **1979**,		
2001	Pyruvate dehydrogenase complex of ascites tumour. Activation by AMP and other properties of potential significance in metabolic regulation. **1980**, 190, 705-10		24
2000	Significance of serum lactic dehydrogenase in stages B and C non-seminomatous testis tumors. **1980**, 123, 516-7		22
1999	Isolation of a Chinese hamster fibroblast mutant defective in hexose transport and aerobic glycolysis: its use to dissect the malignant phenotype. **1980**, 77, 2698-701		90

1998	Physiology aspects of pyridine nucleotide regulation in mammals. **1980**, 33, 135-43	36
1997	Evolution and cancer: possible relationships to changes in environmental hydrogen ion concentration. **1980**, 86, 487-92	9
1996	Covalent binding of polycyclic aromatic compounds to mitochondrial and nuclear DNA. **1980**, 287, 244-5	180
1995	Relationship between increased aerobic glycolysis and DNA synthesis initiation studied using glycolytic mutant fibroblasts. **1980**, 287, 445-7	42
1994	Metastasis of cancer to cancer. **1980**, 30, 293-300	6
1993	Effects of 5-thio-D-glucose on cellular adenosine triphosphate levels and deoxyribonucleic acid rejoining hy hypoxic and aerobic Chinese hamster cells. **1980**, 137, 203-11	27
1992	Metabolic control mechanisms in precancerous liver. **1980**, 7, 189-218	2
1991	Regulation of cellular energy metabolism: the Crabtree effect. **1980**, 591, 209-23	67
1990	The reversibility of cancer: the relevance of cyclic AMP, calcium, essential fatty acids and prostaglandin E1. **1980**, 6, 469-86	74
1989	The extra nuclear control of mitosis & cell function. A theory of cellular organisation. **1980**, 6, 145-92	11
1988	Cytochalasin B binding to Ehrlich ascites tumor cells and its relationship to glucose carrier. **1981**, 642, 392-404	26
1987	Restriction endonuclease analysis of mitochondrial DNA from virus-transformed, tumor and control cells of human, hamster and avian origin. Sequence conservation and intraspecific variation. **1981**, 655, 210-20	8
1986	Cell division in normal and transformed cells: the possible role of superoxide and hydrogen peroxide. **1981**, 7, 21-42	115
1985	Role of aerobic conditions in the control of cell proliferation. **1981**, 65, 250-6	6
1984	Regulation of glucose utilization in chick embryo fibroblasts by bicarbonate ion. **1981**, 107, 295-302	5
1983	Differences in oxygen-dependent regulation of enzymes between tumor and normal cell systems in culture. **1981**, 108, 393-400	31
1982	Evidence for activation of an active electrogenic proton pump in Ehrlich ascites tumor cells during glycolysis. **1981**, 61, 143-53	42
1981	Hemodialysis of amino acids: basic studies in vitro. **1981**, 2, 153-64	3

1980	Handbook of Stable Strontium. **1981**,	4
1979	Maximum activities of some enzymes of glycolysis, the tricarboxylic acid cycle and ketone-body and glutamine utilization pathways in lymphocytes of the rat. **1982**, 208, 743-8	175
1978	Decreased uptake and retention of rhodamine 123 by mitochondria in feline sarcoma virus-transformed mink cells. **1982**, 28, 7-14	82
1977	Metabolic approaches to cancer cachexia. **1982**, 2, 277-301	142
1976	A 'hexokinase effect' in the inhibition of oxidative phosphorylation in heart muscle mitochondria by adriamycin. **1982**, 105, 1440-5	8
1975	Enhancement of hyperthermia-induced cytotoxicity upon ATP deprivation. **1982**, 15, 61-5	20
1974	Microbiological models as screening tools for anticancer agents: potentials and limitations. **1982**, 36, 415-33	18
1973	Stereological analysis of nasal mucosa. **1982**, 40, 311-325	15
1972	Might cancer be a failed response to renegade mitochondria?. **1982**, 94, 173-8	11
1971	Hydrogen ion dynamics and cancer: an appraisal. **1982**, 10, 217-36	21
1970	Theoretical aspects of weight loss in patients with cancer. Possible importance of pyruvate dehydrogenase. **1982**, 50, 2183-8	12
1969	Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using 15O and positron emission tomography: analytical techniques and preliminary results. **1982**, 23, 63-74	168
1968	Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: a new tracer for cancer detection. **1982**, 7, 294-7	62
1967	Microvascular abnormalities in ethylnitrosourea (ENU)-induced rat brain tumors: structural basis for altered blood-brain barrier function. **1983**, 59, 1-10	58
1966	Carcinogenesis from the standpoint of view of molecular geometry and synergism: relevance of oxygen and magnesium. **1983**, 11, 177-84	1
1965	Cancer, a disease of defective glucose metabolism. **1983**, 10, 133-50	8
1964	The fundamental chemistry of life. An attempt to define and identify the basic reaction responsible for life's creation and evolution. **1983**, 12, 359-67	2
1963	The efficiency of (Na+ + K+)-ATPase in tumorigenic cells. **1983**, 730, 271-5	12

1962	Tumor effects on gluconeogenesis in the isolated perfused rat liver. **1983**, 7, 105-9	13
1961	Appearance of a cytosolic protein that stimulates glyceraldehyde-3-phosphate dehydrogenase activity during initiation of renal epithelial cell growth. **1983**, 80, 2941-5	15
1960	Mitochondria, cell surface, and carcinogenesis. **1983**, 15, 157-89	11
1959	PET scanning of human brain tumors. **1984**, 27, 154-69	8
1958	Correlation of experimental and clinical studies of metabolism by PET scanning. **1984**, 27, 170-8	17
1957	The effect of the drug lonidamine on Chinese hamster ovary cells in vitro and on experimental tumors. **1984**, 10, 1595-8	4
1956	Cell cycle regulation by environmental pH. **1984**, 121, 517-25	58
1955	Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. **1984**, 15 Suppl, S138-46	99
1954	Cytochemical changes in lactate dehydrogenase isoenzymes in human brain tumours. **1984**, 71, 243-53	4
1953	Activity of enzymes related to carbohydrate metabolism in the HT 29 colon adenocarcinoma cell line and tumor. **1984**, 16, 87-91	19
1952	Biochemical characterization of three hamster melanoma variants--II. Glycolysis and oxygen consumption. **1984**, 16, 327-31	32
1951	Transformation-associated changes in nuclear-coded mitochondrial proteins in 3T3 cells and SV40-transformed 3T3 cells. **1984**, 804, 285-90	3
1950	A hypothesis on the pathogenesis of rheumatoid and other non-specific synovitides. IV A. The possible intermediate role of local hypoxia and metabolic alterations. **1984**, 13, 257-302	26
1949	Positron emission tomography in the study of human tumors. **1984**, 14, 324-41	81
1948	A general model for the light and electron microscopic morphometry/stereology (M & S) of precancerous epithelial transformation using clinical biopsies. **1984**, 179, 210-5	3
1947	Effects of Lonidamine on murine and human tumor cells in vitro. A morphological and biochemical study. **1984**, 41 Suppl 1, 15-29	35
1946	Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. **1985**, 228, 353-61	160
1945	Suppression of temperature sensitive mutations in oncogene-related CDC genes in Saccharomyces cerevisiae by catabolite repression resistance and cytoplasmic petite mutations. **1985**, 10, 35-7	2

1944	The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. **1985**, 5, 393-400	301
1943	Total parenteral nutrition with and without fat as substrate for growth of rats and transplanted hepatocarcinoma. **1985**, 9, 422-7	10
1942	Prediction of survival in glioma patients by means of positron emission tomography. **1985**, 62, 816-22	303
1941	Nutrition and cancer: physiological interrelationships. **1985**, 5, 435-61	73
1940	Differences in the reduction kinetics of incorporated spin labels in undifferentiated and differentiated mouse neuroblastoma cells. **1985**, 845, 189-95	30
1939	Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro. **1986**, 64, 918-23	34
1938	Inflammation, glycolytic metabolism, and glycosaminoglycans. **1986**, 30, 1-19	10
1937	Metabolism of 2-[18F]fluoro-2-deoxyglucose in tumor-bearing rats: chromatographic and enzymatic studies. **1986**, 13, 577-81	8
1936	The role of oxygen deficiency and cytosolic reactions in cell growth. **1986**, 21, 185-92	1
1935	Oxygen free radicals play a role in cellular differentiation: an hypothesis. **1986**, 2, 175-81	53
1934	Chapter 8 Energy Metabolism of Cellular Activation, Growth, and Transformation. **1986**, 261-291	26
1933	The oxidation of body fuel stores in cancer patients. **1986**, 204, 637-42	42
1932	Preferential accumulation of 11C in human brain tumors after intravenous injection of 11C-1-pyruvate. **1986**, 12, 244-8	6
1931	Glucose transport across the blood-brain barrier in normal human subjects and patients with cerebral tumours studied using [11C]3-O-methyl-D-glucose and positron emission tomography. **1986**, 6, 230-9	47
1930	Studies on regional cerebral pH in patients with cerebral tumours using continuous inhalation of 11CO2 and positron emission tomography. **1986**, 6, 529-35	15
1929	Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. **1986**, 1, 279-91	44
1928	Quantitative evaluation of leukemic mitochondria with a computer-controlled image analyzer. **1986** , 51, 375-84	10
1927	Glutaminolysis in Animal Cells. **1986**, 111-150	55

1926	Localization of aflatoxin B1--nucleic acid adducts in mitochondria and nuclei. **1987**, 8, 109-14	15
1925	Oxidative metabolism and glycolysis in benign brain tumors. **1987**, 67, 336-40	10
1924	Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages. **1987**, 242, 631-6	249
1923	Pyruvate kinase isozymes in oocytes and embryos from the frog Xenopus laevis. **1987**, 88, 743-9	4
1922	Metabolic iteration, evolution and cognition in cellular proliferation. **1987**, 43, 1094-9	1
1921	Glucose utilization in vivo by human pulmonary neoplasms. **1987**, 60, 2682-9	208
1920	Regulation of the pentose phosphate pathway in human astrocytes and gliomas. **1987**, 2, 31-46	24
1919	Are mitochondrial DNA mutations involved in the carcinogenic process?. **1987**, 186, 149-60	111
1918	Carbohydrate metabolism of the rat C6 glioma. An in vivo 13C and in vitro 1H magnetic resonance spectroscopy study. **1988**, 1, 20-6	43
1917	Adenosine-5'-triphosphate levels in experimental CaNT and Fib/t tumours of varying volume and degree of hypoxia. **1988**, 44, 232-4	2
1916	The natural history of a family of transplantable melanomas in hamsters. **1988**, 7, 95-118	59
1915	Effect of lonidamine on human malignant gliomas: biochemical studies. **1988**, 6, 203-9	12
1914	Mitochondrial membrane potential in living cells. **1988**, 4, 155-81	850
1913	Tumor invasion: a consequence of destructive and compositional matrix alterations. **1988**, 19, 628-39	134
1912	Metastatic carcinoma to pituitary adenoma. Report of two cases. **1988**, 30, 286-92	35
1911	Phospholipid and energy metabolism of cancer cells monitored by 31P magnetic resonance spectroscopy: possible clinical significance. **1988**, 63, 1199-207	32
1910	Analysis of antioxidant defense systems during rat hepatocarcinogenesis. **1988**, 9, 2009-13	26
1909	Enolase isoenzymes in adult and developing Xenopus laevis and characterization of a cloned enolase sequence. **1988**, 251, 31-9	42

1908	Mitochondria. **1988**, 191-328	14
1907	Creatine kinase and lactate dehydrogenase isoenzymes in serum and tissues of patients with stomach adenocarcinoma.. **1989**, 35, 1385-1389	16
1906	Activities of glycolytic enzymes in rapidly proliferating and differentiated C6 glioma cells. **1989**, 57, 159-64	3
1905	Oncogene-associated tumor antigens as targets for immunotherapy. **1989**, 3, 1715-22	46
1904	Enhanced glucose transport in response to inhibition of respiration in Clone 9 cells. **1989**, 257, C19-28	58
1903	Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. **1989**, 124, 197-200	50
1902	Oxidative influence on development and differentiation: an overview of a free radical theory of development. **1989**, 6, 631-61	220
1901	Studies on the mechanism of cytotoxicities of polyacetylenes against L1210 cell. **1989**, 12, 207-213	32
1900	Amplification or obfuscation: is localization improving our clinical understanding of phosphorus metabolism?. **1989**, 2, 340-5	8
1899	2-Deoxy-D-glucose inhibits the antitumor effects of alpha-difluoromethylornithine on the growth of colon cancer in vivo. **1989**, 7, 131-8	
1898	A non-parametric grading system for intestinal metaplasia: correlations with gastric tissue enzymes. **1989**, 158, 297-301	
1897	Metabolic control of glucose degradation in yeast and tumor cells. **1989**, 39, 1-28	16
1896	Metabolic regulation during early frog development: glycogenic flux in Xenopus oocytes, eggs, and embryos. **1989**, 132, 512-23	39
1895	Increased level of the mitochondrial ND5 transcript in chemically induced rat hepatomas. **1989**, 184, 158-66	38
1894	Genetic toxicology of oxygen. **1989**, 219, 193-208	156
1893	The effects of 2-deoxy-D-glucose and alpha-difluoromethylornithine on the growth of pancreatic cancer in vivo. **1989**, 4, 38-43	3
1892	The relation of ATP response in CaNT tumours after X-irradiation to varying tumour volumes. **1989**, 46, 400-4	2
1891	Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. **1990**, 265, 503-9	158

1890	Phosphofructokinase and pyruvate kinase in mouse embryonal carcinoma P19 cells in relation to growth and differentiation. **1990**, 45, 199-205	6
1889	Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging?. **1990**, 8, 523-39	449
1888	Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. **1990**, 19, 1005-10	53
1887	A unifying model of the cell proliferation emphasizing plasma membrane fluxes. **1990**, 46, 993-9	
1886	Exogenous Lactate Modifies the Repair of Potentially Lethal Damage in Three Human Tumor Cell Lines Irradiated in Vitro. **1990**, 124, 110	2
1885	Heterogeneity of the glucose transporter in malignant and suppressed hybrid cells. **1990**, 188, 97-104	11
1884	Metabolic control analysis of mammalian serine metabolism. **1990**, 30, 13-32	40
1883	Identification of genes that exhibit increased expression after flat reversion of NIH/3T3 cells transformed by human activated Ha-ras oncogene. **1991**, 59, 37-43	7
1882	Carbon metabolism in early amphibian embryos. **1991**, 16, 229-34	25
1881	Binding of cathepsin D to the mannose receptor on rat peritoneal macrophages. **1991**, 1095, 1-4	7
1880	Thimerosal induces calcium mobilization, fructose 2,6-bisphosphate synthesis and cytoplasmic alkalinization in rat thymus lymphocytes. **1991**, 1091, 110-4	13
1879	Mammalian glucose transporters: structure and molecular regulation. **1991**, 47, 349-87; discussion 387-8	41
1878	Glutamine and glucose metabolism in rat splenocytes and mesenteric lymph node lymphocytes. **1991**, 260, E141-7	20
1877	Tumour pH and response to chemotherapy: an in vivo 31P magnetic resonance spectroscopy study in non-Hodgkin's lymphoma. **1991**, 64, 923-8	12
1876	Regulation of intracellular glutathione levels and lymphocyte functions by lactate. **1991**, 136, 95-104	22
1875	Non-invasive in vivo localized 1H spectroscopy of human astrocytoma implanted in rat brain: regional differences followed in time. **1991**, 4, 125-32	14
1874	Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes. **1991**, 13, 297-303	47
1873	Regulation of interleukin 2 production, interleukin 2 mRNA expression and intracellular glutathione levels in ex vivo derived T lymphocytes by lactate. **1991**, 21, 1933-7	42

1872	1H and 31P NMR and HPLC studies of mouse L1210 leukemia cell extracts: the effect of Au(I) and Cu(I) diphosphine complexes on the cell metabolism. **1991**, 18, 142-58	41
1871	Biology of pancreatic cancer. **1991**, 32, 800-12	61
1870	Adenylate cyclase activity in crude liver membranes during chemical hepatocarcinogenesis. **1991**, 12, 659-64	2
1869	Aberrant Sexual Behavior, Violence, and Reproduction. **1992**, 18, 231-241	2
1868	Glycolysis module activated by hypoxia-inducible factor 1 is related to the aggressive phenotype of hepatocellular carcinoma. **1992**, 33, 725	4
1867	The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. **1992**, 216, 27-34	124
1866	Glucocorticoid protects hepatoma cells against metabolic stress-induced cell death. **1992**, 33, 1263	2
1865	The primordial thesis of cancer. **1992**, 37, 20-3	2
1864	Alpha-enolase is restricted to basal cells of stratified squamous epithelium. **1992**, 151, 18-26	64
1863	The role of positron emission tomography in oncology and other whole-body applications. **1992**, 22, 268-84	59
1862	FDG transport and phosphorylation in human gliomas measured with dynamic PET. **1992**, 12, 159-65	45
1861	A study to investigate the incidence of early satiety in patients with advanced cancer. **1992**, 65, 481-4	12
1860	The contribution made by cell death and oxygenation to 31P MRS observations of tumour energy metabolism. **1992**, 5, 279-89	50
1859	Glycogen breakdown in cleaving Xenopus embryos is limited by ADP. **1992**, 32, 354-62	7
1858	In vivo imaging of glucose consumption and lactate concentration in human gliomas. **1992**, 31, 319-27	101
1857	Localized detection of glioma glycolysis using edited 1H MRS. **1993**, 30, 18-27	66
1856	Effect of glucose-mediated pH reduction and cyclophosphamide on oxygenation of transplanted rat tumors. **1993**, 25, 465-71	6
1855	Metabolic regulation of glucose transport. **1993**, 135, 1-10	68

1854	Glucose metabolism by brown trout peripheral blood lymphocytes. **1993**, 163, 118	1
1853	Modulation of mammalian cell proliferation by a modified tRNA base of bacterial origin. **1993**, 336, 137-42	20
1852	Differential cytotoxicity of buthionine sulfoximine to "normal" and transformed human lung fibroblast cells. **1993**, 33, 210-4	5
1851	Glucose effects in an ovarian cancer protocol of exceptional activity. **1993**, 40, 235-44	4
1850	Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging, and evaluation of chemotherapy. **1993**, 698, 423-8	28
1849	Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. **1993**, 90, 1127-31	164
1848	Positron emission tomography of thyroid masses. **1993**, 3, 195-200	60
1847	Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. **1993**, 79, 853-8	109
1846	Role of oxygen vs. glucose in energy metabolism in a mammary carcinoma perfused ex vivo: direct measurement by 31P NMR. **1993**, 90, 2646-50	45
1845	Nutritional and physiological consequences of tumour glycolysis. **1993**, 107 Suppl, S177-86	24
1844	Models of neoplasia and their diagnostic implications: a historical perspective. **1993**, 39, 2360-2374	18
1843	The prevalence of mtDNA4977 deletion in primary human endometrial carcinomas and matched control samples. **1994**, 20, 683	
1842	Contribution of Magnetic Resonance Spectroscopic Imaging and L-[1-11C]Tyrosine Positron Emission Tomography to Localization of Cerebral Gliomas for Biopsy. **1994**, 34, 994-1002	22
1841	Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells. **1994**, 86, 608-13	37
1840	Positron emission tomography scanning in cancer. **1994**, 12, 74-87	23
1839	Intracellular pH and the control of multidrug resistance. **1994**, 91, 1128-32	229
1838	Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies. **1994**, 31, 285-99	26
1837	Profile of energy metabolism in a murine hybridoma: glucose and glutamine utilization. **1994**, 161, 71-6	60

1836	A qualitative and quantitative protein database approach identifies individual and groups of functionally related proteins that are differentially regulated in simian virus 40 (SV40) transformed human keratinocytes: an overview of the functional changes associated with the transformed phenotype. **1994**, 15, 309-44	65
1835	Two patients with metastasis of cancer to other neoplasm: A thyroid carcinoma metastatic to a lung carcinoma and a gastric carcinoma metastatic to a thyroid adenoma. **1994**, 5, 233-239	6
1834	Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. **1994**, 1, 132-40	94
1833	The nutrient factor queuine protects HeLa cells from hypoxic stress and improves metabolic adaptation to oxygen availability. **1994**, 221, 979-86	25
1832	Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. **1994**, 27, 51-7	117
1831	Transformation linked decrease of pyruvate dehydrogenase complex in human epidermis. **1994**, 85, 239-43	9
1830	Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. **1994**, 58, 698-703	148
1829	FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. **1994**, 21, 827-34	109
1828	PET FDG studies in oncology. **1994**, 21, 739-47	28
1827	pO2- and pH-gradients in multicellular spheroids and their relationship to cellular metabolism and radiation sensitivity of malignant human tumor cells. **1994**, 1227, 105-12	21
1826	Insulin stimulates glycolysis and pentose cycle activity in bovine microvascular endothelial cells. **1994**, 108, 179-85	7
1825	Contributors Needed for New ES&T. **1994**, 28, 487A	
1824	Development and applications of mutational spectra technology. **1994**, 28, 478A-87A	1
1823	Inhibition of electron flow through complex I of the mitochondrial respiratory chain of Ehrlich ascites carcinoma cells by methylglyoxal. **1994**, 303 (Pt 1), 69-72	73
1822	Instability of the homogeneous state as the source of localization, epigenesis, differentiation, and morphogenesis. **1994**, 154, 309-75	12
1821	Pathophysiological Basis and Clinical Value of 18F-Fluorodeoxyglucose and Positron Emission Tomography in Pancreatic Adenocarcinoma. **1994**, 11, 360-365	2
1820	Contribution of magnetic resonance spectroscopic imaging and L-[1-11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. **1994**, 34, 994-1002; discussion 1002	35
1819	Cell biological mechanisms of multidrug resistance in tumors. **1994**, 91, 3497-504	321

1818	High-resolution 1H-magnetic resonance spectroscopy of pediatric posterior fossa tumors in vitro. **1994**, 81, 443-8	43
1817	Interleukin-3 facilitates glucose transport in a myeloid cell line by regulating the affinity of the glucose transporter for glucose: involvement of protein phosphorylation in transporter activation. **1995**, 305 (Pt 3), 843-51	53
1816	Substrate-dependent utilization of the glycerol 3-phosphate or malate/aspartate redox shuttles by Ehrlich ascites cells. **1995**, 310 (Pt 2), 665-71	19
1815	Effect of hematoporphyrin derivative on hematological parameters in rats. **1995**, 62, 320-5	2
1814	Mitochondria-bound hexokinase as target for therapy of malignant gliomas. **1995**, 62, 216-22	48
1813	Interaction of 7H-dibenzo[c,g]carbazole and its organspecific derivatives with hepatic mitochondrial and nuclear DNA in the mouse. **1995**, 25, 202-10	19
1812	Exogenous lactate interferes with cell-cycle control in Balb/3T3 mouse fibroblasts. **1995**, 31, 525-8	6
1811	On the principles underlying the diagnosis of brain tumours--a survey article. **1995**, 135, 1-11	3
1810	Metabolic patterns in malignant gliomas. **1995**, 24, 153-61	33
1809	Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. **1995**, 22, 32-9	50
1808	Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning. **1995**, 7, 334-5	25
1807	Ageing, oscillations and efficiency. **1995**, 36, 1-5	6
1806	Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case. **1995**, 25, 261-4	23
1805	Molecular genetic aspects of human mitochondrial disorders. **1995**, 29, 151-78	392
1804	Detection of scalene lymph node metastases from lung cancer. Positron emission tomography. **1995**, 107, 1174-6	12
1803	Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. **1995**, 36, 771-7	132
1802	Radiosynthesis, rodent biodistribution, and metabolism of 1-deoxy-1-[18F]fluoro-D-fructose. **1995**, 22, 719-25	16
1801	Some characteristics of the glutathione cycle revealed by ionising and non-ionising electromagnetic radiation. **1995**, 45, 345-68	2

1800	Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography. **1995**, 37, 198-206	45
1799	Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers. **1995**, 21, 280-3	46
1798	Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms. **1996**, 26, 65-73	34
1797	Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images. **1996**, 172, 628-32	56
1796	System A amino acid transport in cultured human tumor cells: implications for tumor imaging with PET. **1996**, 23, 779-86	25
1795	Evidence of sodium-dependent glucose transport in human erythroleukemia cells. **1996**, 58, 1445-52	5
1794	Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). **1996**, 35, 2811-7	229
1793	Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. **1996**, 23, 1641-74	386
1792	Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. **1996**, 23, 618-23	118
1791	Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. **1996**, 39, 470-6; discussion 476-7	104
1790	Positron emission tomography: present and future. **1996**, 4, 15-29	2
1789	Functional Imaging with Positron Emission Tomography in Patients with Malignant Melanoma. **1996** , 19, 253-259	1
1788	Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine. **1996**, 73, 966-71	62
1787	Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. **1996**, 9, 2560-4	61
1786	Hepatocyte growth factor and transforming growth factor beta regulate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in rat hepatocyte primary cultures. **1996**, 314 (Pt 1), 235-40	5
1785	Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. **1996**, 111, 642-8	156
1784	Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. **1996**, 78, 1098-106	96
1783	Dissecting the individuality of cancer cells: the morphological and molecular dynamics of single human glioma cells. **1996**, 35, 237-53	6

1782	Alteration of energy-linked functions in rat hepatic mitochondria following aflatoxin B1 administration. **1996**, 11, 235-41	10
1781	Deregulation of protein synthesis as a mechanism of neoplastic transformation. **1996**, 18, 243-50	44
1780	Positron emission tomography: a new investigational area for cancer research. **1996**, 8, 7-14	7
1779	Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. **1996**, 35, 103-11	222
1778	Proton magnetic resonance spectroscopic imaging of pediatric low-grade astrocytomas. **1996**, 12, 130-5	18
1777	High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. **1996**, 74, 839-45	97
1776	18F-fluorodeoxyglucose PET scans in lung cancer. **1996**, 51 Suppl 2, S16-22	13
1775	Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. **1996**, 88, 1204-9	172
1774	Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. **1996**, 271, 8719-24	91
1773	Altered glucose metabolism and the invasive tumor phenotype. **1996**, 8, 597	
1772	Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. **1997**, 7, 327-35	133
1771	Effect of growth factors on the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in Rat-1 fibroblasts. **1997**, 272, 2846-51	13
1770	GLUT1 glucose transporter expression in benign and malignant thyroid nodules. **1997**, 7, 363-7	87
1769	Is there a role for positron emission tomography scanning in HIV-positive patients with Kaposi's sarcoma and lymphadenopathy: two case reports. **1997**, 8, 709-12	5
1768	Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET. **1997**, 36, 741-7	39
1767	c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. **1997**, 94, 6658-63	817
1766	Effect of lactic acid in tumours on antitumour activity of hyperthermia. **1997**, 13, 115-23	3
1765	Insulin-like growth factor I induces tumor hexokinase RNA expression in cancer cells. **1997**, 235, 389-93	12

1764	PET in oncology: will it replace the other modalities?. **1997**, 27, 94-106	152
1763	Reassessment of FDG uptake in tumor cells: high FDG uptake as a reflection of oxygen-independent glycolysis dominant energy production. **1997**, 24, 665-70	19
1762	Improvement in staging of esophageal cancer with the addition of positron emission tomography. **1997**, 64, 770-6; discussion 776-7	202
1761	In vitro influence of sublethal hypoxia on differentiation of the 3T3-L1 preadipose cell line and its physiological implications. **1997**, 60, 1923-31	4
1760	The antineoplastic drug lonidamine interferes with the acidification mechanism of cell organelles. **1997**, 1358, 46-52	9
1759	Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. **1997** , 11, 388-95	328
1758	Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. **1997**, 4, 269-278	1
1757	Positron Emission Tomography for Diagnosis of Breast Tumors. **1997**, 20, 190-195	1
1756	Expression of GLUT1 in stratified squamous epithelia and oral carcinoma from humans and rats. **1997**, 105, 537-45	29
1755	Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation. **1997**, 75, 1605-12	41
1754	Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. **1997**, 75, 311-8	35
1753	Regulation of glucose transport by interleukin-3 in growth factor-dependent and oncogene-transformed bone marrow-derived cell lines. **1997**, 21, 609-18	19
1752	The quest by three giants of science for an understanding of cancer. **1997**, 21, 72-6	13
1751	Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies. **1997**, 43, 15-25	13
1750	Inactivation of glyceraldehyde-3-phosphate dehydrogenase of human malignant cells by methylglyoxal. **1997**, 177, 21-6	25
1749	Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. **1997**, 29, 331-8	80
1748	Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. **1997**, 29, 345-54	89
1747	Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. **1997**, 4, 57-63	85

1746	Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. **1997**, 4, 269-278	29
1745	[Diagnosis of breast carcinoma and locoregional lymph nodes with positron emission tomography]. **1997**, 37, 741-8	4
1744	Energy state in HT-29 cells is linked to differentiation. **1997**, 33, 277-81	5
1743	Novel monosaccharides as potent inhibitors of cell proliferation. **1997**, 15, 243-9	6
1742	Overexpression of recombinant human antithrombin III in Chinese hamster ovary cells results in malformation and decreased secretion of recombinant protein. **1997**, 53, 547-59	43
1741	Positron emission tomography as a diagnostic tool in oncology. **1998**, 8, 1481-94	42
1740	Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human cervical cancers. **1998**, 71, 266-9	44
1739	Somatic mutations of the mitochondrial genome in human colorectal tumours. **1998**, 20, 291-3	720
1738	Fdg-pet in clinical oncology: review and evaluation of results of a private clinical pet center. **1998**, 20, 168-179	
1737	Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved?. **1998**, 398, 19-26	93
1736	The role of FDG PET in the clinical management of head and neck cancer. **1998**, 34, 466-71	26
1735	Convergent effects of growth factors, hormones, and fibronectin are necessary for the enterocyte differentiation of a colon adenocarcinoma cell line (HT29-D4). **1998**, 63, 305-17	11
1734	Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. **1998**, 28, 700-6	166
1733	Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. **1998**, 82, 2227-2234	168
1732	GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. **1998**, 83, 34-40	249
1731	Hyperglycemia regulates the glucose-transport system of clonal choriocarcinoma cells in vitro. A potential molecular mechanism contributing to the adjunct effect of glucose in tumor therapy. **1998**, 78, 353-60	28
1730	Analysis of fluid in cysts accompanying various primary and metastatic brain tumours: proteins, lactate and pH. **1998**, 140, 14-9	14
1729	Role for glucose transporter 1 protein in human breast cancer. **1998**, 4, 115-20	110

1728	The mechanism of accumulation of tumour-localising radiopharmaceuticals. **1998**, 25, 277-305	90
1727	Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours. **1998**, 25, 559-64	50
1726	Long-term cultivation of a neuroblastoma cell line in medium with reduced serum content as a model system for neuronal aging?. **1998**, 27, 251-68	3
1725	Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism?. **1998**, 50, 55-9	93
1724	Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action. **1998**, 50, 501-6	28
1723	FDG accumulation and tumor biology. **1998**, 25, 317-22	271
1722	Recent advances in the analyses of the characteristics of tumors on FDG uptake. **1998**, 25, 589-92	19
1721	Gamma emission imaging in the management of breast disorders. **1998**, 24, 320-9	10
1720	Is absence of pyruvate dehydrogenase complex in mitochondria a possible explanation of significant aerobic glycolysis by normal human leukocytes?. **1998**, 425, 411-4	12
1719	The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease. **1998**, 124, 793-7; discussion 797-8	24
1718	Positron Emission Tomographic Imaging of Pleomorphic Adenoma in the Parotid Gland. **1998**, 118, 214-220	8
1717	Monitoring of Response to Radiotherapy with Fluorine-18 Deoxyglucose PET of Head and Neck Squamous Cell Carcinomas. **1998**, 118, 254-260	8
1716	Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. **1998**, 538, 209-13	22
1715	Mucosal mitochondrial function and antioxidant defences in patients with gastric carcinoma. **1998**, 33, 975-81	25
1714	Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. **1998**, 273, 5294-9	176
1713	Diagnosis of pancreatic carcinoma: role of FDG PET. **1998**, 171, 1565-70	95
1712	Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. **1998**, 20, 331-8	47
1711	Compartmentation of lactate and glucose metabolism in C6 glioma cells. A 13c and 1H NMR study. **1998**, 273, 27162-9	57

1710	Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. **1998**, 171, 1103-10	68
1709	RAF expression in human astrocytic tumors. **1998**, 23, 17	
1708	Diagnostik des duktalen Pankreaskarzinoms. **1998**, 14, 23-27	
1707	Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography. **1998**, 91, 3340-3346	260
1706	The Use of Human Tumor Cells Grown in Multicellular Spheroid Culture for Designing and Improving Therapeutic Strategies. **1998**, 1, 193-207	6
1705	Newer Imaging Modalities. **1998**, 5, 450-464	1
1704	Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. **1999**, 17, 41-5	288
1703	Emerging role of PET in the diagnosis and staging of lung cancer. **1999**, 6, 145-52	8
1702	What Is New in Nuclear Medicine Imaging?. **1999**, 8, 185-204	3
1701	. **1999**,	166
1700	Conference Record of the Thirty-Third Asilomar Conference on Signals, Systems, and Computers (Cat. No.CH37020). **1999**,	
1699	Positron emission tomography in breast cancer: a clinicopathological correlation of results. **1999**, 72, 1064-8	52
1698	Tumor necrosis factor-alpha stimulates lactate dehydrogenase A expression in porcine cultured sertoli cells: mechanisms of action. **1999**, 140, 3054-62	29
1697	Improvement of non-small-cell lung cancer staging by means of positron emission tomography. **1999**, 47, 42-7	32
1696	c-Myc target genes involved in cell growth, apoptosis, and metabolism. **1999**, 19, 1-11	1319
1695	18FDG-positron emission tomography in pancreatic cancer. **1999**, 10, S28-S32	6
1694	Positron emission tomography and the central nervous system. **1999**, 81, 263-70	10
1693	Imaging of pancreatic adenocarcinoma with radiolabeled monoclonal antibodies. **1999**, 10, S37-S40	1

1692	An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. **1999**, 96, 3047-52	220
1691	Antisense oligodeoxynucleotide of glyceraldehyde-3-phosphate dehydrogenase gene inhibits cell proliferation and induces apoptosis in human cervical carcinoma cell lines. **1999**, 9, 507-13	22
1690	Pgp-positive leukaemic cells have increased mtDNA but no increased rate of proliferation. **1999**, 107, 861-9	11
1689	Mechanisms of apoptosis by c-Myc. **1999**, 18, 2967-87	377
1688	Enhancement of chemotherapy by manipulation of tumour pH. **1999**, 80, 1005-11	231
1687	Rate of 14CO2 production from variously labeled forms of [14C]glucose in human breast invasive ductal carcinoma tissues. **1999**, 48, 409-11	1
1686	Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. **1999**, 26, 1547-52	218
1685	Posters: Spectroscopy applications: brain animal. **1999**, 8, 218-222	
1684	Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells. **1999**, 26, 419-30	134
1683	Role of organelle pH in tumor cell biology and drug resistance. **1999**, 4, 32-38	57
1682	Occult breast cancer: a challenge from a surgical perspective. **1999**, 8, 27-33	7
1681	The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. **1999**, 85, 803-11	38
1680	Tumour phospholipid metabolism. **1999**, 12, 413-39	501
1679	Causes and effects of heterogeneous perfusion in tumors. **1999**, 1, 197-207	198
1678	A biophysical basis of enhanced interstitial fluid pressure in tumors. **1999**, 53, 526-9	13
1677	18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). **1999**, 35, 1076-82	112
1676	Application of new imaging techniques for the evaluation of squamous cell carcinoma of the head and neck. **1999**, 20, 187-212	7
1675	Mitochondrial mutagenesis in human cells and tissues. **1999**, 434, 177-203	96

1674	On the promine/retine theory of cell division: now and then. **1999**, 1426, 1-16	31
1673	Uptake of glucose analogues by colonic tumour cells during growth and after treatment with hydroxyurea. **1999**, 141, 85-91	3
1672	Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. **1999**, 9, 797-804	85
1671	Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. **1999**, 456, 113-8	135
1670	Total Synthesis of Carba-d-fructofuranose via a Novel Metathesis Reaction. **1999**, 1, 1463-1465	28
1669	Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. **1999**, 14, 1376-80	106
1668	Immunhistochemischer Nachweis des Glukose-Transportproteins GLUT-1 in primären Ovarialkarzinomen - Ein Charakteristikum des malignen Phänotyps. **1999**, 59, 258-260	
1667	The role of positron emission tomography (PET) in the management of lymphoma patients. **1999**, 10, 1181-4	131
1666	Effect of Cisplatin on the Lactate Dehydrogenase Activity and its Isozyme Pattern in Dalton's Lymphoma Bearing Mice.. **1999**, 64, 259-267	7
1665	An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. **2000**, 200, 167-9	12
1664	Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. **2000**, 232, 743-52	206
1663	Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. **2000**, 88, 2774-2781	68
1662	Increased glyceraldehyde-3-phosphate dehydrogenase expression in renal cell carcinoma identified by RNA-based, arbitrarily primed polymerase chain reaction. **2000**, 89, 152-164	37
1661	Diagnostic imaging approaches and relationship to hepatobiliary cancer staging and therapy. **2000**, 19, 94-115	24
1660	Cerebral mucormycosis: proton MR spectroscopy and MR imaging. **2000**, 18, 915-20	35
1659	Redox regulation of p53 during hypoxia. **2000**, 19, 3840-8	140
1658	The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. **2000**, 120, 1085-92	141
1657	Effect of cisplatin on mitochondrial protein, glutathione, and succinate dehydrogenase in Dalton lymphoma-bearing mice. **2000**, 16, 363-73	24

1656	Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent primary serous peritoneal carcinoma: An initial report. **2000**, 77, 44-7	27
1655	Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. **2000**, 27, 731-43	188
1654	Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. **2000**, 126, 560-74	105
1653	Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer. **2000**, 7, 99-103	24
1652	Lymph node metastasis from breast cancer diagnosed by F-18 FDG whole-body PET (case report). **2000**, 7, 165-8	2
1651	Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. **2000**, 437, 107-15	113
1650	PET and SPECT in Three-Dimensional Treatment Planning of Brain Gliomas. **2000**, 34, 97-105	2
1649	Orbital fibrous histiocytomas. **2000**, 19, 155-159	5
1648	Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. **2000**, 18, 3495-502	417
1647	Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. **2000**, 18, 1689-95	435
1646	Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. **2000**, 18, 3202-10	453
1645	Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. **2000**, 279, E508-19	35
1644	Tridimensional Characteristics of Rat Testicles Submitted to Tumour Cells Implant (Walker 256). **2000**, 6, 572-573	
1643	A conserved mechanism for controlling the translation of beta-F1-ATPase mRNA between the fetal liver and cancer cells. **2000**, 275, 7430-7	52
1642	Structural determinants for post-transcriptional stabilization of lactate dehydrogenase A mRNA by the protein kinase C signal pathway. **2000**, 275, 12963-9	16
1641	Positron emission tomography in imaging spinal cord tumors. **2000**, 15, 465-72	29
1640	Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase. **2000**, 97, 14766-71	107
1639	Design and evaluation of an LSO PET detector for breast cancer imaging. **2000**, 27, 1535-43	91

1638	Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. **2000**, 275, 21797-800	569
1637	Expression of autocrine motility factor/phosphohexose isomerase in Cos7 cells. **2000**, 273, 213-8	11
1636	Purification and characterization of beta-actin-rich tumor cell pseudopodia: role of glycolysis. **2000**, 258, 171-83	47
1635	Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate. **2000**, 160, 61-6	12
1634	PET imaging in oncology. **2000**, 30, 150-85	260
1633	Sublethal oxygen deficiency--the primary cause of cancer. **2000**, 54, 323-5	3
1632	Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?. **2000**, 36, 200-6	32
1631	Whole-Body FDG-PET in Patients with Recurrent Colorectal Carcinoma. A Comparative Study with CT. **2000**, 3, 107-114	27
1630	Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. **2000**, 36, 1038-42	125
1629	Hexokinase I is a Gli2-responsive gene expressed in the embryonic CNS. **2000**, 99, 159-62	4
1628	Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. *Science*, **2000**, 287, 2017-9 33.3	686
1627	HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. **2000**, 2, 365-77	29
1626	Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. **2000**, 35, 883-8	56
1625	Digital mammography, sestamibi breast scintigraphy, and positron emission tomography breast imaging. **2000**, 38, 861-9, x	15
1624	Applications of magnetic resonance in model systems: tumor biology and physiology. **2000**, 2, 139-51	100
1623	Applications of magnetic resonance in model systems: cancer therapeutics. **2000**, 2, 152-65	118
1622	pH and drug resistance in tumors. **2000**, 3, 39-47	137
1621	The role of nuclear medicine in the evaluation of pancreatic disease. **2001**, 81, 345-58	16

1620	Elevation of lactic acid concentration associated with megalophthalmia in Black Moor goldfish. **2001**, 73, 897-900		2
1619	Is induction of type 2 programmed death in cancer cells from solid tumors directly related to mitochondrial mass?. **2001**, 57, 87-90		7
1618	Dysfunctional mitochondria, not oxygen insufficiency, cause cancer cells to produce inordinate amounts of lactic acid: the impact of this on the treatment of cancer. **2001**, 57, 429-31		39
1617	The human ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene (PFKFB3): promoter characterization and genomic structure. **2001**, 264, 131-8		32
1616	Activation of the HIF pathway in cancer. **2001**, 11, 293-9		316
1615	Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. **2001**, 37, 204-9		71
1614	Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. **2001**, 3, 189-95		74
1613	Cooperation and competition in the evolution of ATP-producing pathways. *Science*, **2001**, 292, 504-7	33.3	901
1612	Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). **2001**, 16, 297-304		48
1611	The Use of PET in Evaluating Tumor Response and Cancer Therapy. **2001**, 14, 361-367		
1610	In vivo proton MR spectroscopy of chorea-ballismus in diabetes mellitus. **2001**, 43, 525-31		36
1609	From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. **2001**, 15, 471-86		209
1608	Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. **2001**, 115, 793-800		172
1607	The role of radionuclides in primary musculoskeletal tumors beyond the 'bone scan'. **2001**, 37, 217-26		12
1606	Effect of exogenous lactate on rat glioma metabolism. **2001**, 65, 543-8		14
1605	2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. **2001**, 91, 889-899		189
1604	Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. **2001**, 92, 2237-46		128
1603	Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. **2001**, 32, 136-43		91

1602	Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. **2001**, 82, 17-21	107
1601	Diagnosis and localization of testosterone-producing ovarian tumors: imaging or biochemical evaluation. **2001**, 83, 596-8	22
1600	Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. **2001**, 20, 1910-20	230
1599	Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. **2001**, 8, 71-80	119
1598	High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. **2001**, 28, 147-50	239
1597	Mitochondrial contributions to cancer cell physiology: potential for drug development. **2001**, 49, 45-61	90
1596	Toxicant-induced oxidative stress in cancer. **2001**, 64, 1-3	45
1595	ORTHOMOLECULAR MEDICINE. **2001**, 1361-1461	
1594	Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. **2001**, 285, 914-24	803
1593	Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. **2001**, 15, 635-44	57
1592	Mitochondrial signaling and cancer. **2001**, 7, 103-130	
1591	Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. **2001**, 60, 162-9	50
1590	Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a bio-historical perspective with updates. **2001**, 22, 1903-30	220
1589	Die 18 FDG-Positronen-Emissions-Tomographie zur Erkennung eines okkulten intramammären Rezidivs. **2001**, 61, 35-38	1
1588	The clinical use of PET--where are we now?. **2001**, 74, 399-401	5
1587	Mitochondria and apoptosis: new therapeutic targets. **2002**, 85, 203-42	44
1586	Aminolaevulinic acid-induced photodynamic therapy: cellular responses to glucose starvation. **2002**, 86, 1343-7	21
1585	Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. **2002**, 87, 805-12	192

1584	Increased hexokinase activity, of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. **2002**, 277, 11392-400	108
1583	Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. **2002**, 277, 14821-8	105
1582	Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. **2002**, 22, 5-17	72
1581	Evaluation of esophageal cancer by positron emission tomography. **2002**, 32, 340-6	55
1580	Nasal saline for acute sinusitis. **2002**, 109, 165	34
1579	F-18 FDG-positron emission tomographic scanning and Wegener's granulomatosis. **2002**, 27, 705-6	41
1578	A metabolic hypothesis of cell growth and death in pancreatic cancer. **2002**, 24, 26-33	35
1577	Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. **2002**, 23, 727-34	113
1576	Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. **2002**, 364, 309-15	204
1575	Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. **2002**, 277, 6183-7	255
1574	Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. **2002**, 276, 24-31	156
1573	Glucose uptake and lactate production in cells exposed to CoCl(2) and in cells overexpressing the Glut-1 glucose transporter. **2002**, 399, 206-11	22
1572	Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. **2002**, 3, 56-61	24
1571	Mitochondrial defects in cancer. **2002**, 1, 9	421
1570	Mitochondrial Mutations and Disease. **2002**, 273-325	
1569	Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. **2002**, 277, 23111-5	564
1568	The hypoxic core: a possible answer to the cancer paradox. **2002**, 299, 676-80	66
1567	Model of the outer membrane potential generation by the inner membrane of mitochondria. **2002**, 82, 684-92	49

1566	Mitochondria as targets for detection and treatment of cancer. **2002**, 4, 1-19	144
1565	Value of positron emission tomography for lung cancer staging. **2002**, 28, 55-62	17
1564	Differential action of iodine on mitochondria from human tumoral- and extra-tumoral tissue in inducing the release of apoptogenic proteins. **2002**, 2, 199-210	14
1563	Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). **2002**, 38 Suppl 5, S60-5	180
1562	[Horton's disease and extra-temporal vessel locations: role of 18FDG PET scan. Report of 3 cases and review of the literature]. **2002**, 23, 584-91	12
1561	The adenine nucleotide translocator in apoptosis. **2002**, 84, 167-76	104
1560	The role of hypoxia-inducible signaling pathway in nickel carcinogenesis. **2002**, 110 Suppl 5, 831-4	66
1559	Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo (13)C MRS. **2002**, 283, E623-30	43
1558	Insulin induces PFKFB3 gene expression in HT29 human colon adenocarcinoma cells. **2002**, 1589, 89-92	33
1557	A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. **2002**, 2, 29-42	196
1556	A mitochondrial Achilles' heel in cancer?. **2002**, 2, 1-2	29
1555	Going malignant: the hypoxia-cancer connection in the prostate. **2002**, 24, 749-57	105
1554	Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis?. **2002**, 29, 237-42	34
1553	Nickel essentiality, toxicity, and carcinogenicity. **2002**, 42, 35-56	740
1552	Positron emission tomography and colorectal cancer. **2001**, 88, 176-89	51
1551	Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. **2002**, 21, 7839-49	209
1550	Chemotherapy: targeting the mitochondrial cell death pathway. **2002**, 21, 8786-803	350
1549	Metabolic control analysis in drug discovery and disease. **2002**, 20, 243-9	242

1548	FDG-PET. A possible prognostic factor in head and neck cancer. **2002**, 86, 512-6	169
1547	Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. **2002**, 54, 1024-35	111
1546	Expression of glucose transporter-1 in cervical cancer and its precursors. **2002**, 86, 138-43	54
1545	Growth control of C6 glioma in vivo by nerve growth factor. **2002**, 59, 199-205	28
1544	Positron emission tomography in colorectal cancer. **2002**, 16, 237-51	21
1543	Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. **2003**, 63, 81-6	84
1542	Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-The Warburg effect revisited. **2004**, 20, 353-64	119
1541	Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. **2003**, 103, 645-62	713
1540	Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. **2003**, 30, 396-402	89
1539	The relationship between histopathological findings in oral squamous cell carcinoma and FDG uptake on PET. **2003**, 19, 47-55	2
1538	The potential for strategies using micronutrients and heterocyclic drugs to treat invasive gliomas. **2003**, 145, 683-90	31
1537	Bedeutung der Positronenemissionstomographie in der Onkologie. **2003**, 9, 283-291	0
1536	The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. **2003**, 13, 83-9	170
1535	Nickel carcinogenesis. **2003**, 533, 67-97	512
1534	Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. **2003**, 97, 2035-42	140
1533	Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. **2003**, 107, 177-82	63
1532	Staging of primary cervical cancers: the role of nuclear medicine. **2003**, 46, 275-84	13
1531	Human epidermal energy metabolism is functionally anaerobic. **2003**, 12, 572-9	38

1530	Inhibition of mitochondria prevents cell death in kidney epithelial cells by intra- and extracellular acidification. **2003**, 63, 1725-35	28
1529	Role of ADP-ribosylation in wound repair. The contributions of Thomas K. Hunt, MD. **2003**, 11, 439-44	29
1528	Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. **2003**, 11, 504-9	157
1527	18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. **2003**, 123, 454-62	32
1526	Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. **1998**, 85, 1403-6	73
1525	Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. **2003**, 3, 1801-10	136
1524	Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. **2003**, 3, 1620-32	209
1523	Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. **2003**, 89, 1375-82	175
1522	Apoptosis-resistant phenotype in HL-60-derived cells HCW-2 is related to changes in expression of stress-induced proteins that impact on redox status and mitochondrial metabolism. **2003**, 10, 163-74	24
1521	Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. **2003**, 17, 1437-47	146
1520	The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. **2003**, 38, 451-7	65
1519	Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. **2003**, 24, 651-7	28
1518	Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. **2003**, 3, 119-119	
1517	Targeting the mitochondria to enhance tumor suppression. **2003**, 223, 543-54	12
1516	18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. **2003**, 125, 1235-45	25
1515	Oxyphilic and non-oxyphilic thyroid carcinoma cell lines differ in expressing apoptosis-related genes. **2003**, 26, 660-7	10
1514	The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. **2003**, 115, 449-59	307
1513	Lactate-sensitive response elements in genes involved in hyaluronan catabolism. **2003**, 305, 203-8	47

1512	Differential expression of GLUT12 in breast cancer and normal breast tissue. **2003**, 193, 225-33	66
1511	Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. **2003**, 29, 297-307	417
1510	The common mitochondrial DNA deletion deltamtDNA(4977): shedding new light to the concept of a tumor suppressor mutation. **2003**, 61, 60-3	17
1509	Transcriptional gene expression profile of human esophageal squamous cell carcinoma. **2003**, 81, 481-8	32
1508	Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. **2003**, 3, 119-24	30
1507	Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. **2003**, 5, 135-45	194
1506	Dependence of leukemic cell autofluorescence patterns on the degree of differentiation. **2003**, 2, 981-7	14
1505	Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. **2003**, 278, 37832-9	380
1504	Autofluorescence spectroscopy of normal and malignant human breast cell lines. **2003**, 78, 462-9	67
1503	Mitochondria-mediated nuclear mutator phenotype in Saccharomyces cerevisiae. **2003**, 31, 3909-17	102
1502	GLUT1 Messenger RNA and Protein Induction Relates to the Malignant Transformation of Cervical Cancer. **2003**, 120, 691-698	62
1501	Tumor Suppressor Genes. **2003**,	
1500	Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. **2003**, 23, 7315-28	463
1499	Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 gene (PFKFB3, iPFK2). **2003**, 23, 883	2
1498	Oncological molecular imaging: nuclear medicine techniques. **2003**, 76 Spec No 2, S152-8	27
1497	GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. **2003**, 120, 691-8	30
1496	Oxygen sensing in cancer. **2003**, 35, 380-90	11
1495	Estrogen and progesterone up-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. **2003**, 144, 4527-35	38

1494	Characterization of the autofluorescence of normal and tumoral esophageal epithelium cells. **2003**,	
1493	Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. **2003**, 27, 175-82	22
1492	Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. **2003**, 124, 893-901	118
1491	Utility of FDG-PET scanning in lymphoma by WHO classification. **2003**, 101, 3875-6	352
1490	The adenine nucleotide translocator: a new potential chemotherapeutic target. **2003**, 4, 517-24	26
1489	Understanding the tumor metabolic phenotype in the genomic era. **2003**, 3, 49-59	45
1488	HTLV envelopes and their receptor GLUT1, the ubiquitous glucose transporter: a new vision on HTLV infection?. **2004**, 9, 3218-41	12
1487	Adrenalectomy does not block the inhibition of mammary carcinogenesis by dietary energy restriction in rats. **2004**, 134, 1152-6	10
1486	Unravelling Biological Pathways and the Identification of Clinical Markers and Targets in Renal Cancer. **2004**, 73-96	
1485	. **2004**,	4
1484	Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. **2003**, 19, 69-94	36
1483	The hypoxia-inducible factor and tumor progression along the angiogenic pathway. **2005**, 242, 157-213	61
1482	Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. **2004**, 183, 479-86	88
1481	Regulatory role of lactate in wound repair. **2004**, 381, 565-75	24
1480	Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. **2004**, 183, 1143-7	46
1479	GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. **2004**, 66, 404-10	45
1478	Differential expression of glucose transporters in normal and pathologic thyroid tissue. **2004**, 14, 806-12	55
1477	Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. **2004**, 11, 749-59	53

1476	Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism. **2004**, 10, 2203-4	23
1475	Putting the rap on Akt. **2004**, 22, 4217-26	189
1474	Myocardial ischemia, fluorodeoxyglucose, and severity of coronary artery stenosis: the complexities of metabolic remodeling in hibernating myocardium. **2004**, 109, e167-70; author reply e167-70	10
1473	Defective acidification of intracellular organelles results in aberrant secretion of cathepsin D in cancer cells. **2004**, 279, 39982-8	65
1472	Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. **2004**, 18, 1303-5	144
1471	Autocrine motility factor signaling enhances pancreatic cancer metastasis. **2004**, 10, 7775-84	67
1470	Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. **2004**, 101, 8132-7	182
1469	Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. **2004**, 24, 497	
1468	Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. **2004**, 25, 713	2
1467	Oxygen Sensing by H+: Implications for HIF and Hypoxic Cell Memory. **2004**, 3, 1025-1027	25
1466	Hydrodynamic consequences of glycolysis: thermodynamic basis and clinical relevance. **2004**, 3, 812-5	10
1465	Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. **2004**, 3, 503-4	17
1464	Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. **2004**, 64, 6716-24	103
1463	Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. **2004**, 24, 5923-36	248
1462	Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. **2004**, 101, 16507-12	407
1461	Mitochondrial DNA in tumors. **2004**, 14, 85-90	1
1460	Inhibition of mitochondria and extracellular acidification enhance achratoxin A-induced apoptosis in renal collecting duct-derived MDCK-C7 cells. **2004**, 14, 47-56	20
1459	6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. **2004**, 279, 53562-70	171

1458	The role of positron emission tomography in the management of colorectal cancer. **2004**, 6, 2-9	27
1457	Combined supplementation of vanadium and beta-carotene suppresses placental glutathione S-transferase-positive foci and enhances antioxidant functions during the inhibition of diethylnitrosamine-induced rat liver carcinogenesis. **2004**, 19, 683-93	11
1456	Stimulation of fibroblast proliferation by lactate-mediated oxidants. **2004**, 12, 368-73	27
1455	HIF activation by pH-dependent nucleolar sequestration of VHL. **2004**, 6, 642-7	208
1454	Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase. **2004**, 23, 8118-27	80
1453	Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. **2004**, 90, 2390-6	167
1452	Diagnosis of endometrial cancer in patients with postmenopausal bleeding by analysis of the lactate dehydrogenase isoenzyme activity profile in uterine fluid. **2004**, 93, 385-9	3
1451	The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor alpha. **2004**, 44, 75-92	26
1450	Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. **2004**, 9, 437-47	34
1449	High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. **2004**, 68, 263-74	35
1448	Apoptosis as a novel target for cancer chemoprevention. **2004**, 96, 662-72	429
1447	Mitochondrial gene-knockout (rho0) cells: a versatile model for exploring the secrets of trans-plasma membrane electron transport. **2004**, 20, 199-206	29
1446	Genome-Wide Analysis of Signal Transducers and Regulators of Mitochondrial Dysfunction in Saccharomyces cerevisiae. **2004**, 1011, 284-298	9
1445	The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence. **2004**, 1028, 273-82	23
1444	[PET/CT for colorectal and hepatic tumors]. **2004**, 44, 1068-78	1
1443	Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. **2004**, 31, 1244-56	34
1442	Fluorinated tracers for imaging cancer with positron emission tomography. **2004**, 31, 1182-206	97
1441	Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. **2004**, 53, 209-19	309

1440	Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. **2004**, 4, 2789-95	54
1439	Identification of target proteins of N-acetylglucosaminyl-transferase V and fucosyltransferase 8 in human gastric tissues by glycomic approach. **2004**, 4, 3353-8	21
1438	Positron emission tomography in the staging and management of breast cancer. **2004**, 91, 1398-409	27
1437	Fatty acid synthase: a metabolic oncogene in prostate cancer?. **2004**, 91, 47-53	231
1436	ApcMin/+ mouse model of colon cancer: gene expression profiling in tumors. **2004**, 93, 1242-54	34
1435	Systems biology and the molecular circuits of cancer. **2004**, 5, 1322-33	33
1434	The unique exponential growth of life is powered by anaerobic glycolysis. **2004**, 114, 193-206	
1433	A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. **2005**, 26, 531-9	64
1432	Normal variants in [18F]-fluorodeoxyglucose PET imaging. **2004**, 42, 1063-81, viii	29
1431	Glucose-receptor MR imaging of tumors: study in mice with PEGylated paramagnetic niosomes. **2004**, 231, 135-42	78
1430	Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. **2004**, 5, 62-4	37
1429	Akt stimulates aerobic glycolysis in cancer cells. **2004**, 64, 3892-9	1120
1428	Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. **2004**, 576, 14-20	81
1427	ROS stress in cancer cells and therapeutic implications. **2004**, 7, 97-110	1443
1426	Cancer cell death by programmed necrosis?. **2004**, 7, 321-4	31
1425	Metabolism and developmental competence of the preimplantation embryo. **2004**, 115 Suppl 1, S92-6	71
1424	The possible role of cytochrome c oxidase in stress-induced apoptosis and degenerative diseases. **2004**, 1655, 400-8	175
1423	Cell surface oxygen consumption by mitochondrial gene knockout cells. **2004**, 1656, 79-87	79

1422	Cancer metabolism: facts, fantasy, and fiction. **2004**, 313, 459-65	435
1421	Mitochondrial-dependent regulation of myoblast proliferation. **2004**, 299, 27-35	28
1420	Proteomic analysis of exosomes secreted by human mesothelioma cells. **2004**, 164, 1807-15	289
1419	Tumors may modulate host immunity partly through hypoxia-induced sympathetic bias. **2004**, 63, 352-6	11
1418	Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses?. **2004**, 93, 191-7	24
1417	Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. **2004**, 10, 243-50	25
1416	Imagerie m□abolique et fonctionnelle in vivo des tumeurs c□□brales par tomographie □□mission de positons. **2004**, 1, 1-10	
1415	FDG PET and gallium scintigraphy for diagnosis of an advanced jejunal adenocarcinoma with distant metastases. **2004**, 29, 825-7	2
1414	Dedifferentiated thyroid carcinoma: the imaging role of 18F-FDG PET and non-iodine radiopharmaceuticals. **2004**, 25, 891-5	7
1413	Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. **2004**, 125, 2294-9	51
1412	Mitochondrial correlation as a biophotonic marker for detecting cancer in a single cell. **2005**, 5699, 461	2
1411	Acquired glucose sensitivity of k-ras transformed fibroblasts. **2005**, 33, 297-9	10
1410	Mitochondrial gene knockout HL60rho0 cells show preferential differentiation into monocytes/macrophages. **2005**, 29, 1163-70	9
1409	Metabolic energetics and genetics in the heart. **2005**, 1047, 208-18	85
1408	Stem cell stages and the origins of colon cancer: a multidisciplinary perspective. **2005**, 1, 243-51	16
1407	Positron emission tomography application for gynecologic tumors. **2005**, 15, 701-9	34
1406	Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. **2005**, 18, 185-9	40
1405	Magnetic resonance in surgical oncology: I - on the origin of the spectrum. **2005**, 75, 459-63	3

1404	Mitochondrial tumour suppressors: a genetic and biochemical update. **2005**, 5, 857-66	512
1403	Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. **2005**, 19, 2153-8	93
1402	Immunocytochemical detection of XIAP in body cavity effusions and washes. **2005**, 18, 1618-22	47
1401	Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. **2005**, 142, 102-10	99
1400	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. **2005**, 8, 143-53	740
1399	The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer. **2005**, 201, 948-56	23
1398	The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature. **2005**, 1756, 1-24	103
1397	Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines. **2005**, 69, 1159-66	4
1396	[Mitochondrial DNA mutations and colorectal cancer]. **2005**, 29, 33-40	1
1395	Multifaceted roles of glycolytic enzymes. **2005**, 30, 142-50	491
1394	Pyruvate kinase type M2 and its role in tumor growth and spreading. **2005**, 15, 300-8	597
1393	Amino acids and glucose utilization by different metabolic pathways in ascites-tumour cells. **1981**, 117, 19-25	75
1392	Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors. **2005**, 5, 102	24
1391	Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. **2005**, 202, 654-62	883
1390	Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. **2005**, 44, 19-28	210
1389	Tumor-specific changes in mtDNA content in human cancer. **2005**, 116, 920-4	141
1388	Cancer cachexia and its nutritional implications. **1983**, 70, 352-5	34
1387	Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. **2005**, 181, 507-14	194

1386	Mitochondria: A novel target for the chemoprevention of cancer. **2005**, 10, 687-705	93
1385	Positron emission tomography in recurrent hepatoblastoma. **2005**, 21, 341-5	34
1384	Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. **2005**, 7, 388-92	170
1383	In vivo follow-up of rat tumor models with 2-deoxy-2-[F-18]fluoro-D-glucose/dual-head coincidence gamma camera imaging. **2005**, 7, 220-8	3
1382	ANT2 isoform required for cancer cell glycolysis. **2005**, 37, 307-16	83
1381	Splice isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4: expression and hypoxic regulation. **2005**, 280, 227-34	20
1380	Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. **2005**, 74, 123-33	135
1379	Ultrafast nanolaser flow device for detecting cancer in single cells. **2005**, 7, 331-9	25
1378	Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. **2005**, 22, 25-30	176
1377	Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. **2005**, 5, 5	17
1376	The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence. **2005**, 166, 245-56	15
1375	Hepatocellular carcinoma tumour thrombus in a re-canalised para-umbilical vein: detection by 18-fluoro-2-deoxyglucose positron emission tomography imaging. **2005**, 78, 841-4	9
1374	Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches. **2005**, 291-315	
1373	Mitochondrial DNA mutations in cancer. **2005**, 2, e401	28
1372	Functional imaging in lung cancer. **2005**, 23, 3203-11	29
1371	Advances in paediatric tumour imaging. **2005**, 90, 608-11	20
1370	Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. **2005**, 3, 413-23	160
1369	Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation. **2005**, 280, 10419-26	28

1368	Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. **2005**, 26, 2095-104	144
1367	Clinical value of mitochondrial mutations in colorectal cancer. **2005**, 23, 3517-25	126
1366	Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. **2005**, 11, 5784-92	134
1365	Cisplatin-induced apoptosis is enhanced by hypoxia and by inhibition of mitochondria in renal collecting duct cells. **2005**, 85, 735-42	29
1364	Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. **2005**, 14, 3857-64	108
1363	Metabolic monitoring of chemosensitivity with 18FDG PET. **2005**, 111, 417-40	7
1362	Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. **2005**, 237, 181-8	18
1361	The impact of tumor physiology on camptothecin-based drug development. **2005**, 5, 1-13	34
1360	Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?. **2005**, 14, 569-89	23
1359	Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. **2005**, 102, 13968-73	103
1358	Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. **2005**, 65, 1655-63	224
1357	Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. **2005**, 280, 4254-63	182
1356	Integration/Interaction of Oncologic Growth. **2005**,	3
1355	Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. **2005**, 3, 635-44	17
1354	Thermodynamic Aspects of Cancer: Possible Role of Negative Entropy in Tumor Growth, its Relation to Kinetic and Genetic Resistance. **2005**, 2, 429-438	17
1353	New Insights about the Potential Application of the Association of Vitamins C (Sodium Ascorbate) and K3 (Menadione) as Auxiliary Therapy in Cancer Treatment. **2005**, 2, 277-282	
1352	1H-NMR metabolic markers of malignancy correlate with spontaneous metastases in a murine mammary tumor model. **2005**, 27, 257	
1351	Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. **2005**, 27, 337	

1350	Activation of AKT kinases in cancer: implications for therapeutic targeting. **2005**, 94, 29-86	613
1349	Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. **2005**, 65, 10545-54	326
1348	ATP citrate lyase inhibition can suppress tumor cell growth. **2005**, 8, 311-21	718
1347	ATP citrate lyase is an important component of cell growth and transformation. **2005**, 24, 6314-22	389
1346	Les m□icaments radiopharmaceutiques fluor□. **2005**, 1, 46-55	
1345	[Metabolic imaging for supratentorial oligodendrogliomas]. **2005**, 51, 309-22	4
1344	Mitochondrial DNA as a cancer biomarker. **2005**, 7, 258-67	70
1343	Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. **2005**, 7, 324-30	169
1342	Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. **2005**, 7, 1-6	149
1341	Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. **2005**, 14, 2231-9	683
1340	Anti-Angiogenic and Pro-Apoptotic Effects of Dietary Restriction in Experimental Brain Cancer: Role of Glucose and Ketone Bodies. **2005**, 259-270	7
1339	Glucose transporters in the thyroid. **2005**, 15, 545-50	21
1338	Orthomolecular oncology review: ascorbic acid and cancer 25 years later. **2005**, 4, 32-44	89
1337	Identification of three isoforms for mitochondrial adenine nucleotide translocator in the pufferfish Takifugu rubripes. **2005**, 5, 162-72	4
1336	Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. **2005**, 64, 342-9	55
1335	Retrograde regulation due to mitochondrial dysfunction may be an important mechanism for carcinogenesis. **2005**, 65, 525-9	34
1334	Impact of mitochondria on nuclear genome stability. **2005**, 4, 141-8	7
1333	Redox-sensitive signaling factors as a novel molecular targets for cancer therapy. **2005**, 8, 322-30	64

1332	Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. **2005**, 87, 1005-10	62
1331	Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. **2005**, 218, 1-14	108
1330	Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists. **2005**, 579, 1765-9	17
1329	A genome-wide expression profile and system-level integration of nuclear factor kappa B regulated genes reveals fundamental metabolic adaptations during cell growth and survival. **2005**, 579, 6814-20	3
1328	Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. **2005**, 167, 1763-75	243
1327	Targeting energy metabolism in brain cancer: review and hypothesis. **2005**, 2, 30	160
1326	Mitochondria as functional targets of proteins coded by human tumor viruses. **2005**, 94, 87-142	46
1325	Tumor acidity, chemoresistance and proton pump inhibitors. **2005**, 1, 779-86	189
1324	Cell and tissue autofluorescence research and diagnostic applications. **2005**, 11, 227-56	499
1323	Akt and emerging models for tumor cell energetics. **2005**, 2, 331-336	2
1322	MR Imaging in White Matter Diseases of the Brain and Spinal Cord. **2005**,	7
1321	Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. **2006**, 281, 977-81	149
1320	Interactions between nitric oxide and indoleamine 2,3-dioxygenase. **2006**, 45, 8527-38	63
1319	Imaging Studies of the Liver. **2006**, 317-331	
1318	Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. **2006**, 66, 632-7	353
1317	Nitric oxide and mitochondrial biogenesis. **2006**, 119, 2855-62	219
1316	Repair of mitochondrial DNA in aging and carcinogenesis. **2006**, 5, 190-8	30
1315	Gene-gene, gene-environment & multiple interactions in colorectal cancer. **2006**, 24, 1-101	31

1314	The metabolic syndrome: A high-risk state for cancer?. **2006**, 169, 1505-22	326
1313	[FDG PET and its impact on patient's management in oncology]. **2006**, 35, 1339-46	2
1312	Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis. **2006**, 367, 618-21	65
1311	Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. **2006**, 64, 473-82	62
1310	MondoA-Mlx heterodimers are candidate sensors of cellular energy status: mitochondrial localization and direct regulation of glycolysis. **2006**, 26, 4863-71	83
1309	Measurement of blood flow before and after embolization with use of fluorescent microspheres in an animal model. **2006**, 17, 103-11	6
1308	North American white mitochondrial haplogroups in prostate and renal cancer. **2006**, 175, 468-72; discussion 472-3	103
1307	Pathway analysis of kidney cancer using proteomics and metabolic profiling. **2006**, 5, 64	172
1306	Basic Science of PET and PET/CT. **2006**, 1-16	3
1305	Therapeutic peptides: Targeting the mitochondrion to modulate apoptosis. **2006**, 1757, 1312-23	23
1304	Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. **2006**, 1757, 1338-56	57
1303	In vitro and in vivo magnetic resonance detection of tumor cells by targeting glutamine transporters with Gd-based probes. **2006**, 49, 4926-36	67
1302	Proteomic analysis of MCF-7 cell lines expressing the zinc-finger or the proline-rich domain of retinoblastoma-interacting-zinc-finger protein. **2006**, 5, 1176-85	17
1301	Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. **2006**, 175, 913-23	315
1300	PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. **2006**, 580, 3308-14	85
1299	TIGAR, a p53-inducible regulator of glycolysis and apoptosis. **2006**, 126, 107-20	1460
1298	p53 and metabolism: Inside the TIGAR. **2006**, 126, 30-2	192
1297	Thioredoxin reductase as a novel molecular target for cancer therapy. **2006**, 236, 164-74	127

1296	Cancer's molecular sweet tooth and the Warburg effect. **2006**, 66, 8927-30	954
1295	Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. **2006**, 66, 715-31	10
1294	Mitochondrial disorders in renal tumors. **2006**, 6, 105-17	23
1293	Assessment of residual posttreatment masses in Hodgkin's disease and the need for biopsy in children. **2006**, 41, 972-4	10
1292	Survival Regulation by Ras and Raf. 490-513	1
1291	Analysis of Differentially Expressed Genes in Neuroendocrine Carcinomas of the Lung. **2006**, 1, 780-786	10
1290	Analysis of Differentially Expressed Genes in Neuroendocrine Carcinomas of the Lung. **2006**, 1, 780-786	12
1289	Oxidative metabolism in cancer growth. **2006**, 9, 339-45	100
1288	Signal Transduction Therapy for Cancer - Whither Now?. **2006**, 1, 1-12	11
1287	Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. **2006**, 9, 346-57	73
1286	AEROBIC AND ANAEROBIC CARBOHYDRATE UTILIZATION IN NORMAL AND MELANOTIC FISH PIGMENT CELLS*. **2006**, 100, 857-865	3
1285	Increased lipogenesis in cancer cells: new players, novel targets. **2006**, 9, 358-65	439
1284	Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. **2006**, 6, 3880-93	58
1283	Energy metabolism of the inner cell mass and trophectoderm of the mouse blastocyst. **2006**, 74, 11-8	142
1282	'To repair or not to repair - no longer a question': repair of mitochondrial DNA shielding against age and cancer. **2006**, 15, 1005-15	49
1281	Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. **2000**, 899, 349-62	243
1280	Malignant B-cell Lymphoma, WHO Classification and the Respective 18F-fluoro-deoxy-glucose Positron Emission Tomography Results. **2006**, 10, 14-21	2
1279	Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. **2006**, 97, 582-8	51

1278	Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. **2006**, 97, 1056-60	49
1277	Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization. **2006**, 48, 717-22	20
1276	Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. **2006**, 94, 692-7	52
1275	Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. **2006**, 20, 1731-7	72
1274	Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. **2006**, 25, 3325-34	23
1273	Ras-dependent carbon metabolism and transformation in mouse fibroblasts. **2006**, 25, 5391-404	89
1272	Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. **2006**, 25, 4683-96	379
1271	Glycolysis inhibition for anticancer treatment. **2006**, 25, 4633-46	1088
1270	Mitochondria as therapeutic targets for cancer chemotherapy. **2006**, 25, 4812-30	302
1269	Mitochondria and cancer: is there a morphological connection?. **2006**, 25, 4706-16	130
1268	Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. **2006**, 25, 4768-76	64
1267	Mitochondrial DNA mutations in human cancer. **2006**, 25, 4663-74	450
1266	Mitochondrial mutations in cancer. **2006**, 25, 4647-62	640
1265	The permeability transition pore complex in cancer cell death. **2006**, 25, 4744-56	168
1264	Lack of mitochondrial DNA enhances growth of hepatocellular carcinoma in vitro and in vivo. **2006**, 36, 209-16	7
1263	Targeting GSK-3: a promising approach for cancer therapy?. **2006**, 2, 91-100	109
1262	Signaling pathways influencing SLF and c-kit-mediated survival and proliferation. **2006**, 35, 1-12	8
1261	Antiangiogenic effect of 2-benzoyl-phenoxy acetamide in EAT cell is mediated by HIF-1alpha and down regulation of VEGF of in-vivo. **2006**, 24, 471-8	28

1260	PET imaging of brain astrocytoma with 1-11C-acetate. **2006**, 33, 420-7	36
1259	O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine. **2006**, 33, 1134-9	12
1258	How should we analyse FDG PET studies for monitoring tumour response?. **2006**, 33 Suppl 1, 16-21	54
1257	PET in abdominal pathology: advantages and limitations. **2006**, 31, 174-81	10
1256	Mitochondrial DNA mutations in human neoplasia. **2006**, 47, 67-78	62
1255	[Advancement of PET and PET/CT in prostate carcinoma]. **2006**, 45, 707-10, 712-4	5
1254	Incorporating expression data in metabolic modeling: a case study of lactate dehydrogenase. **2006**, 240, 464-74	15
1253	Tumor metabolism: new opportunities for cancer therapy. **2006**, 8, 711-6	34
1252	Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. **2006**, 20, 597-604	84
1251	FDG-PET scanning in the management of cancer of the oesophagus and oesophagogastric junction: early experience with 100 consecutive cases. **2006**, 175, 48-54	6
1250	Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. **2006**, 103, 912-8	73
1249	The biology of trophoblast. **1959**, 80, 21-43	17
1248	Search for the essential factors of carcinogenesis. **1963**, 105, 1-24	2
1247	Determination of glucose metabolites in stored erythrocytes and in erythrocytes from patients with thalassemia by analytical isotachophoresis. **2006**, 69, 79-87	5
1246	Glucose metabolism and cancer. **2006**, 18, 598-608	441
1245	Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. **2006**, 72, 1246-56	62
1244	Positron emission tomography: a promising diagnostic modality for head and neck pathology. **2006**, 64, 1272-7	5
1243	Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. **2006**, 93, 243-9	51

1242	Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. **2006**, 19, 30-40	184
1241	Progress in tumor enzymology. **1967**, 29, 321-90	6
1240	Altered gene expression induced by ionizing radiation and glycolytic inhibitor 2-deoxy-glucose in a human glioma cell line: implications for radio sensitization. **2006**, 5, 815-23	25
1239	Vitamin C als Prodrug von H2O2: M¶glichkeiten zur intraven¶sen Hochdosistherapie bei Krebserkrankungen?. **2006**, 21, 120-124	
1238	Liver and Biliary Tract Surgery. **2006**,	4
1237	Tumor hypoxia imaging. **2006**, 12, 5260-4	39
1236	Plasma membrane electron transport: a new target for cancer drug development. **2006**, 6, 895-904	51
1235	Peptido-targeting of the mitochondrial transition pore complex for therapeutic apoptosis induction. **2006**, 12, 4501-11	16
1234	Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. **2006**, 66, 5477-86	62
1233	Metabolic regulation of Akt: roles reversed. **2006**, 175, 845-7	16
1232	Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. **2006**, 66, 10760-9	54
1231	Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. **2006**, 15, 2332-5	40
1230	Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. **2006**, 66, 1684-936	95
1229	Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): a possible new target for cancer therapy. **2006**, 281, 2939-44	34
1228	Ultraviolet-induced autofluorescence characterization of normal and tumoral esophageal epithelium cells with quantitation of NAD(P)H. **2006**, 5, 483-92	35
1227	Genetics and Epigenetics in Cancer Biology. **2006**, 25-56	1
1226	PET and PET/CT in Kidney Cancer. **2006**, 89-101	1
1225	Mitochondrial activities of a cell line derived from thyroid H□thle cell tumors. **2006**, 16, 325-31	17

1224	Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. **2006**, 4, 319-30	113
1223	Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism. **2006**, 94, 268-74	48
1222	Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. **2006**, 5, 1119-30	126
1221	The mitochondrial genome: a biosensor for early cancer detection?. **2007**, 1, 169-82	2
1220	Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. **2007**, 104, 1937-42	65
1219	Caspase inhibition blocks cell death and results in cell cycle arrest in cytokine-deprived hematopoietic cells. **2007**, 282, 2144-55	7
1218	Activation of a novel calcineurin-mediated insulin-like growth factor-1 receptor pathway, altered metabolism, and tumor cell invasion in cells subjected to mitochondrial respiratory stress. **2007**, 282, 14536-46	48
1217	The modifier of Min 2 (Mom2) locus: embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression. **2007**, 17, 566-76	37
1216	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. **2007**, 27, 7381-93	450
1215	Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. **2007**, 16, 3136-48	128
1214	Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. **2007**, 282, 3293-301	164
1213	Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. **2007**, 292, C125-36	709
1212	[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. **2007**, 97, 902-9	12
1211	Fatty acid synthase inhibitors: new directions for oncology. **2007**, 16, 1817-29	67
1210	Valproic Acid As Anti-Cancer Drug. **2007**, 13, 3378-3393	91
1209	The hyperproliferative endothelial cell phenotype in idiopathic pulmonary arterial hypertension. **2007**, 293, L546-7	8
1208	Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG. **2007**, 3, 178-185	8
1207	Energy sensing and regulation of gene expression in skeletal muscle. **2007**, 102, 529-40	63

1206	AMPK/LKB1 signaling in epithelial cell polarity and cell division. **2007**, 6, 2755-9	36
1205	Vitamin C als Prodrug von H2O2: M¶glichkeiten zur intraven¶sen Hochdosistherapie bei Krebserkrankungen?. **2007**, 39, 52-57	
1204	Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions. **2007**, 188, 130-8	40
1203	Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. **2007**, 6, 1476-9	75
1202	M¶glichkeiten und Grenzen der modernen Schnittbildverfahren (CT, MRT, PET) in der molekularen Bildgebung. **2007**, 30, 31-41	2
1201	Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. **2007**, 104, 19345-50	1758
1200	2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. **2007**, 67, 3364-70	188
1199	Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. **2007**, 48, 602-7	79
1198	Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. **2007**, 178, 93-105	495
1197	Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. **2007**, 27, 6361-71	40
1196	A glycolytic mechanism regulating an angiogenic switch in prostate cancer. **2007**, 67, 149-59	127
1195	Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. **2007**, 18, 1437-46	402
1194	Adaptation of energy metabolism in breast cancer brain metastases. **2007**, 67, 1472-86	249
1193	A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck. **2007**, 13, 4317-9	
1192	Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. **2007**, 13, 2441-8	92
1191	Why do tumors metastasize?. **2007**, 6, 141-4	12
1190	Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. **2007**, 27, 4328-39	163
1189	Targeted cancer therapy: promise and reality. **2007**, 97, 295-319	14

1188	Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14. **2007**, 67, 8682-9		28
1187	Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. **2007**, 104, 6223-8		199
1186	Cell biology. Aneuploidy in the balance. *Science*, **2007**, 317, 904-5	33.3	11
1185	ATP Production and Necrosis Formation in a Tumour Spheroid Model. **2007**, 2, 30-46		16
1184	Management of recurrent colorectal cancer with positron emission tomography. **2007**, 68, 580-3		1
1183	Metabolic enzymes regulated by the Myc oncogene are possible targets for chemotherapy or chemoprevention. **2007**, 35, 305-10		16
1182	Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. **2007**, 86, s823-35		258
1181	Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET and 18F-FDG PET study. **2007**, 28, 789-97		20
1180	Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera. **2007**, 19, 471-8		14
1179	Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma. **2007**,		1
1178	Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress. **2007**, 141, 140-53		8
1177	Compensatory alterations in energy homeostasis characterized in uterine tumors from hereditary leiomyomatosis and renal cell cancer. **2007**, 88, 1039-48		12
1176	Advanced imaging for veterinary cancer patients. **2007**, 37, 1059-77; v-i		17
1175	Mitochondria and reactive oxygen species in renal cancer. **2007**, 89, 1080-8		56
1174	Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. **2007**, 252, 1-8		490
1173	Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. **2007**, 257, 244-51		83
1172	Withdrawal symptoms on display: Bcl-2 members under investigation. **2007**, 28, 26-32		15
1171	Restoration of cellular energetic balance with L-carnitine in the neuro-bioenergetic approach for cancer prevention and treatment. **2007**, 69, 262-72		8

1170	The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. **2007**, 69, 826-8	30
1169	The Warburg effect might result from the generation of dominating paternal vs. maternal genome in carcinogenesis. **2007**, 69, 965-6	2
1168	Heteroplasmic mutation of mitochondrial DNA D-loop and 4977-bp deletion in human cancer cells during mitochondrial DNA depletion. **2007**, 7, 157-63	25
1167	Regulation of mitochondrial DNA content and cancer. **2007**, 7, 53-7	50
1166	Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane. **2007**, 7, 234-40	50
1165	(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. **2007**, 37, 400-19	164
1164	Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells. **2007**, 79, 8423-30	55
1163	[Arsenic in 2006: an update on sources of poisoning]. **2007**, 134, 402-4	
1162	Metabolic approaches to breast cancer treatment and prevention. **2007**, 9,	1
1161	Drug resistance and the solid tumor microenvironment. **2007**, 99, 1441-54	1529
1160	Upregulation of cellular triacylglycerol - free fatty acid cycling by oleate is associated with long-term serum-free survival of human breast cancer cells. **2007**, 85, 301-10	42
1159	Tumors of the Brain and Spine. **2007**,	9
1158	Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. **2007**, 11, 1043-53	100
1157	Increased expression of mitochondrial glycerophosphate dehydrogenase and antioxidant enzymes in prostate cancer cell lines/cancer. **2007**, 41, 1116-24	27
1156	Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. **2007**, 11, 1055-69	24
1155	Autoantibody signature in human ductal pancreatic adenocarcinoma. **2007**, 6, 4025-31	70
1154	Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. **2007**, 129, 2648-59	128
1153	Targeting vacuolar H+-ATPases as a new strategy against cancer. **2007**, 67, 10627-30	214

1152	In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. **2007**, 14, 1531-9	24
1151	Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. **2007**, 9, 900-8	22
1150	Update on colorectal cancer imaging. **2007**, 45, 85-118	50
1149	Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. **2007**, 18, 95-101	40
1148	Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. **2007**, 53, 233-56	271
1147	Cancer cell: using inflammation to invade the host. **2007**, 6, 29	39
1146	The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. **2007**, 4, 5	192
1145	Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. **2007**, 3, 682-93	87
1144	Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. **2007**, 1767, 170-7	115
1143	Mitochondrial Mutations and Disease. 345-416	
1142	Identification and Characterization of Renal Cell Carcinoma Gene Markers. **2007**, 3, 117693510700300	25
1141	The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer. **2007**, 1, 1177391X0700100	8
1140	Large scale genetic screen identifies MAP17 as protein bypassing TNF-induced growth arrest. **2007**, 101, 112-21	24
1139	Identification and analysis of alpha1,6-fucosylated proteins in human normal liver tissues by a target glycoproteomic approach. **2007**, 28, 4382-91	20
1138	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. **2007**, 2, 505-14	47
1137	A surgical perspective on positron emission tomography. **2007**, 95, 443-6	3
1136	Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future. **2007**, 96, 297-308	31
1135	Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. **2007**, 69, 1222-30	58

1134	The field of cancer research: an indicator of present transformations in biology. **2007**, 26, 7607-10	13
1133	The mitochondrion as janus bifrons. **2007**, 72, 1115-26	41
1132	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. **2007**, 7, 763-77	1887
1131	The paracrine hormone hypothesis of colorectal cancer. **2007**, 82, 441-7	49
1130	Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. **2007**, 96, 1072-82	65
1129	Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. **2007**, 99, 1143-9	45
1128	Cancer as a consequence of the rising level of oxygen in the Late Precambrian. **2007**, 40, 211-220	14
1127	Origin of the phyla and cancer. **2007**, 40, 359-363	3
1126	Pyruvate modifies glycolytic and oxidative metabolism of rat embryonic spinal cord astrocyte cell lines and prevents their spontaneous transformation. **2007**, 100, 1589-98	2
1125	Energy metabolism in tumor cells. **2007**, 274, 1393-418	721
1124	Regulation of mitochondrial oxidative phosphorylation through cell signaling. **2007**, 1773, 1701-20	174
1123	Nuclear HMGA1 nonhistone chromatin proteins directly influence mitochondrial transcription, maintenance, and function. **2007**, 313, 77-87	38
1122	Resveratrol inhibits glucose metabolism in human ovarian cancer cells. **2007**, 107, 450-7	110
1121	Hypoxia, drug therapy and toxicity. **2007**, 113, 229-46	89
1120	Glucosylated heparin derivatives as non-toxic anti-cancer drugs. **2007**, 123, 46-55	13
1119	Fluorescence Anisotropy of Cellular NADH as a Tool to Study Different Metabolic Properties of Human Melanocytes and Melanoma Cells. **2007**, 13, 1671-1679	9
1118	Diagnostic Potential of Autofluorescence for an Assisted Intraoperative Delineation of Glioblastoma Resection Margins¶. **2007**, 77, 309-318	5
1117	Autofluorescence Spectroscopy of Normal and Malignant Human Breast Cell Lines¶. **2007**, 78, 462-469	4

1116	Switching between cooperation and competition in the use of extracellular glucose. **2007**, 65, 328-39	16
1115	The unfolded protein response and cancer: a brighter future unfolding?. **2007**, 85, 331-41	49
1114	Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor. **2007**, 31, 51-9	12
1113	Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. **2007**, 59, 495-505	158
1112	Mitochondrial OXPHOS functions in R1H rhabdomyosarcoma and skeletal muscles of the rat. **2007**, 32, 973-80	3
1111	A pivotal role for p53: balancing aerobic respiration and glycolysis. **2007**, 39, 243-6	114
1110	Oxygen metabolism and a potential role for cytochrome c oxidase in the Warburg effect. **2007**, 39, 247-50	12
1109	The Warburg effect and its cancer therapeutic implications. **2007**, 39, 267-74	245
1108	A message emerging from development: the repression of mitochondrial beta-F1-ATPase expression in cancer. **2007**, 39, 259-65	45
1107	Actuality of Warburg's views in our understanding of renal cancer metabolism. **2007**, 39, 235-41	36
1106	Effects of hypoxia on tumor metabolism. **2007**, 26, 291-8	105
1105	The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. **2007**, 12, 815-33	400
1104	Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways. **2007**, 32, 53-63	23
1103	Hypoxia-inducible factors and cancer. **2007**, 9, 278-89	37
1102	Changes in signaling pathways of cell proliferation and apoptosis during NK/Ly lymphoma aging. **2008**, 32, 1057-63	11
1101	p53 regulation of glycolytic enzymes. **2008**, 253, 16-17	
1100	Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. **2008**, 110, 439-52	53
1099	Non-invasive assessment of tumor neovasculature: techniques and clinical applications. **2008**, 27, 615-30	42

1098	6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas. **2008**, 86, 257-64	49
1097	Use of game-theoretical methods in biochemistry and biophysics. **2008**, 34, 1-17	72
1096	The role of endocrine insulin-like growth factor-I and insulin in breast cancer. **2008**, 13, 371-9	85
1095	Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. **2008**, 65, 3981-99	370
1094	An early and anaerobic scenario for the transition to undifferentiated multicellularity. **2008**, 67, 145-53	9
1093	The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells. **2008**, 62, 215-26	10
1092	Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. **2008**, 62, 985-94	29
1091	Brain mitochondrial lipid abnormalities in mice susceptible to spontaneous gliomas. **2008**, 43, 951-9	29
1090	FDG-PET scans in patients with lymphoma. **2008**, 3, 197-203	
1089	Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. **2008**, 22, 693-8	34
1088	Glukosestoffwechsel und Tumorwachstum. **2008**, 14, 22-30	2
1087	Crit□es des r□onses th□apeutiques TEP dans les h□mopathies lympho□es. **2008**, 10, 299-302	
1086	Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. **2008**, 23, 1223-32	67
1085	Atrophic gastritis: deficient complex I of the respiratory chain in the mitochondria of corpus mucosal cells. **2008**, 43, 780-8	30
1084	Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models. **2008**, 1, 40	8
1083	Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. **2008**, 8, 316-32	109
1082	Altered expression of 12S/MT-RNR1, MT-CO2/COX2, and MT-ATP6 mitochondrial genes in prostate cancer. **2008**, 68, 1086-96	22
1081	In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. **2008**, 21, 723-33	28

1080	Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. **2008**, 113, 1032-42	99
1079	Mitochondrial D310 mutations in colorectal adenomas: an early but not causative genetic event during colorectal carcinogenesis. **2008**, 122, 2242-8	16
1078	Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. **2008**, 123, 1015-24	50
1077	Stable isotope-assisted metabolomics in cancer research. **2008**, 60, 124-9	37
1076	Regulation of GLUT3 and glucose uptake by the cAMP signalling pathway in the breast cancer cell line ZR-75. **2008**, 214, 110-6	30
1075	Energy metabolism transition in multi-cellular human tumor spheroids. **2008**, 216, 189-97	109
1074	The pathogenesis of prostate cancer: from molecular to metabolic alterations. **2008**, 14, 195-201	15
1073	Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. **2008**, 15, 2336-44	143
1072	Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. **2008**, 26, 960-8	486
1071	Thoracic and abdominal organ uptake of 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) with positron emission tomography in the normal dog. **2008**, 49, 182-8	30
1070	Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. **2008**, 88, 1340-8	103
1069	Pyruvate kinase M2 is a phosphotyrosine-binding protein. **2008**, 452, 181-6	767
1068	The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. **2008**, 452, 230-3	2056
1067	Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. **2008**, 26, 1179-86	479
1066	The role of hypoxia-inducible factors in tumorigenesis. **2008**, 15, 678-85	613
1065	Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. **2008**, 10, 1477-83	296
1064	Synthesis enables identification of the cellular target of leucascandrolide A and neopeltolide. **2008**, 4, 418-24	82
1063	The interplay between MYC and HIF in cancer. **2008**, 8, 51-6	467

1062	The impact of O2 availability on human cancer. **2008**, 8, 967-75	983
1061	Human skin keloid fibroblasts display bioenergetics of cancer cells. **2008**, 128, 702-9	94
1060	Dependence of Fibroblast Autofluorescence Properties on Normal and Transformed Conditions. Role of the Metabolic Activity. **2008**, 69, 364-374	53
1059	Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets. **2008**, 49 Suppl 8, 114-6	37
1058	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. **2008**, 41, 59-85	145
1057	Nitric oxide regulates mitochondrial re-modelling in interscapular brown adipose tissue: ultrastructural and morphometric-stereologic studies. **2008**, 232, 542-8	24
1056	Yeast mitochondria import ATP through the calcium-dependent ATP-Mg/Pi carrier Sal1p, and are ATP consumers during aerobic growth in glucose. **2008**, 69, 570-85	50
1055	Long-term effects of rapamycin treatment on insulin mediated phosphorylation of Akt/PKB and glycogen synthase activity. **2008**, 314, 1281-91	4
1054	Systems biology approach to identification of biomarkers for metastatic progression in cancer. **2008**, 9 Suppl 9, S8	33
1053	mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft. **2008**, 9, 521	40
1052	Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites. **2008**, 1, 113	41
1051	Prostatic cancer: generalised malignant pattern of lactate dehydrogenase isoenzymes. **1971**, 43, 321-3	1
1050	Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1alpha) upregulated E-cadherin expression in HepG2 cells. **2008**, 582, 627-34	13
1049	Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. **2008**, 18, 330-7	204
1048	Hyaluronidases in cancer biology. **2008**, 18, 275-80	181
1047	Targeted molecular imaging in oncology: focus on radiation therapy. **2008**, 18, 136-48	23
1046	The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist's perspective. **2008**, 44, 504-8	25
1045	Mitochondrial DNA repair in aging and disease. **2008**, 129, 383-90	125

1044 Unravelling the tumor-suppressive functions of FOXO proteins. **2008**, 18, 421-9 191

1043 New roles for pyruvate kinase M2: working out the Warburg effect. **2008**, 33, 359-62 50

1042 99m-Technetium carbohydrate conjugates as potential agents in molecular imaging. **2008**, 5077-91 68

1041 Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. **2008**, 7, 5157-66 427

1040 Determinants of VO2 max decline with aging: an integrated perspective. **2008**, 33, 130-40 89

1039 Resistance to chemotherapy in cancer: a complex and integrated cellular response. **2008**, 81, 275-300 129

1038 Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes. **2008**, 7, 79 56

1037 Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. **2008**, 5, 33 58

1036 Telomerase: cellular immortalization and neoplastic transformation. Multiple functions of a multifaceted complex. **2008**, 122, 255-62 30

1035 Glycolytic enzyme inhibitors in cancer treatment. **2008**, 17, 1533-45 123

1034 Cancer as an endocrine problem. **2008**, 22, 539-50 13

1033 Frontmatter. i-xvii

1032 Mechanisms and methods in glucose metabolism and cell death. **2008**, 442, 439-57 29

1031 Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. **2008**, 10, R70 20

1030 Sugar and fat - that's where it's at: metabolic changes in tumors. **2008**, 10, 202 119

1029 Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. **2008**, 10, R11 59

1028 Molecular Imaging II. **2008**, 1

1027 Medical Imaging Modalities in Radiotherapy. 625-639

1026	Chronic cellular hypoxia as the prime cause of cancer: what is the de-oxygenating role of adulterated and improper ratios of polyunsaturated fatty acids when incorporated into cell membranes?. **2008**, 70, 298-304	16
1025	New dimensions in tumor immunology: what does 3D culture reveal?. **2008**, 14, 333-40	104
1024	C6ORF66 is an assembly factor of mitochondrial complex I. **2008**, 82, 32-8	139
1023	Anesthesia condition for (18)F-FDG imaging of lung metastasis tumors using small animal PET. **2008**, 35, 143-50	34
1022	Molecular Imaging in Oncology. **2008**, 675-691	1
1021	Application of PET/CT in the development of novel anticancer drugs. **2008**, 13, 25-38	41
1020	Glycosylated zinc(II) phthalocyanines as efficient photosensitisers for photodynamic therapy. Synthesis, photophysical properties and in vitro photodynamic activity. **2008**, 6, 2173-81	78
1019	Constitutive activation of AKT pathway inhibits TNF-induced apoptosis in mitochondrial DNA-deficient human myelogenous leukemia ML-1a. **2008**, 268, 31-7	12
1018	Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. **2008**, 11, 110-21	141
1017	Manipulation of oxidative stress to induce cell death in Ewing's sarcoma family of tumours. **2008**, 44, 2276-87	14
1016	Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells. **2008**, 365, 362-8	45
1015	Identification of poly(ADP-ribose) polymerase-1 as the OXPHOS-generated ATP sensor of nuclei of animal cells. **2008**, 366, 568-73	8
1014	Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. **2008**, 374, 111-6	76
1013	Brick by brick: metabolism and tumor cell growth. **2008**, 18, 54-61	769
1012	The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. **2008**, 7, 11-20	2786
1011	Carbohydrate restriction in patients with advanced cancer: a protocol to assess safety and feasibility with an accompanying hypothesis. **2008**, 5, 22-26	8
1010	The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. **2008**, 172, 1748-56	44
1009	CD133 is a marker of bioenergetic stress in human glioma. **2008**, 3, e3655	177

1008	Finding an "Achilles' heel" of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. **2008**, 7, 2083-9	57
1007	[Mitochondrial DNA mutations in the pathogenesis in the head and neck squamous cell carcinoma]. **2008**, 62, 158-64	9
1006	Causes and consequences of increased glucose metabolism of cancers. **2008**, 49 Suppl 2, 24S-42S	466
1005	Quantitative Issues in Response Measurement by PET. **2008**, 3, 5-11	2
1004	Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. **2008**, 49, 2545-56	199
1003	Has molecular and cellular imaging enhanced drug discovery and drug development?. **2008**, 9, 351-68	22
1002	Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. **2008**, 7, 3525-34	156
1001	ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. **2008**, 68, 8547-54	263
1000	Metabolic changes in flatfish hepatic tumours revealed by NMR-based metabolomics and metabolic correlation networks. **2008**, 7, 5277-85	55
999	Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. **2008**, 105, 18782-7	1379
998	A distinctive physiological role for IkappaBbeta in the propagation of mitochondrial respiratory stress signaling. **2008**, 283, 12586-94	48
997	Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation. **2008**, 283, 36344-53	86
996	Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. **2008**, 7, 1174-85	63
995	Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. **2008**, 180, 4476-86	522
994	Reticuloendothelium malignancy: current role of imaging. **2008**, 143, 455-68	
993	Angiogenesis. **2008**,	25
992	Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. **2008**, 14, 1831-9	63
991	2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. **2008**, 7, 809-17	72

990	Differences in mitochondrial function and antioxidant systems between regions of human glioma. **2008**, 22, 757-68	28
989	Effects of 2-deoxy-D-glucose on proliferation of vascular smooth muscle cells and endothelial cells. **2008**, 36, 986-91	9
988	Dose-dependent new bone formation by extracorporeal shock wave application on the intact femur of rabbits. **2008**, 41, 44-53	29
987	Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo. **2008**, 7, 1128-35	29
986	Hacking hexokinase halts tumor growth. **2008**, 7, 1136-8	8
985	Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. **2008**, 7, 176-87	31
984	The evolving role of nuclear molecular imaging in cancer. **2008**, 2, 829-842	20
983	[Recommendations for hormone treatment with estrogen and progesterone in the climacteric and postmenopausal periods. 37th Workshop of the Zurich Discussion Group , September 2006]. **2008**, 48, 38-46	0
982	Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. **2008**, 14, 2270-5	131
981	The interplay between MYC and HIF in the Warburg effect. **2007**, 35-53	65
980	Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. **2008**, 54, 357-63	11
979	Regulation of the PDK4 isozyme by the Rb-E2F1 complex. **2008**, 283, 27410-27417	78
978	A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. **2008**, 105, 17807-11	116
977	Whole-tumor perfusion CT parameters and glucose metabolism measurements in head and neck squamous cell carcinomas: a pilot study using combined positron-emission tomography/CT imaging. **2008**, 29, 1376-81	53
976	The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. **2008**, 68, 5198-205	134
975	Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. **2008**, 68, 8607-15	451
974	The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. **2008**, 7, 965-70	190
973	Defining Advanced Breast Cancer. **2008**, 555-565	

972	Regulation of the fructose transporter GLUT5 in health and disease. **2008**, 295, E227-37	285
971	Molecular Imaging at Tohoku University: From Cancer to Neuroreceptors. **2008**, 4, 8-13	1
970	Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. **2008**, 7, 954-8	81
969	Molecular imaging: reporter gene imaging. **2008**, 167-223	42
968	Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. **2008**, 100, 1104-12	206
967	The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. **2008**, 6, 829-42	45
966	Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. **2008**, 84, 949-57	326
965	Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. **2008**, 7, 110-20	291
964	Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. **2008**, 327, 32-7	29
963	Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. **2008**, 283, 3731-42	64
962	Influence of genotype and nutrition on survival and metabolism of starving yeast. **2008**, 105, 6930-5	101
961	Laforin confers cancer resistance to energy deprivation-induced apoptosis. **2008**, 68, 4039-44	13
960	The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models. **2008**, 47, 941-7	18
959	Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. **2008**, 14, 7751-62	62
958	Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. **2008**, 10, 767-77	162
957	Construction and identification of an antisense glucose transporter-1 plasmid. **2008**, 36, 1001-7	1
956	Glioma regression in vitro and in vivo by a suicide combined treatment. **2008**, 6, 407-17	17
955	Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. **2008**, 33, 267-77	39

954	A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. **2008**, 7, 3546-55	130
953	Isotopomer-based metabolomic analysis by NMR and mass spectrometry. **2008**, 84, 541-88	93
952	Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. **2008**, 23, 701-14	18
951	Glucose Transporters: Their Abnormalities and Significance in Type 2 Diabetes and Cancer. **2008**, 71-83	1
950	Use of metabolic pathway flux information in anticancer drug design. **2007**, 189-203	4
949	The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. **2008**,	1
948	New Concepts in Targeting and Imaging Liver Cancer. 202-212	
947	Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. **2008**, 63, 286-91; discussion 291	95
946	GRIM-19 in Health and Disease. **2008**, 15, 46-53	18
945	Mitochondrial dysfunction: bench-to-bedside optical monitoring of tissue vitality. **2008**,	3
944	Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. **2008**, 37, 426-31	104
943	. **2008**,	9
942	Tumour Hypoxia: Malignant Mediator. 245-261	
941	Nutrition, Diabetes, and Cancer. **2008**, 114-133	
940	Hyaluronidases in Cancer Biology. **2008**, 207-220	7
939	Novel application of 4-nitro-7-(1-piperazinyl)-2,1,3-benzoxadiazole to visualize lysosomes in live cells. **2008**, 45, 465, 467-8	13
938	Review: mitochondrial defects in breast cancer. **2008**, 2, 199-207	4
937	Janus Face of Glucose and Glucose-Regulating Hormones. **2008**, 44-58	1

936 A Role for the PPARgamma in Cancer Therapy. **2008**, 2008, 314974 29

935 Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation. **2008**, 2008, 930705 45

934 Control System Synthesis by Root Locus Method. **2009**,

933 Appendix. **2009**,

932 [Polymorphism of the mitochondrial microsatellite 303-315 in breast cancer in Tunisia]. **2009**, 96, 337-42

931 Monocarboxylate Transporters 1 and 4 Are Associated with CD147 in Cervical Carcinoma. **2009**, 26, 97-103 48

930 Role of peroxynitrite in the redox regulation of cell signal transduction pathways. **2009**, 14, 4809-14 152

929 The Warburg effect suppresses oxidative stress induced apoptosis in a yeast model for cancer. **2009**, 4, e4592 83

928 Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. **2009**, 4, e4715 107

927 Sulindac enhances the killing of cancer cells exposed to oxidative stress. **2009**, 4, e5804 34

926 Expression of the Bcl-2 protein BAD promotes prostate cancer growth. **2009**, 4, e6224 29

925 Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European Caucasians. **2009**, 4, e6370 25

924 The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. **2009**, 106, 12932-7 179

923 Cellular Respiration and Carcinogenesis. **2009**,

922 Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. *Science*, **2009**, 324, 1713-6 33.3 536

921 Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. **2009**, 50, 1525-32 47

920 Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. **2009**, 29, 4080-90 181

919 A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. **2009**, 18, 2046-53 73

918	Tight coupling between glucose and mitochondrial metabolism in clonal beta-cells is required for robust insulin secretion. **2009**, 284, 32395-404	84
917	The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. **2009**, 8, 3984-4001	890
916	A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. **2009**, 18, 1578-89	180
915	Insulin receptor substrate-2 regulates aerobic glycolysis in mouse mammary tumor cells via glucose transporter 1. **2009**, 284, 2031-7	32
914	Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. **2009**, 284, 26816-30	31
913	Grade-dependent proteomics characterization of kidney cancer. **2009**, 8, 971-85	82
912	Activation and clinical significance of the unfolded protein response in breast cancer. **2009**, 101, 1692-8	115
911	Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. **2009**, 100, 1926-36	54
910	Association of LETM1 and MRPL36 contributes to the regulation of mitochondrial ATP production and necrotic cell death. **2009**, 69, 3397-404	56
909	Biophysical cancer transformation pathway. **2009**, 28, 105-23	22
908	Metabolic approaches to treatment of melanoma. **2009**, 15, 6490-4	26
907	Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. **2009**, 30, 449-56	37
906	Polo-like kinases mediate cell survival in mitochondrial dysfunction. **2009**, 106, 14542-6	53
905	The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. **2009**, 284, 23225-33	88
904	Shifts in growth strategies reflect tradeoffs in cellular economics. **2009**, 5, 323	373
903	Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. **2009**, 418, 29-37	300
902	AMP-activated protein kinase promotes human prostate cancer cell growth and survival. **2009**, 8, 733-41	147
901	Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. **2009**, 50, 239-49	65

900	Expression of PGK1 by prostate cancer cells induces bone formation. **2009**, 7, 1595-604	21
899	Mutant metabolic enzymes are at the origin of gliomas. **2009**, 69, 9157-9	117
898	The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. **2009**, 76, 286-92	29
897	Feasibility of ex vivo FDG PET of the colon. **2009**, 252, 232-9	15
896	Increased lipogenesis in cancer. **2009**, 2, 545-548	3
895	Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. **2009**, 5, 581-5	91
894	In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. **2009**, 16, 1821-30	57
893	Role of oxygen in cancer: looking beyond hypoxia. **2009**, 9, 517-25	16
892	Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. **2009**, 69, 2453-60	81
891	Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. **2009**, 8, 94-100	24
890	The drug targeting and delivery approach applied to pt-antitumour complexes. A coordination point of view. **2009**, 16, 4544-80	60
889	Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. **2009**, 94, 4757-67	305
888	Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. **2009**, 27, 613-23	50
887	Dietary modulation of inflammation-induced colorectal cancer through PPAR**2009**, 2009, 498352	19
886	Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. **2009**, 6, e1000201	172
885	Glucose deprivation-induced metabolic oxidative stress and cancer therapy. **2009**, 5 Suppl 1, S2-6	64
884	Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. **2009**, 5 Suppl 1, S7-15	35
883	Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. **2009**, 69, 2375-83	148

882	HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency. **2009**, 29, 5426-40	22
881	Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. **2009**, 8, 70-85	59
880	Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. **2009**, 15, 1297-307	68
879	High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. **2009**, 20, 1543-1547	105
878	Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. **2009**, 2, 617-24	52
877	Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. **2009**, 16, 919-28	64
876	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. **2009**, 16, 391-400	101
875	Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. **2009**, 15, 3442-50	89
874	Clonal expansion of different mtDNA variants without selective advantage in solid tumors. **2009**, 662, 28-32	11
873	Human bronchial epithelial cells malignantly transformed by hexavalent chromium exhibit an aneuploid phenotype but no microsatellite instability. **2009**, 670, 42-52	40
872	Tumor thickness, depth of invasion, and Bcl-2 expression are correlated with FDG-uptake in oral squamous cell carcinomas. **2009**, 45, 891-7	26
871	Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. **2009**, 121, 29-40	526
870	Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. **2009**, 19, 32-41	119
869	Mitochondria in cancer: not just innocent bystanders. **2009**, 19, 4-11	203
868	Mitochondrial dynamics and cancer. **2009**, 19, 50-6	135
867	The Warburg Effect returns to the cancer stage. **2009**, 19, 1-3	29
866	Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes. **2009**, 10 Suppl 12, S1	6
865	Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. **2009**, 9, 454	64

864	STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. **2009**, 7, 68	114
863	Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. **2009**, 315, 2765-74	86
862	Prospects for clinical cancer metabolomics using stable isotope tracers. **2009**, 86, 165-73	42
861	Structure-based drug design: from nucleic acid to membrane protein targets. **2009**, 86, 141-50	48
860	Metabolic profiling identifies lung tumor responsiveness to erlotinib. **2009**, 87, 83-6	22
859	Nutritional channels in breast cancer. **2009**, 13, 3973-84	6
858	Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. **2009**, 13, 4104-12	26
857	METABOLISM OF H.A.I TUMOUR CELLS. **2009**, 57, 129-144	1
856	Characteristics and possible functions of mitochondrial Ca(2+) transport mechanisms. **2009**, 1787, 1291-308	166
855	Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. **2009**, 1787, 553-60	161
854	Hypoxia and the metabolic phenotype of prostate cancer cells. **2009**, 1787, 1433-43	70
853	Considering the role of pyruvate in tumor cells during hypoxia. **2009**, 1796, 55-62	13
852	Tumor cell energy metabolism and its common features with yeast metabolism. **2009**, 1796, 252-65	69
851	Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. **2009**, 46, 387-96	44
850	Metabolic defects provide a spark for the epigenetic switch in cancer. **2009**, 47, 115-27	67
849	Modulation of tricarboxylic acid cycle dehydrogenases during hepatocarcinogenesis induced by hexachlorocyclohexane in mice. **2009**, 61, 325-32	9
848	Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. **2009**, 31, 1624-33	36
847	Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. **2009** , 125, 2704-10	120

846	Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. **2009**, 115, 4655-66	51
845	Lactic acid in cancer and mitochondrial disease. **2009**, 70, 499-511	9
844	Synthesis of Novel gluco- and galacto-Functionalized Platinum Complexes. **2009**, 2009, 4842-4847	22
843	Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. **2009**, 30, 2182-92	57
842	Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF-7. **2010**, 30, 204-11	4
841	Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy. **2009**, 48, 733-41	20
840	Adenylosuccinate synthetase 1 gene is a novel target of deletion in lung adenocarcinoma. **2009**, 48, 1116-22	4
839	Targeting of cancer energy metabolism. **2009**, 53, 29-48	95
838	Cancer chemoprevention and mitochondria: targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state. **2009**, 53, 49-67	47
837	Mitochondria as targets for cancer therapy. **2009**, 53, 9-28	77
836	Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. **2009**, 132, 21-31	28
835	Mitochondria and cancer. **2009**, 454, 481-95	40
834	Cancer's craving for sugar: an opportunity for clinical exploitation. **2009**, 135, 867-77	46
833	Towards improved boron neutron capture therapy agents: evaluation of in vitro cellular uptake of a glutamine-functionalized carborane. **2009**, 14, 883-90	9
832	New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer. **2009**, 14, 1187-97	20
831	Diabetes and apoptosis: neural crest cells and neural tube. **2009**, 14, 1472-83	49
830	Biomedical applications of hyperpolarized 13C magnetic resonance imaging. **2009**, 55, 285-295	120
829	D-glucose- and D-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-D-glucoses and -D-mannoses. **2009**, 344, 1464-73	16

828	Metabolic acidosis and the importance of balanced equations. **2009**, 5, 163-165	20
827	An insight into tumoral hypoxia: the radiomarkers and clinical applications. **2009**, 3, 3-18	5
826	[PET and PET-CT of malignant tumors of the exocrine pancreas]. **2009**, 49, 131-6	6
825	The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway. **2009**, 65, 143-50	57
824	Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. **2009**, 9, 3889-900	67
823	Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. **2009**, 23, 487-94	47
822	Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. **2009**, 9, 14	61
821	The PFKFB3 splice variant UBI2K4 is downregulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells. **2009**, 35, 566-78	16
820	Hypoxia and low-nutrition double stress induces aggressiveness in a murine model of melanoma. **2009**, 100, 844-51	27
819	Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. **2009**, 19, 802-15	201
818	Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. **2009**, 11, 320-7	78
817	p53 and metabolism. **2009**, 9, 691-700	733
816	Metabolism and cancer: the circadian clock connection. **2009**, 9, 886-96	393
815	Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. **2009**, 100, 923-31	46
814	De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. **2009**, 100, 1369-72	347
813	AMP-activated protein kinase and cancer. **2009**, 196, 55-63	134
812	Mitochondrial metabolism and cancer. **2009**, 1177, 66-73	123
811	Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. **2009**, 158, 588-600	50

810	The current role of PET-CT in the characterization of hepatobiliary malignancies. **2009**, 11, 4-17		16
809	A model combining acid-mediated tumour invasion and nutrient dynamics. **2009**, 10, 1955-1975		10
808	Two-photon autofluorescence dynamics imaging reveals sensitivity of intracellular NADH concentration and conformation to cell physiology at the single-cell level. **2009**, 95, 46-57		195
807	Mathematical modelling of the Warburg effect in tumour cords. **2009**, 258, 578-90		27
806	Synthesis and anticancer activity of N-bis(trifluoromethyl)alkyl-N'-thiazolyl and N-bis(trifluoromethyl)alkyl-N'-benzothiazolyl ureas. **2009**, 44, 4944-53		74
805	Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. **2009**, 384, 254-62		105
804	Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. **2009**, 61, 1250-75		192
803	Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*, **2009**, 324, 1029-33	33.3	9509
802	Mitochondrial genomic instability in colorectal cancer: no correlation to nuclear microsatellite instability and allelic deletion of hMSH2, hMLH1, and p53 genes, but prediction of better survival for Dukes' stage C disease. **2009**, 16, 2918-25		10
801	Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. **2009**, 16, 2834-9		16
800	The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells?. **2009**, 35, 209-25		98
799	Tools and ingredients for the biocatalytic synthesis of metabolites. **2009**, 4, 1253-65		19
798	Reactive Oxygen Species in the Induction of Toxicity. **2009**,		4
797	Redox regulation and its emerging roles in stem cells and stem-like cancer cells. **2009**, 11, 1107-22		82
796	Metabolic transformation in cancer. **2009**, 30, 1269-80		174
795	Therapeutic strategies by modulating oxygen stress in cancer and inflammation. **2009**, 61, 290-302		400
794	Mitochondrial DNA adducts in the lung and liver of F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and (S)-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. **2009**, 22, 406-14		27
793	Proteomic analysis of butyrate effects and loss of butyrate sensitivity in HT29 colorectal cancer cells. **2009**, 8, 1220-7		24

792	Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. **2009**, 69, 4918-25	699
791	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. **2009**, 12, 114-26	167
790	New horizons in prostate cancer imaging. **2009**, 70, 212-26	50
789	Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. **2009**, 35, 1286-94	27
788	Electron microscopy morphology of the mitochondrial network in human cancer. **2009**, 41, 2062-8	77
787	Glucose avidity of carcinomas. **2009**, 276, 125-35	96
786	Early alterations in protein and gene expression in rat kidney following bromate exposure. **2009**, 47, 1154-60	18
785	Fiber-based lactate recordings with fluorescence resonance energy transfer sensors by applying an magnetic resonance-informed correction of hemodynamic artifacts.. **2022**, 9, 032212	0
784	A viral interferon regulatory factor degrades RNA-binding protein hnRNP Q1 to enhance aerobic glycolysis via recruiting E3 ubiquitin ligase KLHL3 and decaying GDPD1 mRNA.. **2022**,	0
783	Ubiquitin-modified proteome analysis of Eriocheir sinensis hemocytes during Spiroplasma eriocheiris infection.. **2022**, 125, 109-119	1
782	SIRT5 is involved in the proliferation and metastasis of breast cancer by promoting aerobic glycolysis.. **2022**, 235, 153943	0
781	Prospects of mitochondrial transplantation in clinical medicine: aspirations and challenges.. **2022**,	0
780	Cancer cells targeting with genetically engineered constructs based on a pH-dependent membrane insertion peptide and fluorescent protein.. **2022**, 612, 141-146	
779	Arsenic exposure elevated ROS promotes energy metabolic reprogramming with enhanced AKT-dependent HK2 expression.. **2022**, 155691	2
778	Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer. **2022**, 10,	0
777	Targeting of the Peritumoral Adipose Tissue Microenvironment as an Innovative Antitumor Therapeutic Strategy. **2022**, 12, 702	0
776	Lung cancer: A radiologic overview. 7-19	1
775	Radiologic evaluation of the solitary pulmonary nodule. 13-26	

774	Crosstalk of Immuno-Oncology and Metabolism: Influence of Akkermansia muciniphila and Personalized Therapy Approach. **2022**, 91-115	
773	Immuno-onco-metabolism and Therapeutic Resistance. **2022**, 45-89	3
772	Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics. **2022**, 23, 5602	2
771	Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.. **2022**,	0
770	Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions.. **2022**, 13, 12489-12503	1
769	The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients.. **2022**,	2
768	Decreased EMILIN2 correlates to metabolism phenotype and poor prognosis of ovarian cancer.. **2022**,	
767	Cancer Biology of Molecular Imaging. **2022**, 1-37	
766	Principles of PET and Its Role in Understanding Drug Delivery to the Brain. **2022**, 329-352	
765	Metabolic Strategies in Healthcare: A New Era. **2022**, 13, 655	0
764	Hyperpolarisierte 13C-Magnetresonanztomographie ein Fenster in den Stoffwechsel. **2022**, 62, 486-495	
763	Elevated Serum Lactate in Glioma Patients: Associated Factors. **2022**, 12,	
762	Emerging applications of high-precision Cu isotopic analysis by MC-ICP-MS. **2022**, 156084	1
761	A Resource to Infer Molecular Paths Linking Cancer Mutations to Perturbation of Cell Metabolism. **2022**, 9,	0
760	Phosphorous Paradox and the Unsuspected Intrinsic Property of Human Beings to Dissociate the Water Molecule.	
759	Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors. **2022**, 14, 2552	1
758	Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. **2022**, 11,	2
757	Developing dietary interventions as therapy for cancer.	4

756	Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. **2022**, 181, 106270	5
755	Microbial OMICS In Oral Cancer. **2022**, 149-161	
754	The development of small-molecule inhibitors targeting hexokinase 2. **2022**,	1
753	Construction of a prognostic glycolysis-related lncRNA signature for patients with colorectal cancer.	
752	Selective inhibition of carbonic anhydrase IX by sulphonylated 1,2,3-triazole incorporated benzenesulphonamides capable of inducing apoptosis. **2022**, 37, 1454-1463	2
751	Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. 12,	2
750	Adverse effects under immune checkpoint inhibitors on 18F-FDG PET/CT imaging.	0
749	Metabolomes of Lewis lung carcinoma metastases and normal lung tissue from mice fed different diets. **2022**, 109051	3
748	Ring finger protein 180 suppresses cell proliferation and energy metabolism of non-small cell lung cancer through downregulating C-myc. **2022**, 20,	0
747	Inhibiting Warburg Effect Can Suppress the Biological Activity and Secretion Function of Keloid Fibroblasts.	
746	The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer. **2022**, 12, 488	0
745	Intracellular localization of the proteasome in response to stress conditions. **2022**, 102083	2
744	Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. **2022**, 104483	0
743	Genipin, an Inhibitor of UCP2 as a Promising New Anticancer Agent: A Review of the Literature. **2022**, 23, 5637	1
742	Metabolic Determinants in Cardiomyocyte Function and Heart Regenerative Strategies. **2022**, 12, 500	0
741	Metabolomic Analysis of Plasma from Breast Cancer Patients Using Ultra-High-Performance Liquid Chromatography Coupled with Mass Spectrometry: An Untargeted Study. **2022**, 12, 447	
740	Identification of natural product inhibitors of de novo lipogenesis enzymes as an anti-cancer strategy: An in silico approach. 1-14	
739	Distinguishing Tumor Admixed in a Radiation Necrosis (RN) Background: 1H and 2H MR With a Novel Mouse Brain-Tumor/RN Model. 12,	0

738	Metformin: Is it a drug for all reasons and diseases?. **2022**, 155223	6
737	Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective. **2022**, 29, 200-222	2
736	Proteomic analysis reveals stage-specific reprogramed metabolism for the primary breast cancer cell lines MGSO-3 and MACL-1. 2200095	1
735	Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. **2022**, 114504	1
734	Method to determine the statistical technical variability of SUV metrics. **2022**, 9,	
733	LncRNA OVAAL enhances nucleotide synthesis via pyruvate carboxylase to promote 5-FU resistance in gastric cancer.	
732	Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster. **2022**, 156, 155917	
731	Effects of silkworm pupa protein on apoptosis and energy metabolism in human colon cancer DLD-1 cells. **2022**, 11, 1171-1176	1
730	Glycolysis by Tumor Mitochondria and the Action of Insulin. **1957**, 125, 496-498	0
729	Glycolysis by Tumor Mitochondria and the Action of Insulin. **1957**, 125, 496-498	1
728	Need of integrated management of type ii diabetes mellitus as a serious risk factor in modifying outcomes in cancer management: A literature review. **2021**, 2, 50	
727	Role of MicroRNAs in Cell Growth Proliferation and Tumorigenesis. **2022**, 37-51	1
726	Dual-Sensitive Fluorescent Nanoprobes for Detection of Matrix Metalloproteinases and Low pH in 3D Tumor Microenvironment.	1
725	Targeting the Metabolism in Cancer Cells for Cancer Therapy. **2022**, 1-23	
724	Reactive Oxygen Species and Cancer Stem Cells. **2022**, 1-35	
723	Metabolic Reprogramming of Circulating Tumor Cells for Metastasis. **2022**, 175-183	
722	Cancer metabolism regulation by phytonutrients. **2022**, 237-290	
721	The Use of Seahorse XF Assays to Interrogate Real-Time Energy Metabolism in Cancer Cell Lines. **2022**, 225-234	

720	Effect of Lactate Export Inhibition on Anaplastic Thyroid Cancer Growth and Metabolism. **2022**, 234, 1044-1050	0
719	Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. **2022**, 115153	1
718	Mitochondrial Dysfunction and the Glycolytic Switch Induced by Caveolin-1 Phosphorylation Promote Cancer Cell Migration, Invasion, and Metastasis. **2022**, 14, 2862	0
717	Differential response of hepatocellular carcinoma glycolytic metabolism and oxidative stress markers after exposure to human amniotic membrane proteins.	
716	Identification of oncogenic signaling pathways associated with the dimorphic metabolic dysregulations in gastric cancer subtypes. **2022**, 39,	
715	Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism. **2022**, 14, 2376	0
714	Mitochondria as the Essence of Yang Qi in the Human Body.	0
713	Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy. **2022**, 39,	
712	Transcriptional Profiling of Leishmania infantum Infected Dendritic Cells: Insights into the Role of Immunometabolism in Host-Parasite Interaction. **2022**, 10, 1271	1
711	The mitochondrial adenine nucleotide transporters in myogenesis. **2022**,	0
710	Differentiation and prognostic stratification of acute myeloid leukemia by serum-based spectroscopy coupling with metabolic fingerprints. **2022**, 36,	1
709	Long Noncoding RNAs and Circular RNAs in the Metabolic Reprogramming of Lung Cancer: Functions, Mechanisms, and Clinical Potential. **2022**, 2022, 1-17	
708	3-Bromopyruvic acid regulates glucose metabolism by targeting the c-Myc/TXNIP axis and induces mitochondria-mediated apoptosis in TNBC cells. **2022**, 24,	1
707	SIRT6 promotes mitochondrial fission and subsequent cellular invasion in ovarian cancer.	1
706	Spatiotemporal patterns and bifurcations with degeneration in a symmetry glycolysis model. **2022**, 106644	
705	A hexa-species transcriptome atlas of mammalian embryogenesis delineates metabolic regulation across three different implantation modes. **2022**, 13,	2
704	Isolation of Caldorazole, a Thiazole-Containing Polyketide with Selective Cytotoxicity under Glucose-Restricted Conditions.	1
703	Loss of Heterozygosity for KrasG12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2□c-Myc-Regulated Glutamine Metabolism. **2022**, 23, 6697	0

702	1H qNMR-Based Metabolomics Discrimination of Covid-19 Severity.	4
701	MicroRNAs in the Regulation of Solute Carrier Proteins Behind Xenobiotic and Nutrient Transport in Cells. 9,	
700	Manipulating Metabolic Alterations and Its Consequence to Unleash the Potential of Antitumor Immunotherapy. **2022**, 23,	
699	Cancer is a survival process under persistent microenvironmental and cellular stresses. **2022**,	
698	Designing Lactate Dehydrogenase-Mimicking SnSe Nanosheets To Reprogram Tumor-Associated Macrophages for Potentiation of Photothermal Immunotherapy. **2022**, 14, 27651-27665	0
697	Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism.	1
696	A mathematical model of GLUT1 modulation in rods and RPE and its differential impact in cell metabolism. **2022**, 12,	0
695	Analysis of the expression, function and signaling of glycogen phosphorylase isoforms in hepatocellular carcinoma. **2022**, 24,	
694	DLGAP1-AS2-Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma.	1
693	Injectable alginate hydrogels for synergistic tumor combination therapy through repolarization of tumor-associated macrophages. **2022**, 348, 239-249	1
692	N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth. **2022**, 54, 102366	0
691	The emerging role of microbiota-derived short-chain fatty acids in immunometabolism. **2022**, 110, 108983	1
690	Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. **2004**, 3, 537-544	39
689	Novel Allosteric Glutaminase 1 Inhibitors with Macrocyclic Structure Activity Relationship Analysis.	
688	A Serum Metabolomics Study Based on LC-MS: Chemosensitization Effects of Rauvolfia Vomitoria Afzel. Combined with 5-Fluorouracil on Colorectal Cancer Mice.	
687	Cancer Biology of Molecular Imaging. **2022**, 1-37	
686	Lactate receptor HCAR1 regulates cell growth, metastasis and maintenance of cancer-specific energy metabolism in breast cancer cells. **2022**, 26,	2
685	Riluzole regulates pancreatic cancer cell metabolism by suppressing the Wnt-□catenin pathway. **2022**, 12,	0

684	Le transport mitochondrial. **2022**, 38, 585-593	
683	Ketogenic Metabolic Therapy for Glioma. **2022**,	1
682	Physical Exercise and Tumor Energy Metabolism. **2022**, 100600	0
681	Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor-positive breast cancer via regulation of the mTOR pathway.	0
680	Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche. 12,	0
679	GLUT1 production in cancer cells: a tragedy of the commons. **2022**, 8,	1
678	The Mitochondrial HSP90 Paralog TRAP1: Structural Dynamics, Interactome, Role in Metabolic Regulation, and Inhibitors. **2022**, 12, 880	3
677	The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK. **2022**, 20, 418	1
676	Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial. **2022**, 20,	0
675	Glutor, a Glucose Transporter Inhibitor, Exerts Antineoplastic Action on Tumor Cells of Thymic Origin: Implication of Modulated Metabolism, Survival, Oxidative Stress, Mitochondrial Membrane Potential, pH Homeostasis, and Chemosensitivity. 12,	1
674	Aging-associated accumulation of mitochondrial DNA mutations in tumor origin.	1
673	Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma. **2022**, 14, 1380	0
672	Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5.	1
671	PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.	0
670	An Oncological Emergency: Severe Type B Lactic Acidosis From Warburg Effect in Diffuse Large B-cell Lymphoma. **2022**,	0
669	Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells. **2022**, 60, 735-745	2
668	The thermodynamic state of aerobic glycolytic flux plays a critical role in stabilizing aerobic glycolytic flux of cancer cells.	
667	Mitochondrial DNA mutations in aging and cancer.	2

666	Cancer depends on fatty acids for ATP production: a possible link between cancer and obesity. **2022**,	2
665	Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2 Pathway. **2022**,	0
664	Mitochondrial Genetic and Epigenetic Regulations in Cancer: Therapeutic Potential. **2022**, 23, 7897	2
663	GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review. **2022**, 23, 7373	
662	EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis. 12,	0
661	Salivary metabolomics with machine learning for colorectal cancer detection.	1
660	Meaning and Significance of Alkalization Therapy for Cancer12,	0
659	Acetyl-CoA synthetase 2(ACSS2): a review with a focus on metabolism and tumor development. **2022**, 13,	0
658	Mitochondrial function in intestinal epithelium homeostasis and modulation in diet-induced obesity. **2022**, 101546	3
657	Mapping Endocrine Networks by Stable Isotope Tracing. **2022**, 100381	
656	Ca2+ Signalling and Hypoxia/Acidic Tumour Microenvironment Interplay in Tumour Progression. **2022**, 23, 7377	0
655	Historical perspective of tumor glycolysis: A century with Otto Warburg. **2022**,	0
654	AMP-activated protein kinase β1 or β2 deletion enhances colon cancer cell growth and tumorigenesis. **2022**,	
653	Glucose metabolism controls human T-cell-mediated tumor immunosurveillance in diabetes.	0
652	Nonlinear Multi-Objective Flux Balance Analysis of the Warburg Effect. **2022**, 111223	
651	Changes in metabolic profiling of whiteleg shrimp (Penaeus vannamei) under hypoxic stress. **2022**, 107798	1
650	Acid-base homeostasis and implications to the phenotypic behaviors of cancer. **2022**,	0
649	Glucometabolic reprogramming: From trigger to therapeutic target in hepatocellular carcinoma. 12,	0

648	The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome. **2022**, 12,	0
647	Eleutheroside E functions as anti-cervical cancer drug by inhibiting the phosphatidylinositol 3-kinase pathway and reprogramming the metabolic responses.	
646	RNA m 1 A methylation regulates glycolysis of cancer cells through modulating ATP5D. **2022**, 119,	3
645	Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review). **2022**, 48,	0
644	Targeting mitochondrial metabolism for precision medicine in cancer. **2022**, 29, 1304-1317	5
643	Classification of Cancer Response to Antiglycolytic Agents: An Approach to Understanding and Predicting Cancer.	
642	VIOLATIONS OF HUMAN PROTEIN PROFILE IN HEAVY METALS EXPOSURE. **2012**, 19, 7-14	2
641	Cancer Biology and Implications for the Perioperative Period. **2023**, 24-45	
640	Miro proteins and their role in mitochondrial transfer in cancer and beyond. 10,	
639	Developing a Method to Estimate the Downstream Metabolite Signals from Hyperpolarized [1-13C]Pyruvate. **2022**, 22, 5480	
638	Prognostic implication of an energy metabolism-related 11-gene signature in lung cancer.	
637	Vitamin B3, nicotinamide, enhances mitochondrial metabolism to promote differentiation of the retinal pigment epithelium. **2022**, 102286	1
636	Neuropharmacological Study of Posaconazole for Glioblastoma: A Phase 0 Clinical Trial Protocol. **2022**, Publish Ahead of Print,	
635	Integrating a dynamic central metabolism model of cancer cells with a hybrid 3D multiscale model for vascular hepatocellular carcinoma growth. **2022**, 12,	0
634	Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer. 13,	0
633	The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. **2022**, 23, 8141	1
632	NUCLEAR MEDICINE APPROACHES TO MUSCULOSKELETAL DISEASE. **1994**, 32, 227-253	2
631	D-Mannose-appended 5,15-diazaporphyrin for photodynamic therapy.	1

630	Supportive and Palliative Care in Cancer Therapies: Path from Tumor-Driven Therapies to Patient-Driven Ones. **2022**, 13, 287-359	
629	pH-responsive nanomedicine for breast cancer targeting. **2022**, 335-349	
628	Mechanism and application of nonessential amino acid deprivation associated with tumor therapy. **2022**, 1,	1
627	GLUT3 Promotes Epithelial-Mesenchymal Transition via TGF-β/JNK/ATF2 Signaling Pathway in Colorectal Cancer Cells. **2022**, 10, 1837	0
626	Reprogrammed Lipid Metabolism and the Lipid-Associated Hallmarks of Colorectal Cancer. **2022**, 14, 3714	0
625	HPV18 oncoproteins driven expression of PKM2 reprograms HeLa cell metabolism to maintain aerobic glycolysis and viability.	
624	Mitochondrial perturbations enhance cell-mediated innate immunity in Drosophila.	
623	Metabolic reprogramming consequences of sepsis: adaptations and contradictions. **2022**, 79,	0
622	Stearoyl-CoA desaturase 1 as a therapeutic target for cancer: a focus on hepatocellular carcinoma.	4
621	Hypoxia: molecular pathophysiological mechanisms in human diseases.	2
620	The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors. **2022**, 27,	1
619	Mutated FANCA Gene Role in the Modulation of Energy Metabolism and Mitochondrial Dynamics in Head and Neck Squamous Cell Carcinoma. **2022**, 11, 2353	0
618	Roles of mitochondrial genetics in cancer metastasis. **2022**,	
617	Frataxin deficiency disrupts mitochondrial respiration and pulmonary endothelial cell function.	
616	Metabolic reprogramming: A novel metabolic model for pulmonary hypertension. 9,	
615	Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.	1
614	Refining the Role of Pyruvate Dehydrogenase Kinases in Glioblastoma Development. **2022**, 14, 3769	0
613	Long non-coding RNAs play an important regulatory role in tumorigenesis and tumor progression through aerobic glycolysis. 9,	

612	Mitochondrial-encoded complex I impairment induces a targetable dependency on aerobic fermentation in H□thle cell carcinoma of the thyroid.	
611	Cytotoxic derivatives of dichloroacetic acid and some metal complexes.	0
610	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. **2022**, 15,	2
609	Radiodynamic Therapy with Acridine Orange Is an Effective Treatment for Bone Metastases. **2022**, 10, 1904	0
608	Five-to-Seven Carbon Glycols Severely Impair Bioenergetics and Metabolism of Aggressive Lung Cancer Cells. 2200050	
607	Stressed to death: Mitochondrial stress responses connect respiration and apoptosis in cancer. **2022**,	1
606	Mitochondrial DNA is a major source of driver mutations in cancer. **2022**,	3
605	A happy cell stays home: When metabolic stress creates epigenetic advantages in the tumor microenvironment. 12,	1
604	Primary-like Human Hepatocytes Genetically Engineered to Obtain Proliferation Competence as a Capable Application for Energy Metabolism Experiments in In Vitro Oncologic Liver Models. **2022**, 11, 1195	
603	Relationship between metabolic reprogramming and drug resistance in breast cancer. 12,	1
602	Metabolic targeting of malignant tumors: a need for systemic approach.	
601	Data-Independent Acquisition and Quantification of Extracellular Matrix from Human Lung in Chronic Inflammation-Associated Carcinomas.	
600	Effect of diet on molecular relationships between Atlantic cod larval muscle growth dynamics, metabolism, and antioxidant defense system. 9,	
599	Evaluation of Oral Mucosal Lesions Using the IllumiScan□ Fluorescence Visualisation Device: Distinguishing Squamous Cell Carcinoma. **2022**, 19, 10414	
598	Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma. **2022**,	1
597	Development and validation of glycolysis-cholesterol synthesis genes in lung adenocarcinoma.	
596	Editorial. **2022**,	
595	Acidosis induces RIPK1-dependent death of glioblastoma stem cells via acid-sensing ion channel 1a. **2022**, 13,	0

594	Reprogramming of lactate metabolism is linked to the oncogenesis of the virus-induced leukemia.	
593	Identification of subgroups and development of prognostic risk models along the glycolysis-cholesterol synthesis axis in lung adenocarcinoma.	0
592	Effect of Expression of Nuclear-Encoded Cytochrome C Oxidase Subunit 4 Isoforms on Metabolic Profiles of Glioma Cells. **2022**, 12, 748	
591	Restricted Ketogenic Diet Therapy for Primary Lung Cancer With Metastasis to the Brain: A Case Report. **2022**,	0
590	Saturation of the mitochondrial NADH shuttles drives aerobic glycolysis in proliferating cells. **2022**,	4
589	FBP1 /miR-24-1/enhancer axis activation blocks renal cell carcinoma progression via Warburg effect. 12,	
588	Modulating Chaperone-Mediated Autophagy and Its Clinical Applications in Cancer. **2022**, 11, 2562	1
587	Regulation of tumor metabolism by post translational modifications on metabolic enzymes.	0
586	Recent Progress in Analysis of Intermediary Metabolism by ex vivo 13 C NMR.	0
585	Hypermetabolism and Substrate Utilization Rates in Pheochromocytoma and Functional Paraganglioma. **2022**, 10, 1980	
584	CK2 and the Hallmarks of Cancer. **2022**, 10, 1987	1
583	The long noncoding RNA HOXA11-AS promotes lung adenocarcinoma proliferation and glycolysis via the micro RNA -148b-3p/ PKM2 axis.	0
582	Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. **2022**, 27, 4988	0
581	Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews. **2022**, 14, 3834	1
580	Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway. **2022**, 41,	0
579	Research progress on the pharmacological effects of berberine targeting mitochondria. 13,	0
578	Prognostic capacity of the transcriptional expression of lactate dehydrogenase A in patients with head and neck squamous cell carcinoma.	
577	The roles of glycolysis in osteosarcoma. 13,	1

576	Colorectal Cancer and Microbiota Modulation for Clinical Use. A Systematic Review. 1-17	1
575	Commonalities in Metabolic Reprogramming between Tobacco Use and Oral Cancer. **2022**, 19, 10261	1
574	Metabolic management of microenvironment acidity in glioblastoma. 12,	0
573	Sphingosine-1-phosphate-lyase deficiency affects glucose metabolism in a way that abets oncogenesis.	1
572	Advances in measuring cancer cell metabolism with subcellular resolution.	0
571	Weighted Gene Co-Expression Network Analysis and Support Vector Machine Learning in the Proteomic Profiling of Cerebrospinal Fluid from Extraventricular Drainage in Child Medulloblastoma. **2022**, 12, 724	
570	Investigating the role of GLUL as a survival factor in cellular adaptation to glutamine depletion via targeted stable isotope resolved metabolomics. 9,	
569	The F1Fo-ATPase inhibitor protein IF1 in pathophysiology. 13,	0
568	Complex metabolic interactions between ovary, plasma, urine, and hair in ovarian cancer. 12,	
567	Synthesis and In Vitro Evaluation of a Set of 6-Deoxy-6-thio-carboranyl d-Glucoconjugates Shed Light on the Substrate Specificity of the GLUT1 Transporter.	1
566	Harsh intertidal environment enhances metabolism and immunity in oyster (Crassostrea gigas) spat. **2022**, 180, 105709	0
565	Circulating tumor cell isolation for cancer diagnosis and prognosis. **2022**, 83, 104237	9
564	Reprogramming of central carbon metabolism in hepatocellular carcinoma. **2022**, 153, 113485	1
563	AQP9 transports lactate in tumor-associated macrophages to stimulate an M2-like polarization that promotes colon cancer progression. **2022**, 31, 101317	0
562	Aspirin blocks AMPK/SIRT3-mediated glycolysis to inhibit NSCLC cell proliferation. **2022**, 932, 175208	0
561	18F-FDG Micro PET/CT imaging to evaluate the effect of BRCA1 knockdown on MDA-MB231 breast cancer cell radiosensitivity. **2022**, 25, 101517	
560	NIR-light-controlled G-quadruplex hydrogel for synergistically enhancing photodynamic therapy via sustained delivery of metformin and catalase-like activity in breast cancer. **2022**, 16, 100375	1
559	Cascade-reaction-triggered engineering nanocatalytic theranostics reconstructing tumor microenvironment through synergistic oxidative damage and aerobic glycolysis inhibition against colon cancer. **2023**, 451, 138336	1

558	Serum Fructosamine and Subsequent Breast Cancer Risk: A Nested Case-Control Study in the ORDET Prospective Cohort Study. **2005**, 14, 271-274	2
557	TGF- signaling in the tumor metabolic microenvironment and targeted therapies. **2022**, 15,	1
556	Oncogenic and Stemness Signatures of the High-Risk HCMV Strains in Breast Cancer Progression. **2022**, 14, 4271	1
555	Connexins and Glucose Metabolism in Cancer. **2022**, 23, 10172	0
554	Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy. **2022**, 23, 9943	1
553	Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma. 12,	0
552	Walking the high wire: How neurons maintain stability in the crossline of neurodegeneration. **2022**, 34, 1227-1229	0
551	Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37. **2022**, 13,	1
550	Murine blastocysts generated by in vitro fertilization show increased Warburg metabolism and altered lactate production. 11,	0
549	Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression. **2022**, 11, 2857	0
548	HMGA2 mediates Cr (VI)-induced metabolic reprogramming through binding to mitochondrial D-Loop region. **2022**, 244, 114085	1
547	Oral administration of sodium bicarbonate can enhance the therapeutic outcome of Doxil via neutralizing the acidic tumor microenvironment. **2022**, 350, 414-420	0
546	GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism. **2022**, 56, 102458	0
545	A simulation of parental and glycolytic tumor phenotype competition predicts observed responses to pH changes and increased glycolysis after anti-VEGF therapy. **2022**, 352, 108909	0
544	Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis. **2022**, 75, 128956	0
543	lncRNA JPX modulates malignant progress of osteosarcoma through targeting miR-33a-5p and PNMA1 regulatory loop. **2022**, 25, 101504	0
542	The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition. **2022**, 549, 215921	0
541	Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. **2022**, 179, 103796	0

540	Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer. **2022**, 6, 100065	0
539	The role of fatty acids metabolism on cancer progression and therapeutics development. **2023**, 101-132	0
538	Aging-related neoplasia. **2023**, 547-575	0
537	Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics. **2022**, 14, 175883592211180	0
536	Therapy-Induced Toxicities Associated with the Onset of Cachexia. **2022**, 139-153	0
535	Targeting the Metabolism in Cancer Cells for Cancer Therapy. **2022**, 2357-2379	0
534	Emerging Metabolic Regulation of Redox Status in Cancer Stem Cells Progression and Metastasis. **2022**, 2281-2295	0
533	The Effect of Oxidative Nutritional Products on Cancer. **2022**, 637-651	0
532	Genome-scale Metabolic Model Guided Subtyping Lung Cancer towards Personalized Diagnosis. **2022**, 55, 641-646	0
531	Metabolic dysregulation in cancer progression. **2022**, 1-39	0
530	Tumor cell metabolism and autophagy as therapeutic targets. **2022**, 73-107	0
529	Induction of Oxidative Stress: A Promising Approach in Female Gynecological Cancer Therapeutic Arsenal. **2022**, 2489-2508	0
528	Cancer Biology of Molecular Imaging. **2022**, 3-39	0
527	Targeting Tumors Through Enhancers of Oxidative Stress. **2022**, 3629-3648	0
526	Combination of the Natural Product Mensacarcin with Vemurafenib (Zelboraf) Combats BRAF Mutant and Chemo-Resistant Melanoma in Vitro by Affecting Cell Metabolism and Cellular Migration.	0
525	Research Progress of Long Non-Coding RNA Regulating Glucose Metabolism in Acute My-eloid Leukemia Cells. **2022**, 12, 7865-7870	0
524	Reactive Oxygen Species and Cancer Stem Cells: Molecular Interactions and Their Implications in Cancer. **2022**, 2227-2268	0
523	Reactive Oxygen Species and Cancer Stem Cells: Molecular Interactions and Their Implications in Cancer. **2022**, 1-42	0

522	Dynamic fluorescence probing glycolysis suppression process in the cancer cells treated with Trichostatin A.	0
521	Assessment of higher-order singular value decomposition denoising methods on dynamic hyperpolarized [1-13C]pyruvate MRI data from patients with glioma. **2022**, 36, 103155	0
520	Colon microbiota modulation by dairy-derived diet: new strategy for prevention and treatment of colorectal cancer. **2022**, 13, 9183-9194	1
519	Alteration in Plasma Metabolome in High-Fat Diet-Fed Monocyte Chemotactic Protein-1 Knockout Mice Bearing Pulmonary Metastases of Lewis Lung Carcinoma. **2022**, 15, 117863882211111	0
518	Redressal of the Molecular Mechanisms of Colon and Other Cancer Stem Cell Energetics/Oxidative Stress for Possible Translation. **2022**, 2043-2061	0
517	ROS Modulatory Role of HDAC Inhibitors in Cancer Cells. **2022**, 3259-3286	0
516	High-Fidelity ATP Imaging via an Isothermal Cascade Catalytic Amplifier.	2
515	Combined targeting autophagy and metabolism for cancer therapy. **2022**, 215-238	0
514	The Effect of Oxidative Nutritional Products on Cancer. **2022**, 1-15	0
513	Metabolism-Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53-Mutant Colon Cancer. 2201992	0
512	The Role of Neural Signaling in the Pancreatic Cancer Microenvironment. **2022**, 14, 4269	0
511	Brain type of creatine kinase induces doxorubicin resistance via TGF- signaling in MDA-MB-231 breast cancer cells. 1-11	0
510	Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy. 12,	0
509	Phytochemical screening and potential antioxidant, antibacterial and anti-melanoma activities of <i>Rollinia dolabripetala</i> leaves.	0
508	Tumor acidity: From hallmark of cancer to target of treatment. 12,	0
507	Insulin-Lowering Diets in Metastatic Cancer. **2022**, 14, 3542	0
506	[Review] Towards Clinical Application of L-Glucose. **2022**, 12, 140-154	0
505	MicroRNAs as Regulators of Cancer Cell Energy Metabolism. **2022**, 12, 1329	0

504	Preoperative prediction of intrahepatic cholangiocarcinoma lymph node metastasis by means of machine learning: a multicenter study in´China. **2022**, 22,	0
503	Comparative analysis of right ventricular metabolic reprogramming in pre-clinical rat models of severe pulmonary hypertension-induced right ventricular failure. 9,	0
502	A metabolic reprogramming-related prognostic risk model for clear cell renal cell carcinoma: From construction to preliminary application. 12,	0
501	Enabling factor for cancer hallmark acquisition: Small nucleolar RNA host gene 17. 12,	0
500	Effect of TP53 deficiency and KRAS signaling on the bioenergetics of colon cancer cells in response to different substrates: A single cell study. 10,	0
499	Optimization of Bifunctional Antisense Oligonucleotides for Regulation of Mutually Exclusive Alternative Splicing of PKM Gene. **2022**, 27, 5682	0
498	Evolutionary View on Lactate-Dependent Mechanisms of Maintaining Cancer Cell Stemness and Reprimitivization. **2022**, 14, 4552	0
497	AMPK: An odyssey of a metabolic regulator, a tumor suppressor, and now a contextual oncogene. **2022**, 1877, 188785	3
496	YY1 promotes pancreatic cancer cell proliferation by enhancing mitochondrial respiration. **2022**, 22,	0
495	Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma. 13,	0
494	BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway. 10, e14052	0
493	In ovo model in cancer research and tumor immunology. 13,	2
492	Prognostic value of lactate metabolism-related gene expression signature in adult primary gliomas and its impact on the tumor immune microenvironment. 12,	0
491	Glycolytic Inhibitors Potentiated the Activity of Paclitaxel and Their Nanoencapsulation Increased Their Delivery in a Lung Cancer Model. **2022**, 14, 2021	1
490	Co-Infection and Cancer: Host–Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses. **2022**, 14, 2037	2
489	The Long and the Short of It: NEAT1 and Cancer Cell Metabolism. **2022**, 14, 4388	0
488	A preclinical model of cutaneous melanoma based on reconstructed human epidermis. **2022**, 12,	0
487	Advances in Glycolysis Metabolism of Atherosclerosis.	0

486	Out of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis.	0
485	Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells. **2022**, 23, 10037	1
484	The requirement for mitochondrial respiration in cancer varies with disease stage. **2022**, 20, e3001800	0
483	Circ_0136666 aggravates osteosarcoma development through mediating miR-1244/CEP55 axis. **2022**, 17,	0
482	In vivo isotope tracing reveals a requirement for the electron transport chain in glucose and glutamine metabolism by tumors. **2022**, 8,	0
481	Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy. 12,	1
480	Evaporated fraction of thujopsene from Thujopsis dolabrata starves cancer cells via PKM2.	0
479	Role of Polyamines as Biomarkers in Lymphoma Patients: A Pilot Study. **2022**, 12, 2151	2
478	Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma. **2022**, 11, 2956	1
477	CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration. **2022**, 22,	0
476	[18F]FDG PET/CT in rheumatoid arthritis. **2022**, 66,	0
475	Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer. **2022**, 22,	0
474	The metabolic plasticity of B cells. 9,	0
473	Mitochondria-targeting folic acid-modified nanoplatform based on mesoporous carbon and a bioactive peptide for improved colorectal cancer treatment. **2022**,	0
472	Photodynamic Therapy by Glucose Transporter 1-Selective Light Inactivation. **2022**, 7, 34685-34692	2
471	Colorectal cancer: Metabolic interactions reshape the tumor microenvironment. **2022**, 1877, 188797	0
470	Association between use of antacid medications (proton pump inhibitors and histamine-2 receptor antagonists) and the incidence of lung cancer: A population-based cohort analysis. **2022**, 101, e30399	0
469	Cell competition in development, homeostasis and cancer.	0

468	An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis-Based Synergistic Cancer Therapy. 2204733	6
467	A novel lactate metabolism-related signature predicts prognosis and tumor immune microenvironment of breast cancer. 13,	0
466	TGF-Upregulated Lnc-Nr6a1 Acts as a Reservoir of miR-181 and Mediates Assembly of a Glycolytic Complex. **2022**, 8, 62	0
465	Droplet Microfluidic Technology for the Early and Label-Free Isolation of Highly-Glycolytic, Activated T-Cells. **2022**, 13, 1442	0
464	Structural aspects of the glucose and monocarboxylate transporters involved in the Warburg effect.	0
463	Quantitative Proteomics Reveals Down-Regulated Glycolysis/Gluconeogenesis in the Large-Duct Type Intrahepatic Cholangiocarcinoma. **2022**, 21, 2504-2514	0
462	Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology. **2022**, 12, 918	1
461	The Sweet Spot of Targeting Tumor Metabolism in Ovarian Cancers. **2022**, 14, 4696	1
460	Cellular Lactate Spectroscopy Using 1.5 Tesla Clinical Apparatus. **2022**, 23, 11355	0
459	Long-term in vitro 2D-culture of SDHB and SDHD-related human paragangliomas and pheochromocytomas. **2022**, 17, e0274478	0
458	LOC554202 contributes to chordoma progression by sponging miR-377-3p and up-regulating SMAD3. Publish Ahead of Print,	0
457	Co-substrate pools can constrain and regulate pathway fluxes in cell metabolism.	0
456	Glutamine stabilizes myc via alpha-ketoglutarate and regulates paclitaxel sensitivity. **2022**, 39,	0
455	Proposal to Consider Chemical/Physical Microenvironment as a New Therapeutic Off-Target Approach. **2022**, 14, 2084	0
454	Combination of the natural product mensacarcin with vemurafenib (Zelboraf) combats BRAF mutant and chemo-resistant melanoma in vitro by affecting cell metabolism and cellular migration. **2022**, 100070	0
453	ID-Checker Technology for the Highly Selective Macroscale Delivery of Anticancer Agents to the Cancer Cells.	0
452	Sodium channels and the ionic microenvironment of breast tumours.	0
451	Multifunctions of CRIF1 in cancers and mitochondrial dysfunction. 12,	0

450	Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma. **2022**, 10,	0
449	The relationship between objective measures of physical function and serum lactate dehydrogenase in older adults with cancer prior to treatment. **2022**, 17, e0275782	0
448	Non-genomic activation of the AKT-mTOR pathway by the mitochondrial stress response in thyroid cancer.	0
447	Effect of sodium-glucose cotransporter type 2 inhibitors on non-alcoholic fatty liver disease. **2022**, 83-89	0
446	The Distinguishing Electrical Properties of Cancer Cells. **2022**,	0
445	Imidazoquinoxaline as a Privileged Fused Pharmacophore in Anticancer Drug Development: A Review of Synthetic Strategies and Medicinal Aspects. **2022**, 7,	0
444	LOXL2-dependent deacetylation of aldolase A induces metabolic reprogramming and tumor progression. **2022**, 57, 102496	0
443	100 years of the Warburg effect: a historical perspective. **2022**, 29, T1-T13	0
442	3D in vitro cancer models for drug screening: A study of glucose metabolism and drug response in 2D and 3D culture models. **2021**,	0
441	Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. **2022**, 3-65	0
440	Practical Aspects of NMR-Based Metabolomics. **2022**,	0
439	Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer. **2022**, 523-555	0
438	Modulation of DNA/RNA Methylation Signaling Mediating Metabolic Homeostasis in Cancer. **2022**, 201-237	0
437	Sonodynamic therapy for breast cancer: A literature review. **2022**, 20, 1045-1056	0
436	Advances in Fungal Phenalenones: Natural Metabolites with Great Promise: Biosynthesis, Bioactivities, and an In Silico Evaluation of Their Potential as Human Glucose Transporter 1 Inhibitors. **2022**, 27, 6797	0
435	2,4-Dinitrophenol as an Uncoupler Augments the Anthracyclines Toxicity against Prostate Cancer Cells. **2022**, 27, 7227	0
434	The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression.	0
433	Data-independent acquisition and quantification of extracellular matrix from human lung in chronic inflammation-associated carcinomas. 2200021	0

432	Scaffold-mediated switching of lymphoma metabolism in culture. **2022**, 10,	1
431	Pathological implications of metabolic reprogramming and its therapeutic potential in medulloblastoma. 10,	0
430	A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio.	0
429	Hallmarks of Cancer Expression in Oral Lichen Planus: A Scoping Review of Systematic Reviews and Meta-Analyses. **2022**, 23, 13099	0
428	Pancreatic Cancer Research beyond DNA Mutations. **2022**, 12, 1503	0
427	FunHoP analysis reveals upregulation of mitochondrial genes in prostate cancer. **2022**, 17, e0275621	0
426	Data-driven identification of plasma metabolite clusters and metabolites of interest for potential detection of early-stage non-small cell lung cancer cases versus cancer-free controls. **2022**, 10,	0
425	Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease. 12,	1
424	2-Deoxy-D-Glucose. **2022**, 27, 1737-1740	0
423	Characterization of pyruvate metabolism and citric acid cycle patterns predicts response to immunotherapeutic and ferroptosis in gastric cancer. **2022**, 22,	0
422	The ROS/NF-Ƀ/HK2 axis is involved in the arsenic-induced Warburg effect in human L-02 hepatocytes. 1-16	0
421	Targeting mitochondria and oxidative stress in cancer- and chemotherapy-induced muscle wasting.	0
420	Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression. **2022**, 23, 11943	1
419	Correlation of Glucose Metabolism with Cancer and Intervention with Traditional Chinese Medicine. **2022**, 2022, 1-17	0
418	Advances in energy metabolism in renal fibrosis. **2022**, 121033	0
417	Chromatin as a sensor of metabolic changes during early development. 10,	0
416	TRIM family contribute to tumorigenesis, cancer development, and drug resistance. **2022**, 11,	1
415	Glycoconjugation of Quinoline Derivatives Using the C-6 Position in Sugars as a Strategy for Improving the Selectivity and Cytotoxicity of Functionalized Compounds. **2022**, 27, 6918	1

414	Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers. **2022**, 65, 13813-13832	0
413	A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.	0
412	Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres. **2022**, 22,	0
411	Cancer Metabolism. 1-14	0
410	Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis.	2
409	Trends in metabolic signaling pathways of tumor drug resistance: A scientometric analysis. 12,	0
408	Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins. **2022**, 13,	0
407	Searching for the Metabolic Signature of Cancer: A Review from Warburg Time to Now. **2022**, 12, 1412	2
406	Gene signature based on glycolysis is closely related to immune infiltration of patients with osteoarthritis.	0
405	Different Expression Patterns of Metabolic Reprogramming Proteins in Testicular Germ Cell Cancer. **2022**, 3, 578-589	0
404	Fabrication of Molecular Blocks with High Responsiveness to the Cancer Microenvironment by Ursodeoxycholic Acid.	0
403	Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers. **2022**, 15,	0
402	Feasibility and Safety of a Combined Metabolic Strategy in Glioblastoma Multiforme: A Prospective Case Series. **2022**, 2022, 1-10	0
401	Circular RNAs: Emerging regulators of glucose metabolism in cancer. **2022**, 215978	1
400	Tumor microenvironment: barrier or opportunity towards effective cancer therapy. **2022**, 29,	0
399	ATP8B1 Deficiency Results in Elevated Mitochondrial Phosphatidylethanolamine Levels and Increased Mitochondrial Oxidative Phosphorylation in Human Hepatoma Cells. **2022**, 23, 12344	0
398	A Mass Spectrometry Imaging and Lipidomic Investigation Reveals Aberrant Lipid Metabolism in the Orthotopic Mouse Glioma. **2022**, 100304	0
397	Advances in the Study of Hexokinase 2 (HK2) Inhibitors. **2022**, 23,	1

396	Evaluation of Mitochondrial Copy Number in Thyroid Disorders. **2022**,	0
395	Cisplatin conjugation with an exopolysaccharide extracted from Lactobacillus gasseri potentiates its efficacy and attenuates its toxicity. **2022**,	0
394	OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased phosphatidylserine synthesis. **2022**, 41, 111561	0
393	Indole-3-Carbinol Stabilizes p53 to Induce miR-34a, Which Targets LDHA to Block Aerobic Glycolysis in Liver Cancer Cells. **2022**, 15, 1257	0
392	Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway. **2023**, 40,	0
391	PTEN -knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid. **2022**, 36,	1
390	Glutamine metabolism in cancers: Targeting the oxidative homeostasis. 12,	0
389	Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma. 13,	0
388	The Warburg effect and mitochondrial oxidative phosphorylation: Friends or foes?. **2022**, 148931	1
387	High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration. **2022**, 22,	0
386	TRIM36 regulates neuroendocrine differentiation of prostate cancer via HK2 ubiquitination and GPx4 deficiency.	0
385	Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. **2022**, 15,	3
384	Seeking an Important Role on Metabolomics□Effects of □Estradiol on Lipoprotein Metabolism in Mammary Tumors. **2022**, 142, 1191-1199	0
383	Mitochondrial uncoupling induces epigenome remodeling and promotes differentiation in neuroblastoma.	1
382	Deregulated transcription factors in cancer cell metabolisms and reprogramming. **2022**, 86, 1158-1174	1
381	Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.	0
380	An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: Promising potential of new pan-GLUT inhibitors. 13,	0
379	The competition of ecological resonances in the quantum metabolic model of cancer: Potential energetic interventions. **2022**, 222, 104798	0

378	Fibroblast-epithelial metabolic coupling in laryngeal cancer. **2022**, 240, 154177	0
377	Targeting hypoxia-related metabolism molecules: How to improve tumour immune and clinical treatment?. **2022**, 156, 113917	0
376	Progress in research on the role of amino acid metabolic reprogramming in tumour therapy: A review. **2022**, 156, 113923	0
375	ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. **2023**, 552, 215981	0
374	Glycosidase activated prodrugs for targeted cancer therapy.	1
373	Unraveling the therapeutic potential of carbamoyl phosphate synthetase 1 (CPS1) in human diseases. **2023**, 130, 106253	0
372	Editor's Pick: Pyruvate Kinase and Gastric Cancer: A Potential Marker. 42-49	0
371	Diindolylmethane Promotes Metabolic Crisis and Enhances the Efficacy of Centchroman in Breast Cancer: A 1H NMR-Based Approach.	0
370	Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review). **2022**, 25,	0
369	Relationship between [18F]FDG PET/CT and metabolomics in patients with colorectal cancer. **2022**, 18,	0
368	Mitochondrial dynamics and oxidative phosphorylation as targets in cancer. **2022**,	0
367	The function of brother of the regulator of imprinted sites in cancer development.	0
366	pH-Sensitive Targeting of Tumors with Chemotherapy-Laden Nanoparticles: Progress and Challenges. **2022**, 14, 2427	1
365	Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer. **2022**, 188837	0
364	Low-Carbohydrate High-Fat Diet: A SWOC Analysis. **2022**, 12, 1126	0
363	A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer. 28,	0
362	Metformin: a promising antidiabetic medication for cancer treatment. **2022**, 24,	0
361	A cross-reactive pH-dependent anti-EGFR antibody obtained by structure-guided engineering exhibits tumor selectivity and improved tumor penetration. **2022**,	0

360	Noncoding RNA PVT1 in osteosarcoma: The roles of lncRNA PVT1 and circPVT1. **2022**, 8,	0
359	Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. **2022**, 11, 3626	0
358	Probabilistic model checking of cancer metabolism. **2022**, 12,	0
357	Targeting Mitochondrial Metabolism to Reverse Radioresistance: An Alternative to Glucose Metabolism. **2022**, 11, 2202	1
356	The dual energetic supply of eukaryotic cells.	0
355	Glycolytic interference blocks influenza A virus propagation by impairing viral polymerase-driven synthesis of genomic vRNA.	0
354	Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics. **2022**,	3
353	Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology. **2022**, 7,	2
352	On-chip dielectrophoretic recovery and detection of a lactate sensing probiotic from model human saliva.	0
351	Spectroscopic Study of Time-Varying Optical Redox Ratio in NADH/FAD Solution.	0
350	Targeting glycolysis for cancer therapy using drug delivery systems. **2023**, 353, 650-662	0
349	Inclusion of the in-chain sulfur in 3-thiaCTU increases the efficiency of mitochondrial targeting and cell killing by anticancer aryl-urea fatty acids. **2023**, 939, 175470	0
348	Amino-OPE glycosides and blue light: a powerful synergy in photodynamic therapy.	0
347	Increased maternal non-oxidative energy metabolism mediates association between prenatal di-(2-ethylhexyl) phthalate (DEHP) exposure and offspring autism spectrum disorder symptoms in early life: A birth cohort study. **2023**, 171, 107678	0
346	Hypoxia induced □catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the wnt signaling pathway. **2023**, 422, 113439	0
345	Droplet microfluidics for CTC-based liquid biopsy: a review.	1
344	Chemotherapeutic drugs. **2023**, 425-437	0
343	Platinum glycoconjugates: □weet bullets□for targeted cancer therapy?. **2023**, 72, 102236	2

342	Mitochondria as a target of third row transition metal-based anticancer complexes. **2023**, 72, 102235	2
341	The Tumor Microenvironment in Hepatocellular Carcinoma. **2022**,	0
340	Regulation of Tumor Metabolome by Long Non-Coding RNAs. **2022**, 16,	0
339	Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. **2022**,	0
338	The magic bullet: Niclosamide. 12,	1
337	Mitochondrial respiration and dynamics of in vivo neural stem cells. **2022**, 149,	0
336	Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-Bp65/HK2 signalling. **2022**, 41,	0
335	Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment Disease-Specific Findings (Part 1).	1
334	Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target.	0
333	Discovery of highly potent and selective 7-ethyl-10-hydroxycamptothecin-glucose conjugates as potential anti-colorectal cancer agents. 13,	0
332	Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response. **2022**, 10, e004712	1
331	The Involvement of Long Non-Coding RNAs in Glutamine-Metabolic Reprogramming and Therapeutic Resistance in Cancer. **2022**, 23, 14808	0
330	Glucose metabolism and lncRNAs in breast cancer: Sworn friend.	0
329	Escherichia coli methionine-tRNAi/methionyl tRNA synthetase pairs induced protein initiation of interest (PII) expression. **2022**, 65,	0
328	Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets. **2022**, 23, 14360	7
327	The role of immunomodulatory metabolites in shaping the inflammatory response of macrophages. **2022**, 55, 519-527	0
326	An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice.	0
325	A central role for STAT5 in the transcriptional programing of T helper cell metabolism. **2022**, 7,	0

324	Deuterium brain imaging at 7T during D 2 O dosing.	0
323	Lactate: a New Look at the Role of an Evolutionarily Ancient Metabolite. **2022**, 58, 2007-2020	0
322	A Multimodal Atlas of Tumor Metabolism Reveals the Architecture of Gene-Metabolite Co-regulation.	0
321	Overcoming current challenges to T-cell receptor therapy via metabolic targeting to increase antitumor efficacy, durability, and tolerability. 13,	0
320	Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors. **2022**, 12, 1964	0
319	MRI Contrast Agents in Glycobiology. **2022**, 27, 8297	1
318	Metabolische Tumorbildgebung bei muskosalen Kopf- und Hals-Karzinomen. **2022**, 111, 878-883	0
317	Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review.	0
316	Progesterone receptor mediated regulation of cellular glucose and 18F-fluorodeoxyglucose uptake in breast cancer.	0
315	Recent Progress in the Therapeutic Modulation of Lactate for Cancer Treatment. 2200254	0
314	Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer. **2022**, 12, 1214	0
313	Lipid Droplet-Associated Proteins Perilipin 1 and 2: Molecular Markers of Steatosis and Microvesicular Steatotic Foci in Chronic Hepatitis C. **2022**, 23, 15456	0
312	Differentiation of Glioblastoma and Brain Metastases by MRI-Based Oxygen Metabolomic Radiomics and Deep Learning. **2022**, 12, 1264	0
311	The Emerging Role of Tumor Microenvironmental Stimuli in Regulating Metabolic Rewiring of Liver Cancer Stem Cells. **2023**, 15, 5	0
310	Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. 13,	2
309	Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy and glycolysis in PDAC. **2022**, 12,	0
308	Association between diabetes and cancer. Current mechanistic insights into the association and future challenges.	0
307	Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer. **2022**,	0

306	Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity. **2022**, 10,	0
305	New horizons in modulating the radio-sensitivity of head and neck cancer - 100 years after Warburg effect discovery. 12,	0
304	Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy.	0
303	Probing Folate-Responsive and Stage-Sensitive Metabolomics and Transcriptional Co-Expression Network Markers to Predict Prognosis of Non-Small Cell Lung Cancer Patients. **2023**, 15, 3	0
302	Dietary digestible carbohydrates are associated with higher prevalence of asthma in humans and with aggravated lung allergic inflammation in mice.	0
301	Oral Spatial-to-Point Cascade Targeting Sugar-coated bullets for Precise and Safe Chemotherapy by Intervention Warburg Effect. **2022**, 113108	0
300	A Missense Variant in PDK1 Associated with Severe Neurodevelopmental Delay and Epilepsy. **2022**, 10, 3171	0
299	Ferroptosis: From regulation of lipid peroxidation to the treatment of diseases.	0
298	Thioridazine Reverses Trastuzumab Resistance in HER2 Positive Gastric Cancer Cells Through Down-regulation of Skp2 Expression.	0
297	Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance. **2022**, 14, 6267	0
296	Structural Determination of the Nanocomplex of Borate with Styrene Maleic Acid Copolymer-Conjugated Glucosamine Used as a Multifunctional Anticancer Drug. **2022**, 5, 5953-5964	0
295	Stiffer-Matrix-Induced PGC-1 Upregulation Enhanced Mitochondrial Biogenesis and Oxidative Stress Resistance in Non-small Cell Lung Cancer.	0
294	High-throughput in situ perturbation of metabolite levels in the tumor micro-environment reveals favorable metabolic condition for increased fitness of infiltrated T-cells. 10,	0
293	Selective Inhibitors of Autophagy Reveal New Link between the Cell Cycle and Autophagy and Lead to Discovery of Novel Synergistic Drug Combinations. **2022**, 17, 3290-3297	0
292	Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review. 12,	0
291	Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics profiling of breast cancer. **2022**, 17, e0278711	0
290	EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. **2022**, 41, 111827	0
289	Effects of metabolic cancer therapy on tumor microenvironment. 12,	0

288	The dual energy supply of eukaryotic cells.	0
287	Role of hypoxia-inducible proteins in ameloblastoma: A review. **2022**,	0
286	Turbulence of glutamine metabolism in pan-cancer prognosis and immune microenvironment. 12,	0
285	Therapeutic Targeting of Glutaminolysis as a Novel Strategy to Combat Cancer Stem Cells. **2022**, 23, 15296	1
284	Microneedle-Assisted Transdermal Delivery of 2D Bimetallic Metal□Organic Framework Nanosheet-Based Cascade Biocatalysts for Enhanced Catalytic Therapy of Melanoma. 2202474	1
283	Oxygen and the Spark of Human Brain Evolution: Complex Interactions of Metabolism and Cortical Expansion across Development and Evolution. 107385842211380	0
282	Bcl11b and Atoh8 Coordinate Cellular Plasticity for Reprogramming and Transformation. **2022**, 24, 324-326	0
281	Phytochemicals and mitochondria: Therapeutic allies against gastric cancer. **2022**, 154608	0
280	Construction of a metabolism-related gene prognostic model to predict survival of pancreatic cancer patients. **2022**, e12378	0
279	Development of an oxidative phosphorylation signature in high-grade glioma and screening of potential inhibitors.	0
278	Mitochondrial uncoupler DNP induces coexistence of dual-state hyper-energy metabolism leading to tumor growth advantage in human glioma xenografts. 12,	0
277	Importance of lactate dehydrogenase (LDH) and monocarboxylate transporters (MCTs) in cancer cells. **2023**, 6,	0
276	The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. **2023**, 15, 62	0
275	Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand. **2023**, 15, 107	0
274	Integrated Metabolomics and Transcriptomics Reveal Metabolic Patterns in Retina of STZ-Induced Diabetic Retinopathy Mouse Model. **2022**, 12, 1245	0
273	Endogenous drivers of altered immune cell metabolism. 153537022211340	1
272	Immunohistochemical Analysis of Nicotinamide Phosphoribosyltransferase Expression in Gastric and Esophageal Adenocarcinoma (AEG). **2022**, 4, 333-340	0
271	Machine learning prediction of cancer cell metabolism from autofluorescence lifetime images.	0

270	Pancreatic Cancer Cells Undergo Immunogenic Cell Death upon Exposure to Gas Plasma-Oxidized Ringers Lactate. **2023**, 15, 319	0
269	Metabolic Adaptations of Cancer in Extreme Tumor Microenvironments.	0
268	Nutraceuticals as Potential Therapeutic Modulators in Immunometabolism. **2023**, 15, 411	1
267	IDH2 stabilizes HIF -1□nduced metabolic reprogramming and promotes chemoresistance in urothelial cancer.	0
266	Bioactive Compounds from Curcuma amada and their effect on Acute Myeloid Leukemia. **2023**,	0
265	Reinventing Radiobiology in the Light of FLASH Radiotherapy. **2023**, 7,	0
264	Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer. **2023**, 13, 157	0
263	RNAi screening reveals a synthetic chemical-genetic interaction between ATP synthase and PFK1 in cancer cells.	1
262	TRPM8 promotes hepatocellular carcinoma progression by inducing SNORA55 mediated nuclear-mitochondrial communication.	0
261	Non-coding RNAs regulate mitochondrial dynamics in the development of gastric cancer. 10,	0
260	The Anti-Tubercular Aminolipopeptide Trichoderin A Displays Selective Toxicity against Human Pancreatic Ductal Adenocarcinoma Cells Cultured under Glucose Starvation. **2023**, 15, 287	0
259	A Novel Four Mitochondrial Respiration-Related Signature for Predicting Biochemical Recurrence of Prostate Cancer. **2023**, 12, 654	0
258	Metabolic regulation of stress erythropoiesis, outstanding questions, and possible paradigms. 13,	0
257	Anticancer Properties of Hexosamine Analogs Designed to Attenuate Metabolic Flux through the Hexosamine Biosynthetic Pathway.	0
256	Selective Nanoblocker of Cellular Stress Response for Improved Drug-Free Tumor Therapy. 2202893	0
255	Introduction to Tumor Microenvironment. **2023**, 1-13	0
254	Metabolomics of small extracellular vesicles derived from isocitrate dehydrogenase 1-mutant HCT116 cells collected by semi-automated size exclusion chromatography. 9,	0
253	Bioresponsive Immunotherapeutic Materials. 2209778	0

252	Lactate oxidase/catalase-displaying nanoparticles efficiently consume lactate in the tumor microenvironment to effectively suppress tumor growth. **2023**, 21,	2
251	Innate sensing and cellular metabolism: role in fine tuning antiviral immune responses.	0
250	Glycolysis Inhibition of Autophagy Drives Malignancy in Ovarian Cancer: Exacerbation by IL-6 and Attenuation by Resveratrol. **2023**, 24, 1723	0
249	Metabolomic profiling identifies hair as a robust biological sample for identifying women with cervical cancer. **2023**, 40,	0
248	Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma. **2023**, 15, 498	0
247	Hypoxia-inducing cryogels uncover key cancer-immune cell interactions in an oxygen-deficient tumor microenvironment.	0
246	The role of serine metabolism in lung cancer: From oncogenesis to tumor treatment. 13,	0
245	Expression of PKM2 in wound keratinocytes is coupled to angiogenesis during skin repair in vivo and in HaCaT keratinocytes in vitro.	0
244	Tumor hypoxia: From basic knowledge to therapeutic implications. **2023**, 88, 172-186	0
243	Pathogenic role of 25-hydroxycholesterol in cancer development and progression.	0
242	Mitochondrial respiration promotes Cdc37-dependent stability of the Cdk1 homolog Cdc28. **2023**, 136,	0
241	Proteomics Characterization of Clear Cell Renal Cell Carcinoma. **2023**, 12, 384	0
240	Atypical location of primary cardiac lymphoma in the left heart with atypical clinical presentation: A case report and literature review. 9,	0
239	The Prime and Integral Cause of Cancer in the Post-Warburg Era. **2023**, 15, 540	0
238	Lactic acid fermentation: A maladaptive mechanism and an evolutionary throwback boosting cancer drug resistance. **2023**,	1
237	Metabolic characteristics of the various incision margins for breast cancer conservation surgery. 12,	0
236	Isolation, Detection and Analysis of Circulating Tumour Cells: A Nanotechnological Bioscope. **2023**, 15, 280	0
235	Rapid metabolomic screening of cancer cells via high-throughput static droplet microfluidics. **2023**, 223, 114966	0

234	Fundamental Role of Pentose Phosphate Pathway within the Endoplasmic Reticulum in Glutamine Addiction of Triple-Negative Breast Cancer Cells. **2023**, 12, 43	0
233	Allopregnanolone: Metabolism, Mechanisms of Action, and Its Role in Cancer. **2023**, 24, 560	0
232	The Role of Inorganic Phosphate Transporters in Highly Proliferative Cells: From Protozoan Parasites to Cancer Cells. **2023**, 13, 42	0
231	Shedding Light on Immunological Research in Lyon, France. IRCI2022 Brings the Scientific World to Lyon and Bridges the Latest Immunological Findings in Cancer and Infection. **2022**, 209, 2251-2259	0
230	Nuclear Receptor Imaging In Vivo□linical and Research Advances. **2023**, 7,	0
229	Novel Specific Pyruvate Kinase M2 Inhibitor, Compound 3h, Induces Apoptosis and Autophagy through Suppressing Akt/mTOR Signaling Pathway in LNCaP Cells. **2023**, 15, 265	0
228	Cancer Microenvironment Defines Tumor-Infiltrating Lymphocyte Density and Tertiary Lymphoid Structure Formation in Laryngeal Cancer.	2
227	Source of Liquid Biopsy Biomarker: Exosome vs Whole Plasma, Fasting vs Non-fasting.	0
226	Gold nanoparticles inhibit tumor growth via targeting the Warburg effect in a c-Myc-dependent way. **2022**,	0
225	A numerical human brain phantom for dynamic glucose-enhanced (DGE) MRI : On the influence of head motion at 3T.	0
224	Advances in Human Mitochondria-Based Therapies. **2023**, 24, 608	0
223	Rise of the natural red pigment □prodigiosin□as an immunomodulator in cancer. **2022**, 22,	0
222	The Warburg Effect is the result of faster ATP production by glycolysis than respiration.	0
221	Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. **2023**, 102, 393-402	0
220	Modulating Glycolysis to Improve Cancer Therapy. **2023**, 24, 2606	0
219	Metabolic Health, Mitochondrial Fitness, Physical Activity, and Cancer. **2023**, 15, 814	0
218	Design, synthesis, and antitumor evaluation of trimethoxyflavonoid with arylurea structure against hepatocellular carcinoma.	0
217	Hypoxia signaling in cancer: Implications for therapeutic interventions. **2023**, 4,	1

216	Role of Serum Lipids, Blood Glucose and Blood Pressure in Breast Cancer Risk for Women with Type 2 Diabetes Mellitus. Volume 15, 109-121	0
215	SEMA5A-PLXNB3 Axis Promotes PDAC Liver Metastasis Outgrowth through Enhancing the Warburg Effect. **2023**, 2023, 1-18	0
214	Glycogen as an Effective Target in Cancer Therapy. **2023**, 1-12	0
213	Beyond metabolic waste: lysine lactylation and its potential roles in cancer progression and cell fate determination.	0
212	The dual energy supply of eukaryotic cells.	0
211	Opposing Effects of ApoE2 and ApoE4 on Glycolytic Metabolism in Neuronal Aging Supports a Warburg Neuroprotective Cascade against Alzheimer□ Disease. **2023**, 12, 410	0
210	The Role of Ketogenic Diet in the Treatment of Neuroblastoma. **2023**, 22, 153473542211507	0
209	lncRNA ELFN1-AS1 promotes proliferation, migration and invasion and suppresses apoptosis in colorectal cancer cells by enhancing G6PD activity. **2023**,	0
208	eEF2K Inhibitor Design: The Progression of Exemplary Structure-Based Drug Design. **2023**, 28, 1095	0
207	Hybrid computational models of multicellular tumour growth considering glucose metabolism. **2023**, 21, 1262-1271	0
206	Mass Spectrometry-Based Glycoproteomic Workflows for Cancer Biomarker Discovery. **2023**, 22, 153303382210488	0
205	Glycolysis-Related Gene Analyses Indicate That DEPDC1 Promotes the Malignant Progression of Oral Squamous Cell Carcinoma via the WNT/□Catenin Signaling Pathway. **2023**, 24, 1992	0
204	Mitochondrial Modulators: The Defender. **2023**, 13, 226	0
203	Usefulness of pyruvate dehydrogenase-E1□expression to determine SUVmax cut-off value of [18F]FDG-PET for predicting lymph node metastasis in lung cancer. **2023**, 13,	0
202	GPRC5B (G protein-coupled receptor class C group 5 member B) suppresses glucose starvation-induced apoptosis in head-and-neck squamous cell carcinoma. **2023**, 44, 1-7	0
201	Starvation-assisted and photothermal-thriving combined chemo/chemodynamic cancer therapy with PT/MR bimodal imaging.	0
200	The regulatory mechanisms of proline and hydroxyproline metabolism: Recent advances in perspective. 12,	0
199	JMJD5 inhibits lung cancer progression by regulating glucose metabolism through the p53/TIGAR pathway.	0

198	Comparing the adult and pre-pubertal testis: Metabolic transitions and the change in the spermatogonial stem cell metabolic microenvironment.	0
197	A novel detection technology for early gastric cancer based on Raman spectroscopy. **2023**, 292, 122422	0
196	Molecular Imaging in Oncology. **2023**, 303-373	0
195	Warburg Effect Revisited: Embodiment of Classical Biochemistry and Organic Chemistry. Current State and Prospects. **2023**, 88, S1-S20	0
194	A new border for circadian rhythm gene NFIL3 in diverse fields of cancer.	0
193	Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma. **2023**, 30, 2845-2861	0
192	The Ketogenic Diet in Colorectal Cancer: A Means to an End. **2023**, 24, 3683	0
191	Mint3 as a Potential Target for Cooling Down HIF-1Mediated Inflammation and Cancer Aggressiveness. **2023**, 11, 549	0
190	1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation. **2023**, 23,	0
189	Mitochondria-associated endoplasmic reticulum membrane: Overview and inextricable link with cancer. **2023**, 27, 906-919	1
188	Inhibition of heterogeneous nuclear ribonucleoproteins A1 and oxidative stress reduces glycolysis via pyruvate kinase M2 in chronic thromboembolic pulmonary hypertension. **2023**,	0
187	Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications.	0
186	Anticancer Potential of Apigenin and Isovitexin with Focus on Oncogenic Metabolism in Cancer Stem Cells. **2023**, 13, 404	0
185	Relationship between anticancer sensitivities and cellular respiration properties in 5-fluorouracil-resistant HCT116 human colorectal cancer cells.	0
184	Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies. **2023**, 560, 216138	0
183	Chemical Memory with Discrete Turing Patterns Appearing in the Glycolytic Reaction. **2023**, 8, 154	0
182	Aiding Cancer Sweet Tooth Role of Hexokinases in Metabolic Reprogramming. **2023**, 13, 946	0
181	Targeting hPKM2 in cancer: A bio isosteric approach for ligand design. **2023**, 158, 106852	0

180	Cancer metabolism within tumor microenvironments. **2023**, 1867, 130330	0
179	Shouhui Tongbian Capsules induce regression of inflammation to improve intestinal barrier in mice with constipation by targeted binding to Prkaa1: With no obvious toxicity. **2023**, 161, 114495	0
178	Estimation of energy pathway fluxes in cancer cells - Beyond the Warburg effect. **2023**, 739, 109559	0
177	OXPHOS inhibitors, metabolism and targeted therapies in cancer. **2023**, 211, 115531	0
176	Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo. **2023**, 161, 114524	0
175	Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives. **2023**, 161, 114503	1
174	Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?. **2023**, 183, 109665	0
173	Survey of genomic and physiological characteristics for survival in lymphoma: The NCI genomic data portal. **2023**, 47, 100955	0
172	The metabolic crosstalk between PIN1 and the tumour microenvironment. **2023**, 91, 143-157	0
171	The tumor ecosystem in head and neck squamous cell carcinoma and advances in ecotherapy. **2023**, 22,	0
170	Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment. 13,	0
169	Interfering biosynthesis by nanoscale metal-organic frameworks for enhanced radiation therapy. **2023**, 295, 122035	0
168	FOXM1: A small fox that makes more tracks for cancer progression and metastasis. **2023**, 92, 1-15	1
167	An updated patent review of glutaminase inhibitors (2019–2022). **2023**, 33, 17-28	0
166	Metabolite interactions between host and microbiota during health and disease: Which feeds the other?. **2023**, 160, 114295	0
165	Vitamin B1 Converted to the Coenzyme Thiamin Pyrophosphate. **2018**, 74-103	0
164	Multifaceted roles of aerobic glycolysis and oxidative phosphorylation in hepatocellular carcinoma. 11, e14797	0
163	Long-term 1,2-dimethylhydrazine triggers pathological remodeling of colon mucosa through repression of sestrin2, nuclear factor (erythroid-derived 2)-like 2, and sirtuin4 stimulating mitochondrial stress and metabolic reprogramming.	0

162	NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma. **2023**, 24,	0
161	Reflections on the Biology of Cell Culture Models: Living on the Edge of Oxidative Metabolism in Cancer Cells. **2023**, 24, 2717	0
160	Is There a Role of Warburg Effect in Prostate Cancer Aggressiveness? Analysis of Expression of Enzymes of Lipidic Metabolism by Immunohistochemistry in Prostate Cancer Patients (DIAMOND Study). **2023**, 15, 948	0
159	Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension. 11,	0
158	Identification and experimental validation of ferroptosis-related gene SLC2A3 is involved in rheumatoid arthritis. **2023**, 943, 175568	0
157	A reduced model of cell metabolism to revisit the glycolysis-OXPHOS relationship in the deregulated tumor microenvironment. **2023**, 562, 111434	0
156	Identification of corticosteroids as potential inhibitor against glycolytic enzyme hexokinase II role in cancer glycolysis pathway: a molecular docking study. **2023**, 36, 173-180	0
155	Nutrient transporters: connecting cancer metabolism to therapeutic opportunities. **2023**, 42, 711-724	0
154	Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities. **2023**, 28, 212-229	0
153	Effect of total glycosides of Cistanche deserticola on the energy metabolism of human HepG2 cells. 10,	0
152	MARS2 drives metabolic switch of non-small-cell lung cancer cells via interaction with MCU. **2023**, 60, 102628	0
151	Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer. **2023**, 21,	1
150	Metabolomics Profiling Reveals the Role of PEDF in Triple-Negative Breast Cancer Cell MDA-MB-231 under Glycaemic Loading. **2023**, 15, 543	0
149	Lactate oxidase/vSIRP□conjugates efficiently consume tumor-produced lactates and locally produce tumor-necrotic H2O2 to suppress tumor growth. **2023**, 231, 123577	0
148	A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer. **2023**, 11, 381	0
147	Prognosis-related metabolic genes in the development of colorectal cancer progress and perspective. **2023**, 862, 147263	0
146	TOMM34 serves as a candidate therapeutic target associated with immune cell infiltration in colon cancer. 13,	0
145	NOX2 and NOX4 control mitochondrial function in chronic myeloid leukaemia. **2023**, 198, 92-108	0

144	Glucose-mediated N-glycosylation of RPTP□affects its subcellular localization and Src activation. **2023**, 42, 1058-1071	0
143	Discovery of aminothiazole derivatives as a chemical scaffold for glutaminase inhibition. **2023**, 5, 100842	0
142	Lactate Dehydrogenase and Risk of Readmission with Gastric Cancer: A´Propensity Score Matching Analysis.	0
141	Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy. **2023**, 24, 3710	0
140	Development of lactate-related gene signature and prediction of overall survival and chemosensitivity in patients with colorectal cancer.	0
139	MicroRNAs as the Critical Regulators of Forkhead Box Protein Family in Pancreatic, Thyroid, and Liver Cancers.	0
138	Chorioallantoic Membrane Assay at the Cross-Roads of Adipose-Tissue-Derived Stem Cell Research. **2023**, 12, 592	0
137	Optimizing the manufacturing and antitumour response of CAR˙T therapy. **2023**, 1, 271-285	0
136	The Therapeutic Mechanism of Schisandrol A and Its Metabolites on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Analysis. Volume 17, 477-496	0
135	MicroRNA-370 as a negative regulator of signaling pathways in tumor cells. **2023**, 127, 127-137	0
134	circPKD2 inhibits the glioma cell proliferation, invasion and glycolytic metabolism through regulating the miR-1278/LATS2 axis. **2023**, 801, 137126	0
133	Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer. **2023**, 15, 1192	0
132	Phenotype-specific estimation of metabolic fluxes using gene expression data. **2023**, 26, 106201	0
131	PFKFB4 Drives the Oncogenicity in TP53-Mutated Hepatocellular Carcinoma in a Phosphatase-Dependent Manner. **2023**, 15, 1325-1350	0
130	Gas Flow Shaping via Novel Modular Nozzle System (MoNoS) Augments kINPen-Mediated Toxicity and Immunogenicity in Tumor Organoids. **2023**, 15, 1254	0
129	Characterization of glycometabolism and tumor immune microenvironment for predicting clinical outcomes in gastric cancer. **2023**, 26, 106214	0
128	WZB117 Decorated Metformin-Carboxymethyl Chitosan Nanoparticles for Targeting Breast Cancer Metabolism. **2023**, 15, 976	1
127	Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. **2023**, 8,	1

126	Trigred motif 36 regulates neuroendocrine differentiation of prostate cancer via HK2 ubiquitination and GPx4 deficiency.	1
125	Cancer Metabolism: Fasting Reset, the Keto-Paradox and Drugs for Undoing. **2023**, 12, 1589	0
124	Filament formation by glutaminase enzymes drives catalysis.	0
123	Lactobacillus plantarum Metabolites Elicit Anticancer Effects by Inhibiting Autophagy-Related Responses. **2023**, 28, 1890	0
122	Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies. **2023**, 28, 1897	0
121	Dynamics of co-substrate pools can constrain and regulate metabolic fluxes. 12,	0
120	Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis. **2023**, 24, 4148	0
119	TIM-4 orchestrates mitochondrial homeostasis to promote lung cancer progression via ANXA2/PI3K/AKT/OPA1 axis. **2023**, 14,	0
118	Flavin fluorescence lifetime and autofluorescence optical redox ratio for improved visualization and classification of brain tumors. 13,	0
117	Serine hydroxymethyltransferase 2 knockdown induces apoptosis in ccRCC by causing lysosomal membrane permeabilization via metabolic reprogramming. **2023**, 14,	0
116	MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration. **2023**, 40,	0
115	Operando NMR metabolomics of a microfluidic cell culture. **2023**, 349, 107405	0
114	Introduction to Immune-Mediated Myopathies. **2023**, 3-8	0
113	Cross-linkable star-hyperbranched unimolecular micelles for the enhancement of the anticancer activity of clotrimazole.	0
112	Features of expression of GLUT-1 and Ki-67 proteins in various components of mixed variants of ameloblastoma. **2023**, 102, 7	0
111	Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy. 2201404	0
110	The mitochondrial chaperone TRAP-1 regulates the glutamine metabolism in tumor cells. **2023**, 69, 159-170	0
109	Consequences of Glucose Enriched Diet on Oncologic Patients. **2023**, 13, 2757	0

108	A Mitochondrial Perspective on Noncommunicable Diseases. **2023**, 11, 647	0
107	Metabolomics in oncology. **2023**, 6,	0
106	Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses.	0
105	Targeting of Glucose Transport and the NAD Pathway in Neuroendocrine Tumor (NET) Cells Reveals New Treatment Options. **2023**, 15, 1415	0
104	Interactions between microbiota and cervical epithelial, immune, and mucus barrier. 13,	0
103	Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin Lymphoma. **2023**, 13, 861	0
102	MiRNAs Action and Impact on Mitochondria Function, Metabolic Reprogramming and Chemoresistance of Cancer Cells: A Systematic Review. **2023**, 11, 693	0
101	The Role of Reprogrammed Glucose Metabolism in Cancer. **2023**, 13, 345	1
100	Evidence of Nrf2/Keap1 Signaling Regulation by Mitochodria-Generated Reactive Oxygen Species in RGK1 Cells. **2023**, 13, 445	0
99	What is cancer metabolism?. **2023**, 186, 1670-1688	0
98	The crosstalking of lactate-Histone lactylation and tumor. 2200102	0
97	LDHA maintains the growth and migration of vascular smooth muscle cells and promotes neointima formation via crosstalk between K5 crotonylation and K76 mono-ubiquitination.	0
96	Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer. 13,	0
95	Polyunsaturated Lipids in the Light-Exposed and Prooxidant Retinal Environment. **2023**, 12, 617	0
94	T regulatory cells metabolism: The influence on functional properties and treatment potential. 14,	0
93	Quantitative proteomics identified a novel invasion biomarker associated with EMT in pituitary adenomas. 14,	0
92	Biochemical Origin of the Warburg Effect in Light of 15 Years of Research Experience: A Novel Evidence-Based View (An Expert Opinion Article). Volume 16, 143-155	1
91	Effects of Au States in Thiol-Organosilica Nanoparticles on Enzyme-like Activity for X-ray Sensitizer Application: Focus on Reactive Oxygen Species Generation in Radiotherapy. **2023**, 8, 9569-9582	0

90	ALKBH5 -induced circular RNA NRIP1 promotes glycolysis in thyroid cancer cells by targeting PKM2.	0
89	Tumor Metabolism: Challenges and Future Perspectives. **2023**, 1-27	0
88	Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer. 13,	0
87	Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine Model of Bladder Cancer. **2023**, 15, 1654	0
86	The role of mitochondria in the development of breast cancer. **2023**, 27, 5-19	0
85	PTB Regulates the Metabolic Pathways and Cell Function of Keloid Fibroblasts through Alternative Splicing of PKM. **2023**, 24, 5162	0
84	Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients. **2023**, 12, 2135	0
83	Musculoskeletal Imaging. **2023**, 577-624	0
82	Transcriptome Analysis on Hepatopancreas Reveals the Metabolic Dysregulation Caused by Vibrio parahaemolyticus Infection in Litopenaeus vannamei. **2023**, 12, 417	0
81	Rare sugar l-sorbose exerts antitumor activity by impairing glucose metabolism. **2023**, 6,	0
80	Glycopolymer-Based Hydrogels Impair Energy Metabolism via Delivering Mannose and Depleting Glucose for Tumor Suppression. **2023**, 5, 1145-1152	0
79	A Small Sugar Molecule with Huge Potential in Targeted Cancer Therapy. **2023**, 15, 913	0
78	Parkin exerts the tumor-suppressive effect through targeting mitochondria.	0
77	Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes. 14,	0
76	Coupling Glucose Phosphorylation to Oxygen in Brain Mitochondria: Would It Be a Redox Set Point?. **2023**, 93-112	0
75	Emerging roles of Aurora-A kinase in cancer therapy resistance. **2023**,	0
74	Can the De Ritis Ratio (AST/ALT) be used to predict colon cancer stages?.	0
73	Model of an Artificial Blastula for Assessing Development Toxicity.	0

72	Lactate regulates cell cycle by remodelling the anaphase promoting complex.	0
71	Identifying cancer cell metabolic states in autofluorescence lifetime images with machine learning. **2023**,	0
70	Current perspectives of mitochondria-targeted antioxidants in cancer prevention and treatment. 11,	0
69	Modeling Gas Plasma-Tissue Interactions in 3D Collagen-Based Hydrogel Cancer Cell Cultures. **2023**, 10, 367	0
68	Counteracting Colon Cancer by Inhibiting Mitochondrial Respiration and Glycolysis with a Selective PKC Activator. **2023**, 24, 5710	0
67	High Expression of COA6 Is Related to Unfavorable Prognosis and Enhanced Oxidative Phosphorylation in Lung Adenocarcinoma. **2023**, 24, 5705	0
66	Metabolic Reprogramming and Its Regulatory Mechanism in Sepsis-Mediated Inflammation. Volume 16, 1195-1207	0
65	Single cell metabolic imaging of tumor and immune cells in vivo in melanoma bearing mice. 13,	0
64	CircRNAs: emerging factors for regulating glucose metabolism in colorectal cancer.	0
63	Heteronuclear dual-metal atom catalysts for nanocatalytic tumor therapy. **2023**, 47, 1-31	0
62	Enhancing Cancer Treatment and Understanding Through Clustering of Gene Responses to Categorical Stressors.	0
61	Clustering of Cancer Responses to Stressors: Insights for Cancer Treatment and Disease Understanding.	0
60	Clustering of Cancer Responses to Stressors: Insights for Cancer Treatment and Disease Understanding.	0
59	RNA virus-mediated changes in organismal oxygen consumption rate in young and old Drosophila melanogaster males. **2023**, 15, 1748-1767	0
58	Enhancing Cancer Treatment and Understanding Through Clustering of Gene Responses to Categorical Stressors.	0
57	Identification and Validation of Lactate Metabolism-Related Genes in Retinopathy of Prematurity.	0
56	Engineered probiotics limit CNS autoimmunity by stabilizing HIF-1 in dendritic cells.	0
55	To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. **2023**, 8,	0

54	Enhancing Cancer Treatment and Understanding Through Clustering of Gene Responses to Categorical Stressors.	0
53	Inflammation Induces Endoplasmic Reticulum Stress and Its Pro-apoptotic Effect is Attenuated by Hexokinase 2-mediated Glycolysis in Lymphatic Endothelial Cells: A Potential Role in Lymphatic Malformations.	0
52	The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer. Volume 15, 311-317	0
51	Optimal LC-MS metabolomic profiling reveals emergent changes to monocyte metabolism in response to lipopolysaccharide. 14,	0
50	Amino acids in hematologic malignancies: Current status and future perspective. 10,	0
49	Mitochondrial Signaling Pathways Associated with DNA Damage Responses. **2023**, 24, 6128	0
48	Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. **2023**, 15, 1936	0
47	Mitochondrial transfer in PC-3 cells fingerprinted in ferroptosis sensitivity: a brand new approach targeting cancer metabolism.	0
46	The Interaction between Gut Microbiota and Host Amino Acids Metabolism in Multiple Myeloma. **2023**, 15, 1942	0
45	Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2. **2023**, 13, 467	0
44	An Organismal Perspective on the Warburg Effect and Models for Proliferation Studies. **2023**, 12, 502	0
43	Emerging role of substance and energy metabolism associated with neuroendocrine regulation in tumor cells. 14,	0
42	Fatty acid metabolism: A new therapeutic target for cervical cancer. 13,	0
41	The p52-ZER6/G6PD axis alters aerobic glycolysis and promotes tumor progression by activating the pentose phosphate pathway. **2023**, 12,	0
40	Hyperglycemia induces PFKFB3 overexpression and promotes malignant phenotype of breast cancer through RAS/MAPK activation. **2023**, 21,	0
39	Effectiveness for Diagnosis of Malignancy of Bile Pyruvate Kinase M2 in Patients with Indeterminate Biliary Stricture. **2023**, 33, 147-151	0
38	Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer. 14,	0
37	Structural basis for activation of glutaminase.	0

36	Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation. **2023**, 124, 495-519	0
35	Transcriptional programing of T cell metabolism by STAT family transcription factors.	0
34	PLC promotes the Warburg effect and tumorigenesis through AKT/GSK3/Cdc25a in bladder cancer. 1-15	0
33	Let-7b-5p inhibits breast cancer cell growth and metastasis via repression of hexokinase 2-mediated aerobic glycolysis. **2023**, 9,	0
32	DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation.	0
31	Redox Proteomic Profile of Tirapazamine-Resistant Murine Hepatoma Cells. **2023**, 24, 6863	0
30	Proline Maintains the Proliferation of Hepatocellular Carcinoma Cells by Decreasing Intracellular Oxidative Stress and Reducing Autophagy During Acute Nutrient Stress.	0
29	??????????????????????????. **2023**, 44, 36-46	0
28	Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway. **2023**, 18, e0284242	0
27	On the Role of Glycolysis in Early Tumorigenesis Permissive and Executioner Effects. **2023**, 12, 1124	0
26	Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection.	0
25	Biomaterial-Based Delivery Systems for Chemotherapeutics. **2023**, 105-178	0
24	Development of Amino Acid Metabolism-Related Prognostic Model and Immune Infiltration Analysis in Patients with Stomach Adenocarcinoma.	0
23	Vehicles for Delivery of Therapeutic Agent for Cancer Therapy. **2023**, 719-753	0
22	Lactate-Modulated the Immunosuppressive Function of Myeloid-Derived Suppressor Cells through TET2-mediated SGK1 demethylation.	0
21	The Effect of Xanthium strumarium Root Extracts on Growth Inhibition of Epithelial Ovarian Cancer SK-OV-3 Cell Line: A Metabolomics-Based Study. **2023**, In Press,	0
20	JMJD5 inhibits lung cancer progression by regulating glucose metabolism through the p53/TIGAR pathway. **2023**, 40,	0
19	The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies. **2023**, 13, 996	0

18	Metabolic dependencies and targets in ovarian cancer. **2023**, 245, 108413	0
17	Functions of N6-methyladenosine in cancer metabolism: from mechanism to targeted therapy. **2023**, 11,	0
16	Role of Hypoxia and Reactive Oxygen Species in Cancer Biology. **2023**, 41-63	0
15	Fabrication of Molecular Blocks with High Responsiveness to the Cancer Microenvironment by Ursodeoxycholic Acid.	0
14	Metabolic Rewiring in Adult-Type Diffuse Gliomas. **2023**, 24, 7348	0
13	Molecular docking, ADMET and molecular dynamics simulation revealed metralindole as a multitargeted inhibitor for division kinases. 83,	0
12	Integrating Multi-Omics Data to Construct Reliable Interconnected Models of Signaling, Gene Regulatory, and Metabolic Pathways. **2023**, 139-151	0
11	Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.	0
10	Finding New Molecular Targets of Two Copper(II)-Hydrazone Complexes on Triple-Negative Breast Cancer Cells Using Mass-Spectrometry-Based Quantitative Proteomics. **2023**, 24, 7531	0
9	Uncoupled glycerol-3-phosphate shuttle in kidney cancer reveals that cytosolic GPD is essential to support lipid synthesis. **2023**, 83, 1340-1349.e7	0
8	Enhancing cancer treatment and understanding through clustering of gene responses to categorical stressors. **2023**, 13,	0
7	Pan-cancer analysis of aldolase B gene as a novel prognostic biomarker for human cancers. **2023**, 102, e33577	0
6	The Emerging Role of Molecular Dynamics Simulations in Cancer Research. **2023**,	0
5	Knockdown of heat shock protein family D member 1 (HSPD1) promotes proliferation and migration of ovarian cancer cells via disrupting the stability of mitochondrial 3-oxoacyl-ACP synthase (OXSM). **2023**, 16,	0
4	Adrenergic regulation of astroglial aerobic glycolysis and lipid metabolism: Towards a noradrenergic hypothesis of neurodegeneration. **2023**, 106132	0
3	The Warburg effect: a signature of mitochondrial overload. **2023**,	0
2	Predictive value of intratumoral-metabolic heterogeneity derived from 18F-FDG PET/CT in distinguishing microsatellite instability status of colorectal carcinoma. 13,	0
1	USP7 - a crucial regulator of cancer hallmarks. **2023**, 1878, 188903	0